 
 
Protocol : I8F-MC-GPHM  
 
 Eﬃcacy and Safety of Tirzepa�de Once Weekly Versus Placebo A�er an Intensive Lifestyle Program in Par�cipants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight -Related 
Comorbidi�es: A Randomized, Double Blind, Placebo -Controlled Trial (SURMOUNT-3)  
  [STUDY_ID_REMOVED]   
Approval Date: 19-Nov -2020  
CONFIDENTIAL Protocol  number I8F -MC-GPHM
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of tirzepatide (LY3298176) , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company 
or its subsidiaries. 
Note to Regulatory Authorities:   This document may contain protected personal data and/or commerci ally confidential 
information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title: Efficacy and Safet y of Tirzepat ide Once Weekly versus Placebo After an 
Intensive Lifest yle Program in Particip ants wi thout Ty pe 2 Di abetes who have Obesit y or are 
Overweight with Weight -Related Com orbidi ties: A Rando mized, Double -Blind, Pl acebo -
Controlled Trial (SURMOUNT -3)
Protocol Number: I8F-MC-GPHM
Amendment number: This is the init ial protocol .
Compound :LY3298176   
Study Phase: 3
Short Title: Effect of Tirzepat ide versus Pl acebo after Intensive Li festyle Program
(SURMOUNT -3)
Acronym :SURMOUNT -3
Sponsor Name: Eli Lilly  and Company
Legal Registered Address: Indianapo lis, Indiana USA  46285
Regulatory Agency Identifier Number(s)
IND: 139721
Approval Date :Protocol Electronically Signed and Approved by Lilly ondate provi ded bel ow.
Approval Date: 19-Nov-2020 GMT
CONFIDENTIAL Protocol  number I8F -MC-GPHM
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
3Table of Contents
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis ....................................................................................................................... 6
1.2. Schema ....................................................................................................................... 11
1.3. Schedule of Act ivities (SoA) ...................................................................................... 12
2. Introduction .............................................................................................................. 18
2.1. Study  Rati onale .......................................................................................................... 18
2.2. Background ................................................................................................................ 19
2.3. Benefit/Risk Assessment ............................................................................................ 20
3. O bjectives and Endpoints ......................................................................................... 21
4. Study Design ............................................................................................................. 23
4.1. Overall Design ............................................................................................................ 23
4.1.1. Overview of Study  Periods ......................................................................................... 23
4.1.2. Study  Procedures ........................................................................................................ 27
4.2. Scientific Rationale for Study  Design ......................................................................... 28
4.3. Justification for Dose .................................................................................................. 29
4.4. End of Study  Definit ion.............................................................................................. 30
5. Study Population ...................................................................................................... 31
5.1. Inclusio nCriteria........................................................................................................ 31
5.2. Exclusio n Cri teria....................................................................................................... 33
5.3. Lifest yle Considerat ions............................................................................................. 37
5.3.1. Meals and Dietary  Restri ctions................................................................................... 37
5.3.2. Physical Act ivity........................................................................................................ 38
5.4. Scree n Failures ........................................................................................................... 39
6. Study Intervention .................................................................................................... 40
6.1. Study  Intervent ion(s) Administered ............................................................................ 40
6.1.1. Medical Devices ......................................................................................................... 40
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 41
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 41
6.4. Study  Intervent ion Compliance ................................................................................... 42
6.5. Concomitant Therapy .................................................................................................42
6.6. Dose Modificat ion...................................................................................................... 43
6.6.1. Tirzepati de................................................................................................................. 43
6.6.2. Management of Participants with Gastrointestinal Symptoms ..................................... 43
6.7. Intervention after the End of the Study ........................................................................ 43
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 44
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 44
7.1.1. Temporary  Discont inuat ion........................................................................................ 47
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 47
7.2.1. Parti cipant Disposi tion and Timing of Safet y Follow-Up............................................ 49
7.2.2. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 50
CONFIDENTIAL Protocol  number I8F -MC-GPHM
47.3. Lost to Follow up ....................................................................................................... 50
8. Study Assessments and Procedures ......................................................................... 51
8.1. Efficacy Assessments .................................................................................................51
8.1.1. Primary Efficacy  Assessments .................................................................................... 51
8.1.2. Secondary  Efficacy  Assessments ................................................................................ 51
8.1.3. Patient-Reported Outcomes Assessments .................................................................... 51
8.2. Safety Assessments .................................................................................................... 53
8.2.1. Physical Examinat ions................................................................................................ 53
8.2.2. Vital Signs.................................................................................................................. 53
8.2.3. Electrocardiograms ..................................................................................................... 53
8.2.4. Clinical Safety  Laboratory  Assessments ..................................................................... 54
8.2.5. Safety Moni toring ....................................................................................................... 55
8.2.6. Depressio n, Sui cidal  Ideat ion and Behavior Risk Monitoring ...................................... 57
8.3. Adverse Events, Serious Adverse Events, and Product 
Com plaint s................................................................................................................. 57
8.3.1. Timing and Mechanism for Collect ing Events ............................................................ 58
8.3.2. Speci al Safet y Topi cs.................................................................................................60
8.4. Treatment of Overdose ............................................................................................... 65
8.5. Pharmacokinet ics........................................................................................................ 65
8.6. Pharmacodynamics ..................................................................................................... 65
8.7. Genet ics..................................................................................................................... 65
8.8. Biomarkers ................................................................................................................. 66
8.9. Immunogenicit y Assessments ..................................................................................... 66
8.10. Health Economics ....................................................................................................... 67
9. Statistical Considerations ......................................................................................... 68
9.1. Statistical Hypotheses .................................................................................................68
9.2. Sample Si ze Determinat ion......................................................................................... 68
9.3. Popul ations for Analyses ............................................................................................ 69
9.4. Statistical Analyses ..................................................................................................... 69
9.4.1. G eneral Considerations ............................................................................................... 69
9.4.2. Treatment Group Comparabilit y................................................................................. 70
9.4.3. Efficacy Analyses ....................................................................................................... 71
9.4.4. Safety Analyses .......................................................................................................... 72
9.4.5. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 73
9.4.6. Evaluat ion of Immunogenicit y.................................................................................... 73
9.4.7. Other Analyses ........................................................................................................... 74
9.5. Interim Analyses ......................................................................................................... 74
9.6. Data Monitoring Committee (DMC) ........................................................................... 74
10. Supporting Documentation and Operational Considerations ................................ 75
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 75
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 75
10.1.2. Inform edConsent Process .......................................................................................... 75
10.1.3. Data Protection ........................................................................................................... 76
10.1.4. Committees Structure .................................................................................................76
CONFIDENTIAL Protocol  number I8F -MC-GPHM
510.1.5. Disseminat ion of Clinical Study  Data ......................................................................... 76
10.1.6. Data Qualit y Assurance .............................................................................................. 77
10.1.7. Source Documents ...................................................................................................... 78
10.1.8. Study  and Si te Start and Cl osure ................................................................................. 78
10.1.9. Publicat ion Policy ....................................................................................................... 79
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 80
10.3. Appendix 3: Laboratory  Assessments for Hy persensit ivity 
Events ........................................................................................................................ 83
10.4. Appendix 4: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 85
10.4.1. Definit ion of AE......................................................................................................... 85
10.4.2. Definit ion of SAE ....................................................................................................... 86
10.4.3. Definit ion of Product Complaint ................................................................................. 87
10.4.4. Recording and Fo llow-Up of AE and/or SAE and Product 
Com plaint s................................................................................................................. 87
10.4.5. Reporting of SAEs ...................................................................................................... 89
10.4.6. Regulatory  Reporting Requirements ........................................................................... 90
10.5. Appendix 5: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 91
10.6. Appendix 6: Liver Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................... 95
10.7. Appendix 7: Protoc ol GPHM Standardi zed Protocol s for the 
Measurement of Height, Weight, Waist Circumference, Vital 
Signs and El ectrocardi ogram ...................................................................................... 97
10.8. Appendix 8: Suggested Visit Structure ........................................................................ 99
10.9. Appendix 9: Management of Gastrointestinal Symptoms .......................................... 100
10.10. Appendix 10: Provisio ns for Changes in Study  Conduct During 
Except ional Circumstances ....................................................................................... 101
10.11. Appendix 11: Abbreviat ions..................................................................................... 105
11. References ............................................................................................................... 110
CONFIDENTIAL Protocol  number I8F -MC-GPHM
61. Protocol Summary
1.1. Synopsis
Protocol Title: Efficacy and Safet y of Tirzepat ide Once Weekly versus Placebo After an 
Intensive Lifest yle Program in Participants without Ty pe 2 Di abetes who have Obesit y or are 
Overweight with Weight -Related Com orbidi ties:A Rando mized, Double -Blind, Pl acebo -
Controlled Trial (SURMOUNT -3) 
Short Title: Effect of Tirzepat ide versus Pl acebo after Intensive Li festyle Program
(SUMROUNT -3)
Rationale :
Obesit y is a chronic disease and its increasing prevalence is a public healt h concern associated 
with rising incidence of Type 2 di abetes m ellitus (T2DM), increased risk for premature death, 
and increased risk for some cancers ( American Medical Associat ion [AMA ]2013; Council on 
Science and Public Healt h 2013 ; Lauby -Secretan et al . 2016 ). The cornerstone of obesit y 
treatm ent is lifest yle-based therapy  combining reduced -calorie diet, physical act ivity,and 
behavioral counseling (NHLBI 2000; Jensen et al. 2014; Garvey et al . 2016 ).Evidence -based 
clinical approaches to cal oricrestri ction include moderate energy  deficits of 500 to 750 kcal/day 
based on calculat ion of an individual’s energy  needs ormore intensive low-calorie diets (LCDs) 
with gender -specific energy  intake target sof 1200 to 1800 kcal/day . Ad libi tum approaches
involving restri ction or eliminat ion of particular food swithout specific energy  targets mayalso 
beused (Jensen et al. 
2014; Garvey et al . 201 6). 
Lifestyle intervent ions lead to 5to 10% body weight loss,which has been shown to reduce
obesit y-related cardi ovascular ri sk factors , and in some cases improve healt h-related qualit y of 
life(Mertens and Van Gaal 2000; Kno wler et al . 2002; Jensen et al. 2014; Kolotkin and 
Andersen 2017) .However, diet-and exercise -induced weight loss is not m aintained in 80% of 
patients, in part due to metabo lic adaptations that promote regain in response to caloric deficits 
(Leibel et al. 1995 ;Sumit hran et al. 2011; Doucet et al . 2018 ). Moreover, greater weight losses 
can maximize metabo lic and healt h-related qualit y of life benefits and may be required to realize 
clinically meaningful improvements in other obesity -related com orbidi ties such as sleep apnea, 
nonalcoho lic steatohepatit is, and cardiovascular disease ( Garvey  et al . 2016; Ko lotkin and 
Anderson 2017 ; Ryan and Yockey 2017).
There i s widespread consensus that pharmacotherapy  for wei ght m anagement should only be 
used as an adjunct to lifest yle-based approaches (NHL BI 2000; Jensen et al. 201 4; Garvey et al .
2016) . There seems to be less clarit y, however, on when and in who m obesit y treatm ent shoul d 
be advanced fro m lifest yle-based monothera pyto lifest yle plus medicat ion combinat ion therapy . 
While so me guidelines reco mmend pharmacotherapy only after diet and exercise fail to achieve 
weight loss over 6 m onths(NHL BI 2000) , others add that it should also be considered if init ial 
weight loss is not m aintained over time ( Jensen et al. 201 4), and still others imply that even 
responders to diet and exercise may  benefit fro m additional weight loss wi th medicat ions
(Garvey et al. 2016).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
7The gut i ncretin hormones, glucose- dependent insulinotropic po lypept ide (GIP) and 
glucagon -like peptide -1 (GLP -1), are secreted after meal ingest ion and m ediate the incretin 
effect. Both hormones have effects on endocrine cells in t he pancreas, increasing insulin 
biosynt hesis and secret ion, and modifying glucagon secret ion (Skow et al. 2016). Based on these 
properties, several GLP -1 receptor (GLP -1R) agonists have been approved for pharmaco logical 
treatm ent of T2DM ( Tomlinson et al. 2016).
In addit ion to i ts pancreat ic effects, GLP -1R activation decreases gut motilit y, slows gastric 
emptying, and promotes satiet y (presum ably through a combinat ion of GLP -1R act ivation in the 
central  and peri pheral  nervous system s), thereby  regul ating food intake and body  weight(Baggi o 
and Drucker 2007) . The US Food and Drug Administration and the European Medicines Agency 
approved the GLP -1R agonist liraglut ide for the treatm ent of  overwei ght and obesit y 
(
SAXENDA® package insert, 2014; SAXENDA summary of product characterist ics, 2015).
Preclinical data indicate that GIP also exert seffects on appetite regulat ion and food intake, on 
adipose ti ssue, and on peri pheral  energy metabo lism. Although studies evaluat ing effects of GIP 
on body  weight have yielde d equivocal results, GIP receptor (GIPR) activation may  play a rol e 
in body  weight regul ation and targeting both the GLP
-1R and the GIPR simultaneously could 
potenti ally resul t in addit ive or synergistic effects of the 2 incret ins on body weight (Coskun et
al. 2018).
Tirzepati de is  
 It is 
administered once- weekly (QW) by subcutaneous (SC) inject ion.
As a dual  GIP/GLP -1R agoni st, tirzepat ide could exceed the efficacy o f select ive GLP -1R
agonists by recruit ing metabo lically active tissues not targeted by select ive GLP -1R agonists (for 
example, adipose tissue as indicated by the observation o f increased energy ut ilizat ion) (M
üller 
et al. 2018) and has the potential to reach higher efficacy in target tissues that express both GIPR 
and GLP -
1R. T herefore, tirzepat ide has the potential to impact several aspects of energy 
regul ation and to be a tre atment of overwei ght and obesit y. 
In a 26 -week Phase 2 study in pat ients with T2DM, ti rzepat ide 10 mg and 15 mg doses produced 
statist ically significant and clinically relevant weight loss co mpared to placebo and compared to 
the GLP -1 Ragonist, dulaglut ide. Tirzepat ide is subsequent ly being evaluated in Phase 3 studies 
in patients with obesit y for its effects on wei ght lossas an adjunct to a 500 kcal/day defici t diet 
and increased physical act ivity.There i s a need to better understand the benefits of tirzepati de 
after a m ore intensive lifest yle program, especially as current recommendat ions vary with 
regards to when to prescribe pharmacotherapy  to diet and exercise responder s and goals of 
treatm ent in such pat ients may range from  prom oting maintenance to augment ingthe init ial 
response .
Study  18F-MC-GPHM (GPHM; SURMOUNT -3) is a Phase 3, mult icenter, randomized, 
parallel- arm, doubl e-blind, placebo -controlled, 84-week study  that will invest igate the effects of 
treatm ent wi thmaximum tolerated dose (MTD) o ftirzepat ide (10 m g or15mg QW ),compared 
with placebo , on body  weight m anagement in study  parti cipants who do not hav e T2DM and 
have o besity (body  mass index [ BMI ]≥30 kg/m2) or are overwei ght (BMI ≥27kg/m2) with at 
least 1weight -related comorbid condit ionand achieved ≥
5.0% wei ght loss after a 12-week lead -
in peri od wi th an intensive lifest yle modificat ion program
.
CCI
CONFIDENTIAL Protocol  number I8F -MC-GPHM
8Objectives and Endpoint s
Objectives Endpoints
Primary
To demonstrate that tirzepatide MTD is superior to 
placebo from randomization for the following 
(measured at 72 weeks ):
Percent change in body weight AND 
Proportio n of participants with ≥5% body 
weight reduction Mean percent change in body weight
Percentage of study participants who achieve 
≥5% body weight reduction 
Key Secondary (controlled for type I error)
To demonstrate that tirzepatide MTD is superior to 
placebo from randomization for the following 
(measured at 72 weeks): 
Maintaining body weight reduction achieved 
during the 12-week lead- in periodPercentage of study  participants who maintain 
≥80% of the body weight lost during the 
12-week lead- in period 
Body weight Percentage of study participants who achieve:
o≥10% body weight redu ction 
o≥15% body weight reduction 
Waist circumference Mean change in waist circumference (cm)
Additional Secondary
To demonstrate that tirzepatide MTD is superior to 
placebo from randomization for the following 
(measured at 72 weeks): 
Body weight and BMI Mean change in body weight (kg) 
Mean change in BMI (kg/m2)
Blood pressure Mean change in
osystolic blood pressure (mmHg) 
odiastolic blood pressure (mmHg)
Lipid parameters Mean change in: 
oTotal cholesterol (mg/dL)
oHDL -cholesterol (mg/dL)
oLDL -cholesterol (mg/dL)
oVLDL -cholesterol (mg/dL)
oTriglycerides (mg/dL)
oFree fatty acids (mg/dL)
CONFIDENTIAL Protocol  number I8F -MC-GPHM
9Objectives Endpoints
Glycemic control Mean change in 
ofasting glucose (mg/dL)
oHbA1c (%)
Insulin Mean change in fasting insulin (pmol/L)
Patient- reported outcomesMean change in 
oSF-36v2 acute form Physical 
Functioning domain score 
oIWQOL -Lite-CT Phy sical Function 
composite score
To demonstrate that tirzepatide MTD is superior to 
placebo from Visit 2 for the following (measured at 
72weeks):
Body weight and BMI
Waist circumferenceMean change in absolute body weight (kg)
Mean percent change in body weight
Mean change in BMI (kg/m2)
Mean change in waist circumference (cm)
Abbreviations: BMI = body mass index ;HbA1c = hemoglobin A1c ;HDL =high-density lipoprotein ;
IWQOL -Lite-CT =Impact of Weight on Quality of Life -Lite Clinical Trials Version; LDL =low-density  
lipoprotein ;MTD =maximum tolerated dose; SF-36v2 acute form =Short Form -36 V ersion 2 Health Survey 
acute form ; VLDL =very low -densi ty lipoprotein.
Overall Design
Study  GPHM i s a Phase 3, m ulticenter, randomized, parallel -arm, doubl e-blind, 
placebo -controlled, 84-week study  that will invest igate the effects of treatment wit h tirzepat ide 
MTD (10 m g or15mg QW ),compared wi th placebo ,on body weight management in study  
participants who have o besity (BMI ≥30 kg/m2) or are overwei ght (BMI ≥27kg/m2) with at least 
1 weight-related comorbid condit ionand achieved ≥5.0% wei ght loss after a 12-week lead -in 
period wi th an intensive lifest yle modificat ion program .
Randomization at the end of the 12 -week l ead-in peri od will be stratified by country , sex, and 
percent weight loss at the end of lead
-in (<10% versus ≥10%). 
Disclosure Statement :This is a study  including 2parallel treatment arms (tirzepat ide MTD 
versus placebo) that is participant -and invest igator -blinded .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
10Number of Participant s:
Approximately  1100participants will be screened and 800 participants enrolled into the 12 -week 
intensive lifest yle modificat ion lead-in period in orde r to get approximately 600 parti cipants who 
will be rando mized in a 1:1 ratio to tirzepat ideMTD (300 participants) or placebo (300 
participants) .An upper limit of 70% enro llment of women will be used to ensure a sufficiently 
large sample of men.
Intervention Groups and Duration :
Study  parti cipants will be randomized in a 1:1 ratio (tirzepat ide MTD QW and placebo QW), 
stratified by country , sexand percent weight loss at the end of lead -in period (<10% versus 
≥10%) .
Study  GPHM will consist of 4 per iods: a 2 -week screening period ;
a 12- week lead-in period 
during which participants undertake an intensive lifest yle modificat ion program  to achi eve 
≥5.0% body  weight l oss;a 72-week double -blind placebo -controlled dose escalation and 
treatm ent peri od;anda 4-week safet y follow
-up peri od.  
Data Monitoring Committee: No
CONFIDENTIAL Protocol  number I8F -MC-GPHM
111.2. Schema
Abbreviations : MTD = maximum tolerated dose, QW =once weekly, (T) =telephone visit.

CONFIDENTIAL Protocol  number I8F -MC-GPHM
121.3. Schedule of Activities (SoA)
The Schedule o f Activities described below should be fo llowed for all pa rticipant s enrolled in Study  GPH M. However, for those 
participants whose participat ion in this study  is affected by  except ionalcircumstances (such as pandemics or natural disas ters), pl ease 
refer to Section 10.10 (Appendix 10)for addi tional gui dance.
Visit 12345678910111213141516171819202122232425262728 99 ED 801
Week of Treatment -14-12-11-10-9-8-6-4-2 04812162024283236404448525660646872 724 wks 
Post 
TxP
Allowable Deviation (days) ±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±7 ±7 ±3
Fasting Visit XX X X X XXXXXXX X X X X X X X
Telephone Visit X X X X XX XX XX XX
Lifestyle Program Instruction only X X X X
Informed consent X
Inclusion and exclusion criteria 
reviewX X
Pree xisting conditions and medical
history, including relevant surgical 
historyX
Medical history includes assessment ofpreexisting conditions (for example, history ofgallbladder disease, cardiovascular 
disease, and medullary thyroid carcinoma) and substance usage (such as alcohol and tobacco).
Concomitant medications X X X X X X X X X X X X XX X XX X XX X XX X X X X
Adve rse events and product 
complaintsX X X X X X X X X X X X XX X XX X XX X XX X X X X
Phys ical Evaluation or Clinical Assessments
Height X
WeightX X X X X X X X X X X X X X X X X X X
Weight measurements should be obtained per the detailed protocol guidance in Section 10.7 . Body weight must be measured 
in the fasting state. If the participant is not fasting, the participant should be called in for a new visit within the visit window to 
have the fasting body weig ht measured.
Waist circumference X X X X X X X X X X X X X X X X X X
Vital Signs (systolic and diastolic 
blood pressure, pulse rate)X X X X X X X X X X X X X X X X X X
Vital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for 
laboratory testing, per the instruction sin Section 10.7 .
Physical examination X
Electrocardiogram X X X X X X
CONFIDENTIAL Protocol  number I8F -MC-GPHM
13Visit 12345678910111213141516171819202122232425262728 99 ED 801
Week of Treatment -14-12-11-10-9-8-6-4-2 04812162024283236404448525660646872 724 wks 
Post 
TxP
Allowable Deviation (days) ±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±7 ±7 ±3
Fasting Visit XX X X X XXXXXXX X X X X X X X
Telephone Visit X X X X XX XX XX XX
Lifestyle Program Instruction only X X X X
ECG measurements should be obtained per the instructions in Section 10.7 .ECGs should be collected at least 30 minutes prior 
to collection of blood samples for laboratory testing .
Participant Education and Assessment
Lifestyle Program InstructionXX X X X X X XX X X X X X X X
Counselling on diet and exercise, to be performed by a dietician or equivalent qualified delegate, to include calculation of 
individualized energy requirement and behavior modification strategies to change dietary composition and amount of physical 
activity (See Section 5.3for details) . The Lifestyle Program Instruction may be delivered on a separate day from the rest of that 
visit’s study procedures but must occur within the visit window. After Week 0 (Visit 10, randomization), the remaining Lifestyle 
Program Instruction may be deliver ed by phone.
Review diet and exercise 
goalsXXXXXXXXX X X X X X X XX X XX X XX X XX X X
All training should be repeated as needed to encourage participant compliance. Study personnel to provide reinforcement and 
encouragement for lifestyle modifications.  
Injection training with 
autoinjector demonstration 
deviceX
Participant Diary (paper)
Dispense diary, instruct in useX X X X X X X X X X
All training should be repeated as needed to encourage participant compliance.
Diary review X X X X X X XX X XX X XX X XX X X
Patient Reported Outcomes
PGIsX X X X
SF-36 v2, acute formX X X X
IWQO L-Lite-CT X X X X
CONFIDENTIAL Protocol  number I8F -MC-GPHM
14Visit 12345678910111213141516171819202122232425262728 99 ED 801
Week of Treatment -14-12-11-10-9-8-6-4-2 04812162024283236404448525660646872 724 wks 
Post 
TxP
Allowable Deviation (days) ±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±7 ±7 ±3
Fasting Visit XX X X X XXXXXXX X X X X X X X
Telephone Visit X X X X XX XX XX XX
Lifestyle Program Instruction only X X X X
EQ-5D-5LX X X X
Ment al Health Qu estionnaires
PHQ -9X X X X X X X X X X X
The PHQ -9 is self -administered and should be completed after assessment of adverse events.
C-SSRS (Baseline/Screening 
Version)X
The C -SSRS should be administered after assessment of adverse events. For this study, the C -SSRS is a dapted for the 
assessment of the ideation and behavior categories only. The Intensity of Ideation and Lethality of Behavior sections are 
removed.
C-SSRS (Since Last Visit Version)X X X X X X X X X X X XX X XX X XX X XX X X X X
The C -SSRS should be administered after assessment of adverse events and capture information since most recent C -SSRS 
administration . For this study, the C -SSRS is a dapted for the assessment of the ideation and behavior categori es only. The 
Intensity of Ideation and Lethality of Behavior sections are removed.
Self-Harm Supplement FormX X X X X X X X X X X X XX X XX X XX X XX X X X X
The Self -Harm Supplement Form should be administered after assessment of adverse events.
Self-Harm Follow -up FormX X X X X X X X X X X X XX X XX X XX X XX X X X X
The Self-Harm Follow -up Form is only required if triggered by the Self -Harm Supplement Form, per instructions in the form.
Laboratory Tests and Sample Collections
Hematology X X X X X X X
HbA1c X X X X X X X X X X
CONFIDENTIAL Protocol  number I8F -MC-GPHM
15Visit 12345678910111213141516171819202122232425262728 99 ED 801
Week of Treatment -14-12-11-10-9-8-6-4-2 04812162024283236404448525660646872 724 wks 
Post 
TxP
Allowable Deviation (days) ±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±7 ±7 ±3
Fasting Visit XX X X X XXXXXXX X X X X X X X
Telephone Visit X X X X XX XX XX XX
Lifestyle Program Instruction only X X X X
Chem istry panel (includes Cr 
for eGFR calculation and 
glucose)X X X X X X X X X X
The CKD -EPI equation will be used by the central lab to estimate and report eGFR.
Insulin X X X X X X X X X X
C-peptide X X X X X X X X X X
Lipid panel X X X X X X
Free fatty acids X X X X X X
Serum pregnancy X X
For women of childbearing potential only .
Urine pregnancy (local)X X X X X X X X
A urine pregnancy test must be performed at Visit 10 with the result available prior to first injection of study drug(s) for 
women of childbearing potential only. Additional pregnancy tests (beyond those required by the S oA) should be performed at 
any time during the trial if a menstrual period is missed, there is clinical suspicion of pregnancy, or as required by local lawor 
regulation.
Follicle -stimulating hormone 
test X
Follicle -stimulating hormone test is to be performed at Visit 1 for postmenopausal women at least 40 years of age with an 
intact uterus, not on hormone therapy, and who have had spontaneous amenorrhea for more than 1 year without an 
alternative medical cause.  
Calcitonin X X X X X X X
Pancreatic amylase X X X X X X X
Lipase X X X X X X X
Urinary albumin/creatinine 
ratioX X X X X X
Cystatin -c X X X X X X
CONFIDENTIAL Protocol  number I8F -MC-GPHM
16Visit 12345678910111213141516171819202122232425262728 99 ED 801
Week of Treatment -14-12-11-10-9-8-6-4-2 04812162024283236404448525660646872 724 wks 
Post 
TxP
Allowable Deviation (days) ±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±3±7 ±7 ±3
Fasting Visit XX X X X XXXXXXX X X X X X X X
Telephone Visit X X X X XX XX XX XX
Lifestyle Program Instruction only X X X X
Thyroid stimulating hormoneX
Immunogenicity (includes PK 
sample)X X X X X X X X
In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional unscheduled samples should 
be collected as detailed in Section 8.3.2.7 (Hypersensitivity Reactions). Immunogenicity samples and PK samples for 
immunogenicity must be taken prior to drug administration.
Stored Samples
Pharmacogenetic sample X
Nonpharmacogenetic sample X X X X X X X X
Randomization and Dosing
Randomization X
Dispense study intervention(s) X X X X X X X X X X
Observe participant administer 
study drug interventionX
Participants should administer their first dose of study drug at the end of Visit 10, after other study procedures are completed.
Participant returns study drug 
intervention and injection suppliesX X X X X X X X X X X
Assess study intervention(s) 
complianceX X X X X X XX X XX X XX X XX X X
CONFIDENTIAL Protocol  number I8F -MC-GPHM
17Abbreviations: CKD -EPI = Chronic Kidney Disease -Epidemiology; C-SSRS =Columbia Suicide Severity Rating Scale ;Cr= creatinine; ED = early 
discontinuation; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; IWQOL -Lite-CT = Impact of Weigh t on Quality  of Life -Lite-
Clinical Trials Version; PGIs = Patient Global Impression of status for physical activity ; PHQ -9 = Patient Health Questionnaire -9; PK = pharmacokinetics ; 
SF-36v2 acute form = Sho rt Form -36 Versio n 2 Health Survey acute form; SoA = schedule of activities; TxP = treatment period ; wks = weeks .
Note:
The visit date is determined in relation to the date of Visit 2 for the lead-in period and Visit 10 (randomization) for the treatment period.
For all office visits, remind participants to report to the site in a fasting condition, after a period of approximately 8 hours without eating, drinking 
(except water), or any significant physical activity Since some screening procedures need to be completed in the fasting stat e, Visit 1 may be condu cted 
over more than 1 day to ensure necessary conditions are met . Eligible participants enter a lifestyle modification lead-in period, during which they 
receive instruction in an intensive dietary  (1200 kcal/day for women or 1500 kcal/day for men) and exer cise program to achieve a ≥5.0% body weight 
loss. 
On Lifestyle Program Instruction Only Visits, all spontaneous lyreported adverse events by participant will be documented by the investigator and any 
qualified designee. 
Visit 10assessments must be compl eted before processing in the interactive web -response system (IWRS).
Visit 99 is only applicable to participants who discontinue the double -blind study  treatment prematurely (after Week 0 and before Week 72) and decline 
to complete the remaining scheduled study visits. Participants wanting to discontinue the study treatment after randomization and before Week 72 will 
be asked to return for Visit 99 ( 72weeks ±7 days after Visit 10) primarily for body weight measurement and assessment of adverse events. If the 
participant is unwilling to attend Visit 99, it should be documented in the participant medical record that the participant h as refused to attend. 
Participants who are unable or unwilling to continue th e study intensive lifesty le intervention (during lead -in period) or study drug intervention (during 
treatmen tperiod) for any reason will perform an ED visit. If the participant is discontinuing during an unscheduled visit or a scheduled visit , that visit 
should be performed as an ED visit. 
Visit 801 (safety follow -
up visit) should be performed 4 weeks after the last visit of the participant ’s treatment period (after randomization, see 
Section 4.1.1.2.3 )
CONFIDENTIAL Protocol  number I8F -MC-GPHM
182. Introduction
Obesit y is a chronic disease and its increasing prevalence is a public healt h concern associated 
with rising incidence of t ype 2 diabetes mellitus (T2DM), increased risk for premature death, and 
increased risk for some cancers ( American Medical Association [ AMA ]2013; Council on 
Science and Public Healt h 2013 ; Lauby -Secretan et al . 2016 ). The cornerst one of obesit y 
treatm ent is lifest yle-based therapy  combining reduced -calorie diet, physical act ivity and 
behavioral counseling (NHL BI 2000; Jensen et al. 2014; Garvey et al . 2016). Evidence -based 
clinical approaches to cal oricrestri ction include moderate energy deficits of 500 to 750 kcal/day 
based on calculat ion of an individual’s energy  needs or m ore intensive l ow-calorie diets (LCDs) 
with gender -specific energy  intake target s of 1 200 to 1 800 kcal/day. A d libi tum approaches
involving restri ction or elim ination of particular food swithout specific energy  targets m ay also 
be used ( Jensen et al. 
2014; Garv ey et al .2016). 
These lifest yle intervent ions lead to 5to 10% body weight loss that has been shown to reduce
obesit y-related cardi ovascular ri sk factors , and in some cases improve healt h-related qualit y of 
life(Mertens and Van Gaal 2000; Knowler et al. 2002; Jensen et al. 2014; Kolotkin and 
Andersen 2017) . However, diet -and exercise -induced weight loss is not maintained in 80% of 
patients, in par t due to m etabolic adaptations that promote regain in response tocaloric deficits 
(Leibel et al. 1995 ;Sumit hran et al. 2011 ; Doucet et al . 2018 ).Adjunctive therapies, including 
medicat ions, devices, and surgical treatments, for obesit y are evol ving as a re the clinical 
guidelines for the application o f these therapies in the clinical management of patients with 
obesit y.
2.1. Study Rationale
The gut i ncretin hormones, glucose- dependent insulinotropic po lypept ide (GIP) and 
glucagon -like peptide -1 (GLP -1), are se creted after meal ingest ion and m ediate the incretin 
effect.  
Both hormones have effects on endocrine cells in the pancreas, increasing insulin biosynt hesis 
and secretion, stimulat ing beta-cell neogenesis and proliferation, and protecting beta cells fro m 
apoptosis. They  also exert acti ons on al pha cells, modifying glucagon secret ion (Skow et al. 
2016). Based on these properties, several GLP -1 receptor (GLP -1R) agonists have been approved 
for pharmaco logical treatm ent of  T2DM ( Tomlinson et al. 2016).
In addition to i ts pancreat ic effects, GLP -1R activation decreases gut motilit y, slows gastric 
emptying, and promotes satiet y (presum ably through a combinat ion of GLP -1R act ivation in the 
central  and peri pheral  nervous system s), thereby  regul ating food intake and body  weight(Baggi o 
and Drucker 2007) . The US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) approved the GLP -1R agoni st liraglutide for the treatm ent of overweight and 
obesit y (
SAXENDA package insert, 2014; SAXENDA summary of product characteri stics, 
2015).
Preclinical data indicate that GIP also exert seffects on appetite regulat ion and food intake as 
well as on adi pose tissue and peri pheral energy  metabolism. Alt hough studi es evaluat ing effects 
of GIP on body  weight have yielded equivocal results, GIP receptor (GIPR) activation may play 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
19a role in body  weight regul ation and targeting both the GLP -1R and the GIPR simultaneously 
could potentially result in addit ive or synergist ic effects of the 2 incret ins on body weight 
(Cos kun et al. 2018).
Tirzepati de is  
 
 It is administered once- weekly (QW ) by subcutaneous (SC) inject ion.As a 
dual GIP/GLP -1R agoni st, tirzepat idecould exceed the efficacy of selective GLP- 1R agoni sts by 
recrui ting metabo lically active tissues not targeted by select ive GLP -1R agoni sts (for example, 
adipose ti ssue as indicated by the observat ion of increased energy ut ilizat ion) (Mülleret al.
2018) and has the potential to reach higher efficacy in target tissues that express both GIPR and 
GLP -1R. Therefore, tirzepat ide has the potential to impact several aspects of ene rgy regulati on 
and be a treatment for overweight and obesit y.  
There i s widespread consensus that pharmacotherapy  for wei ght m anagement should only be 
used as an adjunct to lifest yle-based approaches (NHL BI 2000; Jensen et al. 
2014; Garvey et al .
2016) . There seems to be less clarit y, however, on when and in who m obesit y treatm ent shoul d 
be advanced fro m lifest yle-based monothera pyto lifest yle plus medicat ion combinat ion therapy . 
While so me guidelines reco mmend pharmacotherapy only after diet and exercise fail to achieve 
weight loss over 6 m onths (NHL BI 2000) , others add that it should also be considered if init ial 
weight loss is not m aintained over time (Jensen et al. 2014) , and still others imply that even 
responders to diet and exercise may benefit fro madditional weight loss wi th medicat ions
(Garvey et al. 2016). There is a need to better understand the benefits o f tirzepat ide after init ial 
success with lifest yle-induced weight loss, especially as current recommendations vary  and goals 
of treatm ent in s uch pat ients may range from  promoting m aintenance to augm enting weight loss.  
Study  18F-MC-GPHM i s a Phase 3, m ulticenter, randomized, parallel -arm, double -blind, 
placebo -controlled, 84-week study  that will invest igate the effects of treatment with maximu m 
tolerated dose ( MTD ) oftirzepati de (10 m g or15mg QW ), compared wi th placebo ,on body  
weight management in study  parti cipants who have obesit y (body  mass index [ BMI ]≥30 kg/m2) 
or are overweight (BMI ≥27kg/m2) with at least one weight -related comorbid condi tionand 
achieved ≥
5.0% wei ght loss after a 12-week lead -in period with an intensive lifest yle 
modificati on program .
2.2. Background
There rem ains an unmet need in the pharmaco logic treatment of obesit y for drugs that are safe, 
efficacious ,and well tolerated. There are currently only a fe
wmedicat ions FDA -approved for 
long-term use for the treatm ent of obesit ythat yield a placebo -adjusted average weight loss
between 3% and 7% (Srivastava and Apovian 2018 ;FDA 2020 ). Although moderate wei ght loss 
of 5% to 10% in individuals wit h obesit y/overweight has long been shown to yield significant 
metabo lic benefits including improvements in cho lesterol, blood pressure, and glucose 
param eters (Gol dstein 1992; Wing et al. 2011 ), greater weight loss can maximize these benefits 
and may berequi red to realize clinically meaningful improvements in other obesit y-related 
comorbidi ties such as sleep apnea, non -alcoho lic steatohepatit is, and cardiovascular disease 
(Ryan and Yockey 2017). In addit ion to m oderate efficac y, som e centrally -acting weight -loss 
agents to date have had adverse neurocognit ive, psychiatric or cardiovascular effects, further 
limit ing their applicat ion in clinical practice (Srivastava and Apovian 2018). 
CCI
CONFIDENTIAL Protocol  number I8F -MC-GPHM
20Weight l oss induced by  GLP -1Ragonists , while appear ingto be centrally -mediated through a 
combinat ion of hormonal inputs to satiet y centers (van Bloemendaal et al. 2014), has not been 
consistent ly associated with changes in mental  healt h or with potential for addict ion in long-term 
studies conducted to establish cardiovascular safety  in pat ients with diabetes (Marso et al. 2016a,
2016b, Gerstein et al. 2019) . Tirzepat ide, which isboth a GLP -1Rand GIP Ragonist , has been 
associ ated wi th predominant ly mild to m oderate gastrointestinal (GI) adverse effects similar to 
currently marketed GLP -
1Ragonists , but has also dem onstrated significant wei ght loss at both 
the 10-mgand 15 -mg doses in Phase 2 studies with nearly half o f the parti cipants in each dose 
arm achieving >10% wei ght loss (Frias et al . 2018).
Tirzepati de dose sel ection for obesit y treatm ent has been informed by  3clinical tri als:a Phase 1 
study , Study I8F-MC-GPGA (GPGA), and 2Phase 2 studi es, Study  I8F-MC-GPGB (GPGB) and 
I8F-MC-GPGF (GPGF).  
Phase 1 Study  GPGA was a combinat ion of single -ascending dose (SAD) and mult iple-
ascending dose (MAD) study  in healthy subjects followed by a mul tiple-dose study in patients 
with T2DM . A total  of 142 participant s (89 healthy subjects and 53 patients wi th T2DM) 
received at least 1 dose of treatment. Doses of tirzepatide ranged from:
0.25 m g to 8 mg in the SAD (with maximum tol erated dose [ MTD] achieved at 5 mg) in 
healt hy subjects ,
multiple doses in the MAD from 0.5mg to 4.5 mg QW and ti trated doses up to 10 mg 
QW for 4 weeks in healt hy subjects , and 
multiple doses at 0.5 mg and 5 mg QW and titrated to 15 mg QW for 4 weeks in pat ients 
with T2DM.  
Thesafet y and tol erabilit y and pharmacokinet ic/pharm acodynamic (PK/PD )profiles of 
tirzepat ide at doses and escalat ionregimens administered in this Phase 1 study  supported further 
development of tirzepat ide for QW dosing in pat ients with T2DM .
Phas e 2 studi es GPGB and GPGF provided init ial safet y, tolerabili ty and efficacy  data in the 
tirzepat ide 1 -mgto 15 -mg dose -range when used in treatment of patients with T2DM. In the dose 
range of 5 mgto 15 m g, tirzepat ide provided significant ly greater reduc tions in hemoglo bin A1c
(HbA1c) and body  weight com pared wi th placebo. In addition, the 10 -mg and 15 -mg dose arms 
demonstrated si gnificant ly greater weight loss compared to the GLP -1Ragonist, dulaglut ide 1.5 
mg QW. The m ost comm on adverse events ( AEs), which were also dose -dependent, were mild-
to-moderate nausea, vo miting, and diarrhea. Study  GPGF showed that adjustments in the 
tirzepat ide dose -escalat ion al gorithm resul ted in addi tional reduct ions in the frequency  of GI AEs 
and reduced the frequency  of treatm ent di scont inuations due to GI AEs. 
2.3. Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and risks and reasonably  
expected AEs of tirzepat idemay be found in the Investi gator’s Brochure (IB).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
213. Objectives and Endpoints
Objectives Endpoints
Primary
To demonstrate that tirzepatide MTD is superior to 
placebo from randomization for the following 
(measured at 72 weeks) 
Percent change in body weight AND 
Proportio n of participants with ≥5% body 
weight reduction Mean percent change in body weight
Percentage of study participants who achieve 
≥5% body weight reduction 
Key Secondary (controlled for type I error)
To demonstrate that tirzepatide MTD is superior to 
placebo from randomization for the following 
(measured at 72 weeks): 
Maintaining body weight reduction achieved 
during the 12 -week lead -in periodPercentage of study  participants who maintain 
≥80% of the body weight lost during the 
12-week lead - in period 
Body weight Percentage of study participants who achieve:
o≥10% body weight reduction 
o≥15% body weight reduction 
Waist circumference Mean change in waist circumference (cm)
Additional Secondary
To demonstrate that tirzepatide MTD is superior to 
placebo from randomization for the following 
(measured at 72 weeks): 
Body weight and BMI Mean change in body weight (kg) 
Mean change in BMI (kg/m2)
Blood pressure Mean change in 
osystolic blood pressure (mmHg) 
odiastolic blood pressure (mmHg)
Lipid parameters Mean change in: 
oTotal cholesterol (mg/dL)
oHDL -cholesterol (mg/dL)
oLDL -cholesterol (mg/dL)
oVLDL -cholesterol (mg/dL)
oTriglycerides (mg/dL)
CONFIDENTIAL Protocol  number I8F -MC-GPHM
22Objectives Endpoints
oFree fatty acids (mg/dL)
Glycemic control Mean change in
ofasting glucose (mg/dL)
oHbA1c (%)
Insulin Mean change in fasting insulin (pmol/L)
Patient- reported outcomesMean change in 
oSF-36v2 acute form Physical 
Functioning domain score 
oIWQOL -Lite-CT Phy sical Function 
composite score
To demonstrate that tirzepatide MTD is superior to 
placebo from Visit 2 for the following (measured at 
72weeks):
Body weight and BMI
Waist circumferenceMean change in absolute body weight (kg)
Mean percent change in body weight
Mean change in BMI (kg/m2)
Mean change in waist circumference (cm)
Abbreviations: BMI = body mass index; HbA1c = hemoglobin A1c ; HDL =high-density lipoprotein ;
IWQOL -Lite-CT =Impact of Weight on Quality of Life -Lite Clinical Trials Version; LDL =low-densit y 
lipoprotein, MTD = maximum tolerated dose; SF-36v2 acute form =Short Form -36 V ersion 2 Health Survey 
acute form ; VLDL =very low -density  lipoprotein.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
234. Study Design
4.1. Overall Design
Study  18F-MC-GPHM i s a Phase 3, m ulticenter, randomized, parallel -arm, double -blind 
placebo -controlled, 84-week study  that will invest igate the effects of treatment with MTD of
tirzepat ide (10 m g or15 m g QW ),compared wi th placebo ,on body  weight m anagement in study  
participants who have o besity (BMI ≥30 kg/m2) or are overwe ight (BMI ≥27kg/m2) with at least 
one weight
-related comorbid condit ionand achieved ≥5.0% wei ght loss after a 12-week lead -in 
period wi th an intensive lifest yle modificat ion program .
Study  GPHM will consist of 4 periods: a 2
-week screening period ;a 12-week lead-inperiod 
during which participants undertake an intensive lifest yle modificat ion program  to achi eve 
≥5.0% body  weight l oss;a 72-week double -blind placebo -controlled treatm ent peri od(including 
a 20-week dose escalation period); and a 4 -week safet y follow
-up peri od. Study part icipants who 
achieve at l east 5 .0% wei ght losswill be rando mized in a 1:1 ratio (tirzepat ide MTD QW or
placebo) at the end of the lead -in peri od. An upper limit of 70% enrollment of women will be 
used to ensure a suffici ently large sample o f men.
4.1.1. Overview of Study Periods
4.1.1.1. Visit Structure for all Office Visits
On all designated fasting o ffice visits, study  parti cipants are required to report to the site in a 
fasting condit ion, after a period of approximately 8 hours without eating, drinking (except 
water), or performing any significant physical act ivity.If a parti cipant is adversely  affected by  
the fast ing condit ion, they  are all owed to eat; however, specific study  procedures need to be 
completed while fasting. See Secti on 10.8 for a suggested order of activit ies that occurs at o ffice 
visits. 
4.1.1.2. Main Study Period 
4.1.1.2.1. Screening Period
Visit 1
The purpose of screening procedures at Visit 1 is to establish init ial eligibilit y, and to ob tain 
blood sam ples for l aboratory  assessments needed to confirm eligibilit y. The participant must sign 
the informed consent form (ICF) before the study  procedures are performed, as outlined in the 
SoA, Secti on1.3.Since so mescreening procedures need to be completed in the fast ing state 
(approximately 8 hours without eating, drinking [except water], or any  significant physical 
activit y), Vi sit 1 m ay be conducted over m ore than 1 day  to ensure necessary  condi tions are m et. 
Parti cipants who m eet all  applicable inclusion criteria and none of the applicable exclusio n 
criteria at Vi sit 1 will  cont inue to Visit 2. 
The Mental  Health questi onnai res (Pati ent Heal th Quest ionnaire -9 [PHQ -9], Columbia -Suicide 
Severit y Rating Scale [
C-SSRS ], and C-SSRS Self-Harm F orm) shoul d be co mpleted after the 
assessment for AEs.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
24Visit 2
At Visit 2, the screening laboratory  resul ts will  be reviewed . For all participants who remain 
eligible, lifest yle program instruction will be provided by a dietician, or equivalent qualified 
delegate, for an intensive dietary  and exercise program.  
Patient-reported outcomes (PROs) quest ionnaires should be administered as early as possible, as 
per Suggested Visit Structure (Section 10.8). Preferred administration order is:  
1.Patient Gl obal Impressi on of status for phy sical activi ty(PGI s)
2.Short Form -36 versi on 2 Health Survey  (SF-36v2) acute form 
3.Impact of Weight on Qualit y of Life -Lite-Clinical Trials Version (IWQOL -Lite-CT)
4.EQ-5D-5L.   
The Mental  Health questi onnai res shoul d be co mpleted after the assessment for AEs .
4.1.1.2.2. Intensive Lifestyle Modification Lead -inPeriod
During the intensive lifest yle modification lead-in period(Visits 2-10), participants will receive 
instructi on from a dietician, or equivalent qualified delegate, according to local standards, to 
reduce thei r daily  caloric energy  intake to approximately
1200 kcal /day for wom en,or 
1500 kcal /day for m en 
for a peri od 
of 12 weeks (H eymsfield et al. 2003) . The di etary  intervent ion may include up to 
2meal replacements per day .Participants will be encouraged to exercise on a regular basis, with 
a recommendat ion of at least 150 minutes per week of moderate intensi ty activity(for example, 
brisk walking). Participants will be counselled on behavio rmodificat ion strategies to hel p 
implement and adhere to the diet and exercise recommendat ions. For m ore details see 
Secti ons5.3.1 and 5.3.2 .
Parti cipants who have >5.0% wei ght loss at Visi t 10willthen proceed to randomizat ion to ei ther 
tirzepat ide or placebo.
Mental  Health quest ionnaires should be co mpleted after the assessment of AEs.   
4.1.1.2.3. Treatment Period
Visit 10
(Randomization )
At Visit 10,eligible participants will perform all required rando mizat ion study  procedures 
(including the co llection of all laboratory measures and quest ionnaires) prior to randomizat ion 
and prior to taking the first dose of study  drug. Only participants who have achieved >
5.0% 
weight loss at Visit 10 will be rando mized and continue in the study . 
Parti cipants will be provi ded diari es and be trained to record key  study  informat ion, as 
appropriate. 
PRO questionnaires should be administered as early as possible, as per Suggested Visit Structure 
(Secti on 10.8).Preferred administration order is:  
1.PGIs
CONFIDENTIAL Protocol  number I8F -MC-GPHM
252. SF- 36 v2 acute form
3.IWQOL -Lite-CT
4.EQ-5D-5L.
Mental  Health quest ionnaires should be co mpleted after the assessment ofAEs.  
Parti cipants will receive consultat ion with a dietician or qualified delegate, according to local 
standards, to set lifest yle goals for caloric intake and physical activity (Sect ion5.3)during the 
treatm ent peri od.
Following rando mizat ion, study  site personnel  will demonstrate use of the autoinjector (also 
referred to as single -dose pen) using the provided demonstration device and observe the study  
participant inject the first dose of tirzepatide or placebo. The date ,time and locat ionof the fi rst 
dose of study  drug willbe recorded on the electronic case report form (eCRF) . Beginning at 
rando mizat ion, all part icipants will receive study  drug according to the randomized treatment 
arm for the durati on of  the 72 -week dose escalat ionand treatm ent peri od.  
End of Visit 10to Visit 2 8
During the treatment period, office visits will occur as indicated in the S oA (Section 1.3).  
Telephone visits will occur at 4- week intervals between the office visits starting at Visit 17.  
Office visit procedures should be conducted according to the 
SoA(Section 1.3), andwill include
weight,waist circumference and vital signs measurements 
laboratory  testing 
administration of PRO quest ionnaires
collect ion of AE s, product complaints and conco mitant m edicati ons  
Mental Heal th quest ionnaires
review of participant diary inform ation (to include reinforcement and co mpliance 
assessments for study  drug administrati on and lifestyle goals)
drug di spensing.
Patient-reported outcomes quest ionnaires should be administered as early as possible, as per 
Suggested Visit Structu
re (Section 10.8).Preferred administration order is the same as Visit 2. 
Mental Heal th quest ionnaires should be co mpleted after the assessment of AEs.  
Dietician consultat ions occur every  12 weeks from Week 0to Week 72. Study  drug and injection 
supplies will be returned per the S oA(Sectio n1.3) and according to local requirements. New 
supplies will be dispensed as needed.
The starting dose of tirzepat ide is 2.5 mg QW (or matching placebo) for 4weeks, then the dose is 
increased by 2.5 mg (or m atching pl acebo) every 4 weeks (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg) 
up to MTD (either 10 mgor 15 m g). 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
26Interventions to optimize study  drug tol erance and adherence may be emplo yed throughout the 
study  and incl ude, but are not limit ed to, brief temporary  interrupti ons and use of addit ional 
medicat ions to manage GIsymptom s (for exam ple,nausea, vo miting, and diarrhea , see 
Secti on6.6.2 . for details ). 
During the first 24 weeks of the treatment period (20 -week dose escalat ion plus 4 weeks),
participants u nable to tolerate 2.5 mg or 5 mg despite the above measures will be discont inued 
from the study  drug but remain in the study  for continued follow up. For p
articipants unable to 
tolerate any dose escalat ion between 7.5 mg and 15 mg inclusive, despite the above measures, 
the invest igator should contact Lilly to consider a dose de -escalat ion step with subsequent 
re-escalation in a blinded fashio n to reach either the 10- mg or 15 -mg dose as described below 
(only 1 cycle of dose de -escala tion and re -escalat ion is permitted during the first 24 weeks of the 
treatm entperiod):
7.5 m g to 5 m g, then the dose is increased by 2.5 mg every  4 weeks up to MTD (either 
10mg or 15 mg)
10 m g to 7.5 m g, then the dose is increased by 2.5 mg every  4 weeks up to MTD (ei ther 
10mg or 15 mg)
12.5 mg to 10 m g, then the dose is increased by 2.5 mg every  4 weeks up to MTD (ei ther 
10mg or 15 mg)
15 m g to 12.5 m g, then the dose is increased by 2.5 mg every  4 weeks up to MTD (ei ther 
10mg or 15 mg)
Parti cipants wh o tolerate 15 m g will cont inue on 15 mg as thei r MTD dose.
Parti cipants who tol erate 10 m g,but do not tolerate 12.5 mg or 15 m g even after one 
de
-escalat ion and re -escalat ion attem pt, will cont inue on 10 mg as thei r MTD dose.
Parti cipants who tol erate 12. 5 mg but do not tolerate 15 mg even after 1 de- escalat ion and 
re-escalation attempt ,will cont inue on 10 mg as their MTD dose.
Parti cipants who do not tol erate up to 10 m g even after 1 de- escalat ion and re -escalat ion attempt ,
will be discont inued fro m the study  drug but remain in the study for continued fo llow up.
At each of the 8 scheduled treatment period telephone visits, procedures will include
collect ion of AE s, product complaints, and concomitant medications
administration of Mental Healt h quest ionnaires , and
review of participant diary inform ation (to include reinforcement and co mpliance 
assessments for study  drug administrati on and lifestyle goals ).
Parti cipants shoul d be instructed to contact the investiga tive si te for assi stance as soon as 
possible if they experience any difficult ies administering their study  medicat ion. Parti cipants 
shoul d also be advised about the appropriate course of action in the event that study  drug i s not 
taken at the required time (late/missing doses).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
27Visit 99
Visit 99is only applicable to participants who discontinue the study treatment prematurely 
(between Visit 10and Visit 28) and decline to complete the remaining scheduled study visits . 
These p articipants will be asked to return for Visit 99at 72 weeks ±7 days after randomizat ion
(Secti on 7.2.1 ). This visit is crit ical to ensure complete data collect ion for the primary  endpoint . 
Parti cipants shoul d attend thi s visi t in the fasting state. Procedures to be completed are
measurement of weight and waist circumference,
listing of conco mitant m edicati ons,
assessment of AEs, and 
completion of the Mental  Health quest ionnaires (after the AE assessment).
For parti cipants unwilling to attend this visit, their refusal to attend should be documented in the 
participant m edical  record. 
4.1.1.2.4. Early Discontinuation of Treatment Visit
Parti cipants unable or unwilling to continue the study  intensive lifestyle intervent ion(during 
lead-in period) or study  drug intervent ion (duri ng treatm ent peri od)for any  reason will perform 
an early  discontinuati on (ED) visit (Section 7.2.1 ). If the participant is discont inuing during an 
unscheduled visit or a scheduled visit, that visit should be performed as an ED visit. Procedures 
shoul d be com pleted according to the S oA.Patient-reported outcomes quest ionnaires should be 
administered as early as possible, as per Suggested Visit Structure (Section 10.8). Administration 
of Mental Heal th questi onnai res shoul d follow assessment ofAEs.
4.1.1.3. Safety Follow -
Up Period
Visit 801
All randomized participants are required to complete a safet y follow-up visit (Visit 801), 
according to the S oA. Parti cipants di scont inuing the study  drug early  and performing an E Dvisit 
will also be asked to perform the safet y follow-up visit (see Sect ion 7.2). During the safet y 
follow-up period, part icipants will not receive study  drug. Parti cipants are also required to return 
any remaining study  diari es to the study  site at the end of this period.
Visit 801 (safet y follow-up visi t) shoul d be performed 4 weeks after the last visit in the treatm ent 
period(Visit 28or Visit 99) or 4 weeks after the E Dvisit for randomized participants who 
decline to return for Visit 99.  
4.1.2. Study Procedures
Parti cipants will perform  study  procedures listed in the S oA(Section 1.3).
Study  parti cipants will be permitted to use concomitant medications that they  requi re during the 
study , except certain excluded medicat ions (see Secti on 5.2)thatmay interfere wi th the 
assessment of efficacy  and safet y characteri stics of the study  treatm ents.  
Study  governance considerations are described in detail in Sect ion 10.1 (Appendix 1).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
284.2. Scientific Rationale for Study Design
Tirzepati de is  
 
 It is administered QW by SC injection.
As a dual  GIP/GLP -1R agoni st, tirzepat idecould exceed the efficacy  of select iveGLP -1R 
analogs by recruit ing metabo lically active tissues not targeted by select ive GLP -1R anal ogs(for 
example, adipose tissue as indicated by the observation of increased energy ut ilizat ion) (Müller 
2018) and has the potential to reach higher efficacy in target tissues ,such as insulin -producing 
pancreat ic beta-cells that express both GIPR and GLP -
1R,before reaching its therapeutic
limitation. Result s from a Phase 2 study  (GPGB) demonstrated that tirzepat ide use in part icipant s 
with T2DMwas associated with a substant ial, dose -dependent weight loss, greater than the 
weight change observed with dulaglut ide, a specific GLP -1R agoni st. General safet y 
characterist ics of all  studi ed doses of ti rzepati de were similar to that of the GLP -
1Ragonist class, 
consist ing mainly of nausea, vo miting, and diarrhea. In general, these events were transient and 
mild or moderate in severit y, with few severe episodes. These data suggest that tirzepat ide has 
the potent ia
l to be a pharmacol ogic treatm entfor chronic weight m anagement. 
Although GIAEs were more commo n inthe 15-mg arm of tirzepat idein the Phase 2 study 
(GPGB), this dose demonstrated the highest efficacy  in term s of weight loss
.An optimized dose 
escalat ionregimen proposed in the current Phase 3 S tudy (GPHM) to improve tolerabilit y(and 
supported by  a dose -escalat ion algorithm fro m study  GPGF and PK/PD modelling) shoul d 
enable a use of the 15-mg dose to maximize effects on body  weight .
Study GPHM is designed to determine the impact of treatment with t irzepat ideMTD ( 10 m g or
15 m g QW )compared wi th placebo on body  weight m anagement after an intensive lifest yle 
modificati on program  in study participants wi thout T2DM who have obesit y or are overwei ght.
Study  GPHM consists of a lead -in period of 12 weeks during which participants will undertake 
an intensive lifest yle modificat ion program (Heymsfield et al. 2003) . Tradi tionally , guidelines 
have restri cted pharm acotherapy  use to those who do not respond to diet and exercise but newer 
guidelines are recommending the addit ion of pharmacotherapy  in those who l ose weight wi th 
diet and exercise but m ay not be able to m aintain the weight l oss or m ay require addi tional 
weight loss. The goal  of the l ead-in period , therefore, is to ident ify part icipants who initially 
respond to lifest yle-based therapy  so that the benefit of tirzepat ide can be evaluated in this 
popul ation. Only those participants who achieve >5.0% weight loss during the intensive lifest yle 
lead-in period will be rando mized. 
A low-calorie diet (LCD) was chosen for the lead- in peri od because it is a discrete, structured 
and intensive intervent ion that is recognized as the centerpiece of dietary therapy for overwei ght 
and obesit y(NHL BI 2000). In those who can adhere to it, an LCD may achieve greater wei ght 
loss in the short -term than the moderate 500 kcal/day deficit diet being applied in co mbinat ion 
with tirzepatide throughout the obesit y Phase 3 program .Moreover, a nLCD was chosen over the 
option of  a very  low-calorie diet (VLCD ) because VLCDs are only used in limited circumstances 
by specialized practit ioners experienced in their use and with special mo nitoring and 
supplementati on(NHL BI 2000) .Because VLCDs are not recommended as routine therapy for 
overwei ght or obesi ty, using a VLCD would have affected the generalizabilit y of the resul ts. 
CCI
CONFIDENTIAL Protocol  number I8F -MC-GPHM
29Clinical trials have also shown that LCDs are as effect ive as VLCDs at 1 y earin achieving 
weight loss(Wadden et al . 1994) .
After rando mizat ion, participants in both the placebo and MTD tirzepat ide arms will continue to 
receive lifest yle modificat ion counselling consistent with current guidelines for weight 
management ( Jensen et al. 2014; NH LBI 201 3). Specifically , parti cipants will consult with a 
dietician, or equivalent qualified delegate ,throughout the post -randomizat ion treatment period to 
achieve an approximately  500 kcal /day energy defici t through a combinat ion of caloric 
restri ction and increased physical activit y (see Secti on5.3).
The pl anned durat ion of treatment for the primary endpo int at 72 weeks allows for a 52 -week 
treatm ent peri od at the dose achieved fo llowing dose escalat ion to ei ther 10 mg or 15 m g. Thi s 
durati on is consi dered appropriate to assess the full effects and b alance of ri sk and benefit for 
tirzepat ide MTD compared wi th placebo on body  weight and is consistent with regulatory  
guidelines (FDA 2007; EMA 2016). A placebo comparator was selected for this trial in 
accordance with regulatory  guidance (FDA 2007; EMA 2016). 
The effects of drug cessation will be assessed in the 4 -week safet y follow-up/observational 
period. To minimize the potential confounding effect of changes to concomitant medicat ions, 
participants will be permitted to use conco mitant medicat ions that do not interfere with the 
assessment of efficacy  andsafety characteri stics of the study  treatm ents.
4.3. Justification for Dose
Tirzepatide MTD (10 mg or 15 m g QW) will be evaluated in this study. These doses and 
associ ated escalat ion schemes were selected based on assessment of safet y, efficacy  (weight 
loss), and GI tol erabi lity data in Phase 1 and 2 studies in patients with T2DM , followed by 
exposure -response modeling o f the data that predicted weight loss in pat ientswith overwei ght or 
obesit y.
In a 26 -week, Phase 2 study  (GPGB) of participants with T2DM, tirzepat ide reduc ed body  
weight by  4.8 kg, 8.7 kg, and 11.3 kg at dose levels of 5, 10, and 15 mg, respect ively, whereas 
the wei ght loss observed in participants on dulaglutide, a selective GLP -1R agoni st, used at the 
dose of 1.5 mg, was 2.7 kg (Frias et al. 2018).  
Similar to the GLP -1R agoni st class, m ost of the tirzepatide AEs were dose-dependent and 
GI-related , consist ing mainly o f nausea, vo miting, and diarrhea. In general, these events were 
mild or moderate in severit y, with few severe episodes, and transient. 
Tirzepatide doses of 10 m g and 15 m g were selected based principally  on the foll owing cri teria:
each dose provides robust weight loss relat ive to placebo
the percent of patients achieving ≥10% weight loss is higher with 15 m g than 10 mg, and 
safet y and tolerabilit y were supported by  Phase 2 results and/or PK/PD modeling.
Dosing algorithms starting at a low dose of 2.5 mg accompanied by  dose escalat ion of 2.5- mg 
increments ev ery 4 weeks shoul d permi t time for development of tolerance to GI events and are 
predi cted to minimize GI tolerabilit y concerns. The m aximum  proposed dose of 15 mg maintains 
an exposure mult iple of 1.6 to 2.4 to the no- observed adverse effect level doses i n 6-month 
monkey and rat toxico logy studi es.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
304.4. End of Study Definition
Secti on 7.2describes the criteria used to determine if a participant has co mpleted the study .
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
last scheduled procedure shown in the S oAfor the last participant in the trial glo bally .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
315. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclus ion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Type of Participant and Disease Characteristics
1.Have a BMI of :
≥30 kg/m2or 
≥27 kg/m2and previously  diagnosed wi th at least 1of the f ollowing
weight-related comorbidit ies 
oHypertensio n: treated or with systolic blood pressure ≥130 mmHg 
or diastolic blood pressure ≥80 mmHg
oDyslipidemia: treated or with low-densit y lipoprotein ( LDL )
≥160 mg/dL (4.1 mmo l/L) or tri glycerides ≥150 mg/dL
(1.7mmo l/L), or high-densi ty lipoprotein ( HDL )<40 mg/dL 
(1.0mmo l/L) for men or HDL <50mg/dL (1.3mmo l/L)for
wom en 
oObstructive sleep apnea 
oCardi ovascular di sease (for example, ischemic cardiovascular 
disease, New York Heart Associat ion [NYHA ]Funct ional 
Classifi cation Class I -III heart failure) 
2.Have a history  of at least 1self-reported unsuccessful dietary  effort to l ose body  weight 
3.In the invest igator’s opinio n, are well -motivated, capable, and willing to :
learn how to self- inject study  drug, as requi red for thi s protocol  (visually  impaired 
persons who are not able to perform the inject ions must have the assistance of a 
sighted individual trained to inject the study  drug; persons wi th physical 
limitations who are not able to perform the inject ions must have the assistance of 
an individual trained to inject the study  drug) 
inject study  drug (or receive an inject ion from a trained individual if visually 
impaired or with physical limitat ions)
follow study  procedures for the dura tion of  the study , including, but not limited to 
followinglifest yle advice (for example, dietary restrictions, exercise plan), 
maintain inga study  diary , and completingrequi red questi onnaires
Participant Characteristics
4.Are at least18 years of age andage of m ajority per l ocal laws and regulat ions
a.Male parti cipants:
CONFIDENTIAL Protocol  number I8F -MC-GPHM
32Male parti cipants with partners of childbearing potent ial shoul d be willing 
to use reliable contraceptive methods throughout the study  and f or 5 half -
lives o f study  drug pl us 90 days, corre sponding to 4 months after the last 
inject ion.
b.Female participants:
Female participants not of childbearing potential may participate and 
include those who are:
oinfertile due to surgi cal sterilizat ion (hysterectomy ,bilateral 
oophorectomy ,or tubal  ligation)orcongenital anomaly (such as
Mullerian agenesis) or 
oPost-menopausal –defined as either :
A woman at least 40 years of age with an intact uterus , not on 
horm one therapy , who has cessat ion of menses for at least 
1year without an alternat ive medical cause, AND a fo llicle -
stimulat ing hormone (FSH) ≥40mIU/mL ; women in this 
category  must test negative in pregnancy  test pri or to study  
entry
or
A wo man 55 or older not on hormone therapy , who has had at 
least 12 m onths of spontaneous amenorrhea 
or
A woman at l east 55 years of age with a diagnosis of 
menopause prior to starting hormone replacement therapy
Female participants of child -bearing potential (not surgically sterilized 
and between menarche and 1 -year postmenopausal) must:
otest negative for p regnancy at Visit 1 based on a serum pregnancy 
test
oif sexually  active, agree to use 2 forms of effect ive contraception, 
where at least 1form is highly effect ive for the durati on of  the tri al 
plus30 days , corresponding to 2 months after the last inject ion,
and
onot be breastfeeding
Note: Contraceptive use by men or women should be consistent with local regulations 
regarding the methods of contraception for those participat ing in clinical studies.
Informed Consent
5.Capable of giving signed informed consent as described in Section 10.1 (Appendix 1 ),
which includes co mpliance wit h the requirements and restrictions listed in the ICF and in 
this protocol .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
335.2. Exclusion Criteria
Parti cipants are excl uded from  study enrollment if they meet any  of the fo llowing cri teriaat 
screening :
Medical Conditions
Diabetes -Related
6.Have Type 1 di abetes m ellitus(T1DM) or T2DM , history  of keto acidosis , or 
hyperosmo lar state/coma 
7.Have at least 1laboratory value suggest iveof diabetes mellitus during screening , 
including 1or more of:  HbA1c ≥6.5% ( ≥48 mmo l/mol), fasting glucose ≥126 m g/dL 
(≥7.0mmo l/L), or random glucose ≥200 m g/dL ( ≥11.1 mmo l/L) 
Obesity -Related
8.Have a self -reported change in body  weight >5 kg within 3 mo nths prior to screenin g
9.Have a prior or planned surgical treatment for obesit y (excluding liposuct ion or 
abdo minoplast y, if performed >1 y ear pri or to screening)
10.Have or plan to have endoscopi c and/or device -based therapy  for obesi ty or have had 
device removal within the l ast 6 months prior to screening
 mucosal ablat ion 
 gastri c artery  embo lization 
 intragastri c balloon 
 duodenal -jejunal endol uminal liner
Other Medical
11.Have renal impairment measured as est imated glomerular filtration rate (eGFR) 
<30mL/min/1.73 m2, calculated by Chronic Kidney  Disease -Epidemi ology (CKD -EPI) 
as determined by  central  laboratory  during screening 
12.Have a known clinically significant gastric empt ying abnormalit y (for example, severe 
gastroparesi s or gastri c outl et obstructi on) or chronically take drug s that direct ly affect GI
motility
13.Have a history of chronic or acute pancreatit is 
14.Have thyroid -stimulat ing hormone (TSH) outside of the range of 0.4 -6.0 mIU/L at the
screening visit
Note :Participants receiving treatment for hy pothyroi dism  may be incl uded, provi ded 
their thyroid horm one repl acement dose has been stable for at least 3 months and thei r 
TSH at screening falls wit hin the range indicated above.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
34Note:   Participants with a history  ofsubclinical  hypothy roidism but a TSH at screening 
within the range indicated above, may  be included ifin the investigator’s opinio n, the 
patientis unlikely to require init iation of thy roid horm one repl acement during the course 
of the study .
15.Have obesi tyinduced by  other endocrino logic disorders (for example, Cushing 
syndro me) or diagnosed monogenet ic or syndromic forms of obesit y (for example, 
Melanocorti n 4 Receptor deficiency or Prader Willi Syndro me)
16.Have a history  of significant active or unstable M ajor Depressive Disorder (MD D)or 
other severe psychiatric disorder (for example, schizophrenia, bipo lar disorder , or other 
serious m ood or anxiet y disorder ) within the last 2 years
Note: Participants with MDD or generalized anxiety  disorder whose disease state is 
considered stable for the past 2 y ears and expected to remain stable throughout the course 
of the study , in the opinio n of the invest igator, may be considered for inclusio n if they are 
not on excluded medicat ions
17.Have a lifet ime history  of suicide attempt
18.Have a PHQ -9 score of 15 or more at Visit 1 
19.On the C -SSRS at any time fro m Visit 1 to Visi t 2:
 a "yes" answer to Questi on 4 (Active Sui cidal  Ideati on wi th Some Intent to Act, 
Without Specific Plan) on the "Suicidal Ideat ion" porti on of  the C -SSRS
or
 a "yes" answer to Questi
on 5 (Active Sui cidal  Ideati on wi th Specific Plan and 
Intent) on the "Suicidal Ideation" portion of the C- SSRS 
or 
 a "yes" answer to any  of the suicide -related behaviors (actual attempt, interrupted 
attem pt, aborted attempt, preparatory  act or b ehavior) on the "Suicidal Behavior" 
porti on of  the C -SSRS 
and
 the ideati on or behavior occurred within the past month 
20.Have uncontrolled hypertensio n (systolic blood pressure above or equal to 160 mmHg 
and/or diastolic blood pressure above or equal to 10 0 mmHg)
21. H ave any of the fo llowing cardi ovascular condi tions wi thin 3 mo nths prior to Visit 2:
 acute my ocardial  infarct ion 
 cerebrovascular accident (stroke)
 unstable angina, or 
 hospi talizati on due to congestive heart failure (CHF)
22.Have NYHA Funct ional Classificat ion Class IV CHF
CONFIDENTIAL Protocol  number I8F -MC-GPHM
3523.Have acute or chronic hepat itis, signs and symptoms of any other liver disease other than 
nonalcoho lic fatty liver di sease (NAFLD), or any of the fo llowing, as determined by  the 
central  laboratory  during screening :
 alanine aminotransferase (ALT) level >3.0Xupper limit of normal (ULN) for the 
reference range
 alkaline phosphatase (ALP) level >1.5X ULN for the reference range, or
total bilirubin (TBL) level >1.2X ULN for the reference range (except for 
cases o f known G ilbert’s Syndrome)
Note: Participants wi th NAFLD are eligible to participate in this trial if their ALT 
level is ≤3.0X ULN for the reference range.
24.Have a serum calcitonin level (at Vi sit 1) of
 ≥20 ng/L, if eGFR ≥60 mL/min/1.73 m2
 ≥35 ng/L, if eGFR <60 mL/min/1.73 m2
25.Have a family or personal history  of medullary  thyroi d carcino ma (MTC) or mult iple 
endocrine neoplasia (MEN) syndro me type 2
26.Have a history  of an act ive or untreated malignancy or are in remissio n from a clinically  
significant malignancy  (other than basal or squamous cell skin cancer, in situ carcino mas 
of the cervix, or in situ prostate cancer) for less than 5 y ears
27.Have any other condit ion not listed in this sect ion (for example, hypersensit ivity or 
intolerance) that i s a contraindicat ion to GLP-1R agonists
28.Have a history  of any other condit ion (such as known drug or alcoho l abuse, di agnosed 
eating disorder ,or other psy chiatri c disorder) that, in the opinio n of the invest igator, may 
precl ude the pa rticipant from following and co mpleting the protocol
29.Have history  of use of marijuana or tetrahy drocannabino l(THC) -containing products 
within 3 m onths of enrollment or unwillingness to abstain from marijuana or THC -
containing products use during the trial
Note: If a pa rticipant has used cannabidio l oil during the past 3 m onths but agrees to 
refrain fro m use for the duration of the study , the pa rticipant can be enro lled. 
30.Have had a transplanted organ (corneal transplants [keratoplasty] are allowed) or are 
awaiting an organ transplant
31.Have any hematological condit ion that m ay interfere with HbA1c measurement (for 
example, hemo lytic anemias, sickle cell disease)
Prior/Concomitant Therapy
32.Are receiving or have received wit hin 3 months prior to screening chroni c (>2 weeks or 
14 day s)systemic glucocorticoid therapy  (excluding topi cal, intra -ocular, intranasal, 
intra-articular, or inhaled preparations) or have evidence of a significant, active 
autoimmune abnormalit y (for example, l upus or rheum atoid arthri tis) that has required 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
36(withinthe last 3 months) or is likely to require, in the opinio n of the invest igator, 
concurrent treatment with systemic glucocortico ids (excluding topical, intra -ocular, 
intranasal, intra -articular, or inhaled preparat ions) during the course of the study
33.Have current treatm ent wi th or hi story  of (within 3 m onths pri or to Visit 2 ) treatment 
with medications that m ay cause significant wei ght gain, including but not limited to :
tricyclic ant idepressants, aty pical  antipsychoti cs, and m ood s tabilizers
Examples:
 imipramine 
 amitript yline 
 mirtazapine
 paroxetine
 phenelzine
 chlorpromazine
 thioridazine
 clozapine
 olanzapine
 valpro ic acid (and its derivat ives), or
 lithium
Note:   Select ive serotonin reuptake inhibitors (SSRIs) other than paroxetine are 
permitted . 
34.Have taken ,within 3 m onths prior to Visit 2 ,medications (prescribed or 
over-the-counter) or alternat ive remedies that promote weight loss  
Examples include, but are not limited to:
 Saxenda (liraglut ide 3.0 mg)
 Xenical® /Alli®(orlistat)
 Meri dia® (sibutramine)
 Acutrim® (phenylpropanolamine)
 Sanorex® (mazindo l)
 Apidex® (phentermine)
 BELVIQ® (lorcaserin)
 Bontril ®(phendimetrazine)
 QsymiaTM(phentermine/topiramate combination)
 Contrave® (naltrexone/bupropion) 
Note: Use of metformin, or any  other gl ucose-lowering medication , whether prescribed 
forpolycyst ic ovarian syndrome ( PCOS )or diabetes prevent ion is not permitted.
35.Have started implantable or injectable contraceptives (such as Depo Provera ®) wi thin 
18months pri or to screening
CONFIDENTIAL Protocol  number I8F -MC-GPHM
37Prior/Concurrent Clinical Study Experience
36.Are current lyenrolled in any other clinical study  involving an invest igational product
(IP)or any  other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
37.Withinthe last 30 day s, have participated in a clinical study  and received treatm ent, 
whether act ive or placebo. If the study invo lved an IP, 5 half -lives or 30 day s, whichever 
is longer, should have passed
38.Have previously co mpleted or withdrawn fro m this study or any  other study  invest igating 
tirzepat ide after receiving at least 1dose of IP
Other Exclusions
39.Are invest igator site personnel directly affiliated wit h this study  and/or thei r immediate 
families. Immediate family  is defined as a spouse, parent, child , or sibling, whether 
biological  or legally  adopted
40.Are Lilly  empl oyees
5.3. Lifestyle Considerations
Per the S oA(Section 1.3), participants will consult  with a dietician, or equivalent qualified 
delegate , according to local standards, to receive lifest yle management counseling at 
Weeks -12, -11,-10, -9, -8,-6, -4 and - 2 prior to rando mizat ion and then at Weeks 0, 12, 24, 36, 
48, 60 and 72 post-randomization .
Diet and exercise goal s established during the lifestyle consultat ion and the importance of 
adherence to the lifest yle co mponent of the trial will be reinforc ed at each tri al contact by  study  
staff.
5.3.1. Meals and Dietary Restrictions
During the intensive lifest yle modificat ion lead-in period, parti cipants will receive instruction 
from a dietician, or equivalent qualified delegate, to reduce their daily caloric energy  intake to 
approximately  1200 kcal/day for women or 1500 kcal/day for men for 12 weeks. During this
lead-in period ,up to 2 liquid meal replacements per day  are permitted, but not required, to 
achieve the target ed energy defic it. In addi tion to the diet modificat ion, parti cipants will be 
encouraged to exercise on a regular basis, wit h a recommendat ion of at least 150 minutes per 
week of moderate i ntensity activi ty (for exam ple, brisk walking). Participants will be counseled 
on behavior modification strat egies to help implement and adhere to the diet and exercise 
recommendat ions. Participants who achieve a ≥5.0% body  weight l ossatthe end of the 12-week 
lead-in period ( Week 0)will proceed to randomization to either tirzepat ide or placebo.  
After rando mization, participants will be advised to maintain their daily energy intake at 
500kcal below their individualized energy requirements (Garvey et al. 2016), as calculated by 
the Food and Agriculture Organization o f the Unit ed Nati ons/Worl d Heal th Organizat i
on 
[WHO]/United Nations Universit y (FAO/WHO/UNU )estimates of human energy  requi rements, 
using a “sedentary ” physical  activity level  (PAL) of 1.3 (FAO/WHO/UNU 2004).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
38Parti cipants will be encouraged to maintain moderate intensit y physical act ivity of at least 
150minutes per week. Liquid meal replacement is permitted but will not be provided during the 
post-randomizat iontreatm ent peri od. The recommended macronutrient distribution will be
maximum  30% of  energy  from fat 
approximately  20% of energy  from protein
approximately  50% of  energy  from carbohydrates , and
an energy  defici t of approximately 500 kcal/day  compared to the participant’s est imated 
total energy  expendi ture (TEE). 
To encourage adherence, it is reco mmended that behavior modificat ion tools be used ,such as 
completion of a 3-day diet and exercise logprior to each counseling visit. During each visit, the 
participant’s di et will  be reviewed and behavi or modificat ion strategies to maximize adherence 
will be provided asneeded.
The hypocaloric d iet will be continued throughout the treatment period. If a BMI ≤22kg/m 2is 
reached, the recommended energy  intake shoul d be recal culated wi th no kcal  deficit for the 
remainder of the trial.
Total  energy expenditure is calculated by  multiplying the estima ted Basal Metabolic Rate (BMR) 
(see tabl e bel ow) wi th a PAL value of 1.3 (FAO/WHO/ UNU 2004 ), whi ch reflects an inact ive 
lifest yle. This calculat ion provi des a conservat ive estimate of caloric requirements:
TEE (kcal/day) =BMR X 1.3
Equations for Estimating BMR in kcal/ Day*
Sex Age BMR (kcal/day)
Men 18-30years 15.057 X actual weight in kg +692.2
31-60years 11.472 Xactual weight in kg + 873.1
>60 y ears 11.711 Xactual weight in kg + 587.7
Women 18-30years 14.818 Xactual weight in kg +486.6
31-60years 8.126 Xactual weight in kg + 845.6
>60 y ears 9.082 Xactual weight in kg + 658.5
Abbreviation: BMR = basal metabolic rate ; WHO =World Health Organization.
*Revised WHO equations (adapted from: FAO/WHO/UNU 2004) .
5.3.2. Physical Activity
At Visit 2 and all subsequent visits, p articipants will be advised to increase their physical act ivity 
to moderate intensit y (for exam ple, brisk walking) for at least 150 minutes per week .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
395.4. Screen Failures
Screen failure s are defined as participant s who consent to participate in the clinical study but are 
not subsequently enrolled in the study .A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure partici pants to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries fro m regulatory  
authori ties. Minimal informat ion includes demography, screen failure details, eligibilit y criteria, 
and any  serious adverse event (SAE) .
Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
406. Study Intervention
Study  intervent ion is defined as an y study  drug intervent ion, invest igational intervent ion(s), 
marketed prod uct(s), placebo ,or medical device (s)intended to be administered to /used by a 
study  participant according to the study  protocol .
6.1. Study Intervention(s) Administered
Arm Name Tirzepati de MTD Placebo
Dose 10 m g or 15 m g QW N/A
Route of 
AdministrationSC
Sourcing Provi ded centrally  by the sponsor and dispensed via IWRS
Packaging and 
LabelingStudy  drug intervent ion will be provided in autoinjector s (single- dose pens)
packaged in cartons to be dispensed. Clinical study materials will be 
labeled according to country  regul atory  requi rements.
Abbreviations: IWRS = interactive web -response sy stem ; MTD = maximum tolerated dose ; N/A = not applicable ;
QW = once-weekly ;SC= subcutaneous .
There are no restrict ions on the time of day  each weekly dose of study  drug is given, but it is 
advisable to administer the SCinjections on the same day and same time each week. The actual 
date,time, and inject ion site location of all dose administrati ons will be recorded in the diary by 
the participant. If a dose of study drug is missed, the participant should take it as soon as possible 
unless it i s within 72hours of the next dose, in which case, that dose should be skipped and the 
next dose should be taken at the appropriate time. The day  of weekly administration can be 
changed if necessary ,as long as the l ast dose was administered 72 or more hours before.
All participant s will inject study  drug SC in the abdomen or thigh using the injection supplies 
provi ded; a caregiver may admini ster the inject ion in the part icipant’s upper arm. The inject ion-
site locati on of  all dose administrati ons will  be recorded in the diary by the participant. A new
autoinjector will be used for each inject ion.If study drug is to always be injected in the same 
body  region, participants shoul dbe advised to rotate inject ion site seach week.
6.1.1. Medical Devices
The combinat ion products provided for use in the study  are tirzepat ideinvest igational 
autoinjector (or matching placebo). Any AEresul ting fro m device deficiencies, misuse , or 
malfunct ions must be detected, docum ented, and reported by  the invest igator through out the 
study (see Sect ion 10.4.3 ).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
416.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate storage conditions have been 
maintained during transit for all study  drug intervent ion received and any discrepancies 
are reported and resolved before use of the study  drug intervent ion.
Only participants rando mized in the study  may receive study  drug intervention .Only 
study  personnel may supply , prepare, or administer study  drug intervent ion. All study
drug intervent ion must be stored in a secure, environmentally  controlled, and m onitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access 
limited to the investigator and authorized study  personnel .
The investigator or authorized study  personnel are responsible for study  drug intervent ion 
accountabilit y, reconciliat ion, and record maintenance ( for example , recei pt, 
reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  drug
intervent ions are provided in the study  training m aterials.
6.3. Mea sures to Minimize Bias: Randomization and Blinding
This is a double -blind , randomized study .
Participants who meet all criteria for en rollment will undergo a 12 -week intensive lifest yle 
modificati on lead -in period. Those who achieve ≥5.0% wei ght loss at Vi sit 10will be 
rando mized to one of the study  treatm ent groups (tirzepat ide MTD or placebo) for the duration 
of the treatm ent peri od. Assignment to treatment groups will be determined by a 
computer -generated random sequence using an IWRS. Participant s will be rando mized in a 
1:1ratio to receive tirzepati deMTD or placebo .  
The rando mizat ion will be stratified by  country , sex (female, m ale), and percent weight loss at 
the end of lead- in(<10% versus ≥10%) .
Invest igators, site s taff, clinical monitors and participants will remain blinded to the treatm ent 
assignments unt il the study is complete .
Emergency  unblinding for AEs may be performed through the IWRS. This opti on m ay be used 
ONLY if the part icipant’s well -being requires k nowl edge of the participant’s treatm ent 
assignment. All emergency  unblinding event sare recorded and reported by  the IWRS .
If an invest igator ,site personnel performing assessments, or participant is unblinded, the 
participant must be di scont inued fro m thestudy . In cases where there are ethical reasons to have 
theparticipant remain in the study  the invest igator must obtain specific approval fro m a Lilly 
clinical research physician (CRP) for the participant to continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a parti cipant’s treatment assignment is warranted for medical management of the event. The 
participant ’ssafet y must always be the first consideration in making such a determinat ion. If a 
participant’s treatment assignment is unblinded, Lilly  must be notified immediately . If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and noti fy Lilly as soon as possible.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
426.4. Study Intervention Compliance
Parti cipant com pliance wi th study  drug intervent ion will be assessed at each visit (after 
rando mizat ion). Study  drug com pliance will be determined by the following: 
Study  drug administration dat a will be recorded by the participant and reviewed 
by the investigator at each study  visit.
The parti cipant s will be instructed to return any unused study drug and/or empt y 
cartons at the next office visit to the study  site for the purpose of performing drug 
accountabilit y.
Treatment compliance for each visit interval is defined as taking at least 75% of the required 
doses of study  drug. Similarly, a participant will be considered significant ly nonco mpliant if he 
or she is judged by the invest igator to have intentionally  or repeatedly  taken m ore than the 
prescribed amount of medication (more than 125%) .  
In addit ion to the assessment of a participan t’s compliance wit h the study  drug administration, 
other aspects of compliance with the study  treatm ents will  be assessed at each visit based on the 
participant ’s adherence to the visit schedule, complet ion of study  diaries, and any other 
param eters the invest igator considers necessary.
Parti cipants considered to be poorly co mpliant with their study  drug and/or th e study  procedures 
will receive addit ional training and instruction, as required, and will be reminded of the 
importance of co mplying wit h the protocol.
6.5. Concomitant Therapy
Parti cipants will be permitted to use concomitant medicat ions that they  requi re dur ing the study, 
except certain medicat ions (for exam ple,other medi cations for wei ght m anagement , see 
Secti on5.2)that may interfere wi th the assessm ent of efficacy  and safet y characteri stics of the 
study  treatm ents.
Parti cipants who devel op di abetes during the study may  initiate m edicat ion for glucose control , 
with the excepti on of  dipept idyl pept idase 4 (DPP-4)inhibitors or GLP -1R agonists .Initiation of  
metformin for the treatment of diabetes is permitted, but met formin should not be init iated 
during the study  for the treatm ent of other metabolic condit ions (for example, PCOS , diabetes 
prevent ion).Management of incident diabetes should be p erformed by  parti cipants’ usual care 
provi ders
.
Invest igative site staff will inform partici pants that they  must consul t with the invest igator or a 
designated site staff member upon being prescribed any new medicat ions during the study . This 
may not be pos sible when init iated for treatment of medical emergencies, in which case ,the 
participant will inform the invest igator or a designated site staff member as soon as possible.
Non-study medicat ions taken by participants who are screened but not enrolled willnot be 
reported to Lilly  unless an SAE or AE occurs that the invest igator believes may have been 
caused by  a study  procedure.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
436.6. Dose Modification
6.6.1. Tirzepatide
Tirzepati de is given QW by SC injection. There are no restrict ions on the time of day  each 
weekly d ose of  tirzepat ide is given, but it is advisable to administer the SCinject ions on the 
same day of the week andsimilar time each week. If a dose of ti rzepat ide is missed, the 
participant shoul d take i t as soon as possible unless it is within 72hours of the next dose, in 
which case, that dose should be skipped and the next dose shoul d be taken at the appropriate time
(see Section 6.1).  
Study  drug dose modificat ion is not permitted, except for management of intolerable GI 
symptoms from Week 0 to Week 24 ( see Section 6.6.2 ).  
6.6.2. Manageme nt of Participants with Gastrointestinal Symptoms
Parti cipants who experi ence intol erable GI symptoms (for example, nausea, vomit ing, or 
diarrhea) at any  time during the study , shoul d first be counseled on dietary  behavi ors that m ay 
help mit igate nausea an d vomiting (for example, eating smaller meals, splitt ing 3 daily meals 
into 4 or m ore smaller ones, and stopping eat ing when they feel full )(see Section 10.9). If 
symptoms persist, the participant should be prescribed, at the invest igator’s discret ion, 
symptom atic medicat ion (for example, antiemetic or anti diarrheal  medication) . A tem porary  
interrupti on of  study  drug for 1dose is permitted, provided the participant has taken the last 
3weekly doses. Study  treatm ent shoul d be resumed immediately, either alone or in co mbinat ion 
with symptom atic m edicat ion, which can also be utilized to manage symptoms. Management of 
study  drug after interruptions >1 dose isdiscussed in Section 7.1.1 .
During thefirst 24 weeks of the treatment period (20-week dose -escalat ion plus 4 weeks ), if 
intolerable GI symptom s (for example, nausea, vomit ing, or diarrhea) persist despite the above 
measures, the invest igator should contact Lilly to consider a dose de -escalat ion step wi th 
subsequent re -escalat ion (Secti on 4.1.1.2.3 ). During the remaining treatm entperiod (Week 24 to 
Week 72) ,dose de -escalat ion with subsequent re -escalat ion,or dose de -escalat ion to a lower 
maintenance dose, isnot permi tted. Those with intolerable GI symptoms that develop after 
24weeks and persist despite the above measures (for example, dietary  counseling, symptom atic 
medicat ion, and interruption of study  drug for onedose) should discont inue study  drug but 
remain in the study  for continued fo llow
-up. 
6.7. Intervention after the End of the Study
Tirzepati de will  not be made available to parti cipants after conclusion o f the study .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
447. Discontinuation of Study Intervention and Partici pant 
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue (definit ive 
discontinuat ion) study  drug intervent ion. If intervent ion is definit ively  discontinued, th e 
participant willremain in the study  to be evaluated for any trial endpo int at the end of the study .
See the SoA for data to be collected at the time of discontinuat ion of study  drug intervention and 
follow-up and for any  further evaluat ions that need to be completed.
In some instances, it may  be necessary  for a parti cipant to perm anent ly discont inue the intensive 
lifest yle intervent ion during the 12 -week l ead-in phase. If the intensive lifest yle interventi on is 
discontinued during the lead-in period, th e parti cipant will be permanently discont inued fro m the 
study .
Possible reasons leading to permanent discontinuation of intensive lifestyle intervention 
during lead -in period or study drug intervention during treatment period :
Participant Decision
oThe participant requests to discontinue intensive lifest yle interventi on during the l ead-
in peri od or study  drug intervent ion during treatm ent peri od.
Clinical Considerations
oInitiation of  open -label GLP -1Ragonist or DPP -4 inhibitor, if part icipants will not or 
cannot di scont inue them
oBMI ≤18.5 kg/m 2is reached at any  time 
Note:   The investigator should contact the sponsor CRP to discuss whether it is 
medically appropriate for the participant to continue study  treatm ent
oDiagnosis of T1DM
oDiagnosis of MTC or MEN syndrome t ype 2
oSignificant el evation of serum calcitonin (Sect ion 8.3.2.4 )
oDiagnosis of acute or chronic pancreat itis 
oDiagnosis of an active or untreated malignancy  (other than basal  or squam ous cell 
skin cancer, in situ carcino mas of the cervix, or in situ prost ate cancer) 
oOnset of pregnancy in a female participant 
oOccurrence of any other treatm ent-emergent AE ( TEAE ), SAE, or clinically 
significant finding for whi ch the invest igator believes that permanent discontinuation 
is the appropriate measure to be taken
oInadvertent enrollment if cont inued intensive lifestyle intervent ion or treatm ent wi th 
study  drug woul d not be medically  appropriate ornotallowed per local regulat ions
oPHQ -
9 score ≥15.  
CONFIDENTIAL Protocol  number I8F -MC-GPHM
45Parti cipants shoul d be referred to a Mental Healt h Professio nal (MHP) to 
assist in deciding whether the participant shoul d be discont inued. If a 
participant’s psychiatric disorder can be adequately  treated wi th 
psycho -and/or pharmacotherapy, then the participant , at the discretion of the 
investi gator (in agreement with the MHP), may be continued in the trial.  
oParti cipants wi th C-SSRS responses at any visit indicat ive of suicidal ideat ion or 
behavior should have intensive lifest yle or study drug intervent ions discontinued and 
be referred to a nMHP. Both intervent ionsmay be restarted, if the MHP and the 
investigator agree it is appropriate for the participant. Responses that should prompt 
mental  health referral and cessat ion of intensive lifest yle interven tion or study  drug
intervent ionare
a “yes”answer to Question 4 (Act ive Suicidal Ideation with Some Intent to 
Act, Without Specific Plan) on the "Suicidal Ideation" portion of the C -SSRS
or
a “yes”answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and 
Intent) on the "Suicidal Ideation" portion of the C- SSRS 
or 
a “yes”answer to any  of the suici de-related behaviors (actual attempt, 
interrupted attem pt, aborted attempt, preparatory  act or behavior) on the 
“Suicidal Behavior” porti on of  the C -SSRS 
Note : A psychiatrist or appropriately  trained professio nal may assist in the decisio n to 
discontinue the participant. 
Discontinuation due to a hepatic event or liver test abnormality.   
oParticipants who are di scont inued fro m intensive lifest yle interventi on or study drug 
intervent iondue to a hepatic event or liver test abnormalit y shoul d have addi tional 
hepat ic safet y data collected via eCRF.
oDiscontinuati on of  intensive lifest yle intervent ion orstudy drug intervent ionfor 
abnorm al liver tests should be considered by the investigator when a particip ant 
meets one of the fo llowing condi tions af ter consul tation wi th the Lilly  designated 
medical mo nitor:
ALT or aspartate aminotransferase (AST) >8X ULN
ALT >2X baseline value or≥300 U/L, whichever occurs first, if baseline 
ALT ≥2X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or internat ional norm alized 
ratio (INR) >1.5 
ALT or AST >3X ULN with the appearance of fatigue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
CONFIDENTIAL Protocol  number I8F -MC-GPHM
46ALP >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fe ver, rash, and/or eosinophilia (>5%)
Note :In this study  baseline m ay refer to l ead-in enrollment visit sor randomizat ion visit , 
whichever i s the most recent point of reference .
The following are also applicable if developing/occurring during intensive lif estyle lead -in 
period:
Ketoacidosis or hy perosm olar state/com a
Uncontrolled hypertensio n (systolic blood pressure above or equal to 160 mmHg 
and/or diastolic blood pressure above or equal to 100 mmHg)
Diagnosis of any  of the f ollowing cardio vascular condit ions:
oAcute my ocardial  infarct ion
oCerebrovascular accident (stroke)
oUnstable angina
oHospitalization due to CHF , or
oNYHA Funct ional Classificat ion Class IV CHF
Chronic (>2 weeks or > 14 days) systemic glucocorticoid therapy (excluding topical, 
intra-ocular, intranasal, intra- articular, or inhaled preparations) or evidence of a 
significant, active autoimmune abnormalit y (for exam ple, l upus or rheum atoid 
arthri tis) that has requi red or is likely to require, in the opinio n of the investigator, 
concurrent treatme nt with systemic gl ucocorti coids (excluding the ones ment ioned 
above)
Surgical treatment or endoscopic and/or device -based therapy  for obesi ty
Initiation oftreatm ent wi th medicat ions that may significant ly impact body weight  
(please refer to Section 5.2. for details)
Initiation of  implantable or i njectable contraceptives (such as Depo Provera®)
The following are also applicable during study drug intervention period (after 
randomization): 
Intolerable GI symptoms despite management as described in Section 6.6.2
If the invest igator, after consultation with the sponsor -designated medical mo nitor, 
determines that a systemic hypersensit ivity react ion has occurred related to study 
drug administration, the participant should be permanent lydiscont inuedfrom the 
investigat ional drug
.
Parti cipants who stop intensive lifest yle intervent ion permanently should perform an early  
discontinuat ion (ED)visit and discont inue from the study . Parti cipants who stop the study  drug 
perm anent ly shoul d perform an ED visi t and continue to attend all scheduled study visit sto 
collect all planned efficacy and safety  measurements. Rando mized p articipants who are 
unwilling to attend all scheduled visit s and stop the study  treatm ent pri or to 72 weeks, shoul d 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
47return for a final weight measurement ( Visit 99). If participants are unwilling to attend Vis it99, 
their refusal to attend should be documented in the patient medical record .
See the SoA for data to be collected at the time of intervent ion discontinuation and fo llow-up and 
for any  further evaluat ions that need to be completed.
7.1.1. Tempora ry Discontinuation
In certain situat ions, after randomizat ion, the investigator may need to temporarily interrupt 
study  drug. Every  effort shoul d be m ade by the investigator to maintain participants on study  
drug and to restart study  drug after any  temporary  interruption, as soon as it i s safe to do so. 
Distribut ion of study  drug at the correct dose will be per IWRS instructions.  
If study  drug interrupti on is… then…
2 consecutive doses or less participant restarts study  drug at l ast administered dose, as 
per escalat ion schedule.
3 consecutive doses or more participant restarts study  drug at 5 m g (managed by  IWRS) 
and repeats dose escalat ion scheme.
due to an AE the event is to be documented and fo llowed according to the 
procedures in Section 8.3of this protocol .
due to intolerable persistent GI 
AEparticipants shoul d be treated as suggested in Sect ion 6.6.2 .
Invest igators should inform the sponsor that study  drug has been temporarily interrupted. The 
data related to temporary  interrupti on of  study  treatm ent will be documented in sou rce 
docum ents and entered on the eCRF.
7.2. Participant Discontinuation/ Withdrawal from the Study
To minimize the amount of missing data and to enable assessment of study  objectives as planned 
in the study  protocol , every  attem pt will be m ade to keep parti cipan ts in the study  irrespect ive of 
the following:
adherence to or discont inuat ion from study  drug
adherence to visit schedule
missing assessments
study  drug di scont inuat ion due to AE 
development of comorbidit ies
development of clinical outcomes
The ci rcumstances listed above are notvalid reasons for discont inuat ion from the study . 
A participant may withdraw from  the study :
CONFIDENTIAL Protocol  number I8F -MC-GPHM
48at any  time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or 
administrative reasons
if enro lledin any other clinical study  involving an IPor enroll edin any other 
type of medical research judged not to be scient ifically or medically  
compatible w ith this study
if the participant , for any  reason, requi res treatm ent (for example, 
pharmaco logical, device -based or surgical) that has been demo nstrated to be 
effect ive for treatm ent of the study  indicat ion, discontinuat ion from the study  
occurs pri or to introducti on of  the new treatm ent
Female participant swill be withdrawn fro m the study  if the parti cipant beco mes pregnant.
Parti cipation in the study  can be stopped for medical, safety , regul atory , or other reasons 
consistent with applicable laws, regulat ions, and Good C linical Practice (GCP). Participants who 
agree to provide information relevant to any  trial endpoint at the end of the study  are not 
considered to have discont inued from the study .
At the time of discont inuing from the study , if possible, an EDvisit should be conducted, as 
shown in the SoA. See the SoA for data to be collected at the time of study discont inuation and 
follow-up and for any  further evaluat ions that need to be complete d.The parti cipant will be 
perm anent ly discont inued from either the intensive lifestyle intervent ion orstudy  drug 
intervent ion,and from the study  at that time.
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
497.2.1. Participant Disposition and Timing of Safety Follow -Up 
Abbreviations:  ED =early  discontinuation; wk(s) =week(s) .

CONFIDENTIAL Protocol  number I8F -MC-GPHM
507.2.2. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or i nvest igator ident ifiesa parti cipant who did not meet enrollment criteria and was 
inadvertent ly enro lled, the invest igator and the sponsor CRP must agree whether conti nuing the 
study drug intervent ionis medically appropriate. Participants ident ified as being inadver tently 
enrolled during lead-in period should be discont inued. Continuat ion of inadvertent ly enro lled 
participants in the study ,with or wi thout study d rug treatm ent, requi res docum ented approval 
from the sponsor CRP . Safety fo llow up shoul d be perform edas outlined in Sect ion 1.3(SoA), 
Secti on 8.3(Adverse Events ,Serious Adverse Events , and Product Complaint s), and Secti on 8.2
(Safet y Assessments) of the protocol.
7.3. Lost to Follow up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site. Site personnel or desi gnee are 
expected to m ake diligent attempts to contact participants who fail to return for a scheduled visit 
or were otherwise unable to be fo llowed-up by the site.
Site personnel , or an independent third party ,will attempt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants enrolled, including those who 
did not get IP. Public sources may  be searched for vital status informat ion. If vital status is 
determined tobe deceased , this will be docum ented, and the participant will not be considered 
lost to foll ow-up.
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Secti on 10.1
(Appendix 1 ).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
518. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  
upon occurrence or awareness to determine if the participant should continue 
or discontinue intensive lifest yle intervent ionor study drug intervent ion
Adherence to the study  design requi rements, including those specified in the 
SoA, i s essent ial and requi red for study conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that
potenti al participant s meet all  eligibili ty criteria. The invest igator will maint ain 
a screening l og to record details of all participant s screened and to confirm 
eligibilit y or record reasons for sc reening failure, as applicab le
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Assessments
The primary  efficacy  measurement in this study  isbody  weight. Body  weight m easurements will 
be co llected at specific clinic visits as summarized in the S oA. Methods for m easuring body  
weight are described in Section 10.7.
8.1.2. Secondary Efficacy Assessments
The fo llowing secondary  efficacy measures will be collected at the ti mes shown in the S oA
(Secti on 1.3)
 BMI (de rived using body  weight in kil ograms divided by  the square of height in 
meters)
 Waist ci rcumference (m easuring method is described in Section 10.7)
 Fasting insulin (measured through central lab)
 HbA1c (measured through central lab)
 Fasting glucose (measured through central lab)
 Blood pressure (measuring method is described in Section 10.7)
 Lipids(measured through central lab)
8.1.3. Patient -Reported Outcomes Assessments
The self-administered questionnaires will be translated into the nat ive language of the region, 
linguist ically validated and administered according to the SoA (Secti on 1.3). At these visits, the 
questionnaires should be co mpleted before the participant has discussed their medical condit ion 
or progress in the study  with the invest igator and/or site staff ,if the participant is not adversely 
affected by  their fast ing condit ion.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
528.1.3.1. Short -Form 36 Version 2 Health Survey , Acute Form, 1-Week Recall Version
The SF -
36v2 acute form, 1-week recall versio nis a 36-item generic, pa rticipant -administered 
measure designed to assess the following 8 dom ains
 Physical functioning 
 Role
-physical
 Bodily pain
 General health
 Vitality
 Social 
functioning 
 Role-emotional 
 Mental  health 
The Physical Functioning domain assesses limitations due to health “now” while the remaining 
domains assess funct ioning “in the past week.” Each do main is scored individually  and 
inform ation from these 8 dom ains are further aggregated into 2 health -component summary 
scores: Physical Com ponent Summary  and Mental Com ponent Summary . Items are answered on 
Likert scales of varying lengths (3 -, 5- or 6-point scales). Scoring of each do main and both 
summary scores are norm -based and presented in the form of T -scores, with a mea n of 50 and 
standard deviat ion (SD) of 10; hi gher scores indicate better levels of funct ion and/or better health 
(Marui sh 2011).
8.1.3.2. Impact of Weight on Quality of Life -Lite Clinical Trials Version
The IWQOL -Lite-CT is a 20 -item, obesi ty-specific PRO instrumen t devel oped f or use in obesi ty 
clinical trials. It assesses 2primary  dom ains o f obesit y
-related healt h-related quali ty of life 
(HRQ oL): Phy sical (7 i tems), and Psychosocial (13 items). A 5 -item subset of the Phy sical 
domain –the Physical Funct ion composite is also supported. Items in the Physical Funct ion 
composite describe physical impacts related to general and specific physical activit ies. All items 
are rated on either a 5 -point frequency (“never” to “always”) scale or a 5 -point truth (“not at a ll 
true” to “completely true”) sc ale (Ko lotkin et a l. 2017, 201 9). 
8.1.3.3. EQ-
5D-5L
Generic HRQoL will be assessed using the EQ -5D- 5L (EuroQoL Research Foundat ion 2019). 
The EQ -
5D-5L is a standardized 5-item instrum ent for use as a m easure of healt h outcome. It 
provi des a simple descriptive profile and a single index value for health status that can be used in 
the clinical and econo mic evaluat ion of healt hcare as well as populat ion healt h surveys. The 
EQ-
5D-5L com prises 5 dimensi ons of health (mobility, self -care, usual  activi ties, pain/discomfort, 
and anxiet y/depressi on). The 5L versio n, introduced in 2005, scores each dimensio n at 5 levels 
(no probl ems, slight problems, moderate problems, severe problems, unable to perform/extreme 
probl ems), for a total of 3 125possible healt h states. In addit ion to the healt h profile, a single 
healt h state index value can be derived based on a formula that attaches weights to each of the 
levels in each dimensio n. This index value ranges between l ess than 0 (where 0is a healt h state 
equivalent to death; negat ive values are valued as worse than dead) to 1 (perfect healt h)(Dolan 
1997). In addit ion, the EQ Visual Analog Scale records the respondent ’s self -rated heal th status 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
53on a verti cal graduated (0 to 100) visual analogscale. I n conjunct ion with the healt h state data ,it 
provi des a com posite picture of  the respondent’s health status.  
The EQ -5D- 5L is used worldwide and is available in more than 170 different languages. Details 
on the instrument, scoring, organizing, and presenting the data collected can be found in the 
EQ-5D- 5L User Guide (EuroQoL Research Foundation 2019) . 
8.1.3.4. Patient Global Impression of Status for Physical A ctivity 
Study  parti cipants will be asked to complete a PGI sitem specifically  devel oped f or thi s study. 
This is a pa rtic
ipant-rated assessment of current limitat ion on physical act ivity due to heal th and is 
rated on a 5 -point scale ranging from “1 -not at all limited” to “5 -extremely limited” .
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provi ded in the SoA.
8.2.1. Physical Examinations
A co mplete physical examinat ion will include, at a minimum, assessments of 
the cardiovascular, respiratory , GI and neurol ogicalsystems , as well as thy roid 
exam . Hei ght, weight , and waist circumference will also be measured and 
recorded , per Section 10.7.
Invest igators should pay special attention to clinical signs related to previous 
serious illnesses.
8.2.2. Vital Signs
For each participant , vital signs m easurements shoul d be conducted according 
to the S oA(Section 1.3) and fo llowing the stud y-specific recommendations 
included in Section10.7 (Appendix 7).
Any clinically  significant findings from vital signs measurement that result in a 
diagnosis shoul d be reported to Lilly  or its desi gnee as an AE via the eCRF.
8.2.3. Electrocardiograms
For each participant, single -tracing 12-lead e lectrocardi ogram s (ECGs) shoul d be collected 
according to the S oA.
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally  
while the participan t is still present, for immediate participant management, should any clinically 
relevant findings be identified . Any clinically  significant findings from ECGs that result in a 
diagnosis shoul d be reported to Lilly  or its desi gnee as an AE via the eCRF.
All digital ECGs will be obtained using centra lly provided ECG machines and will be 
electroni cally transmitted to a designated central ECG laboratory .The central  ECG laboratory  
will perform a basic qualit y control  check ( for example , dem ographics and study  details) and then 
store the ECGs in a databa se.At a future time, the stored ECG data may  be overread by  a 
cardi ologist at the central  ECG l aboratory  for further evaluat ion of machine -read measurements or 
to meet regul atory  requi rements. The m achine -read ECG intervals and heart rate may be used for 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
54data analysis and report -writing purposes, unless a cardio logyoverreading of the ECGs is 
conducted pri or to com pletion of the final study  report (in which case, the overread data would be 
used).
8.2.4. Clinical Safety Laboratory Assessments
SeeSecti on10.2, Appendix 2 : “Clinical Laboratory  Tests ” for the list of 
clinical laboratory  tests to be performed and to the So A for the timing and 
frequency .
Note : see Secti on 10.2 Appendix 2 : “Clinical Laboratory  Tests ”for clinical 
laboratory  tests reported or n ot reported to the investigator
The invest igator must review the laboratory resul ts, docum ent this review, and
report any clinically relevant changes occurring during the study as an AE. The 
laboratory  resul ts must be retained with source documents unless a Source 
Docum ent Agreement or com parable docum entcites an electroni c locati on that 
accommodates the expected retention duration . Clinically significant abnormal 
laboratory  findings are those which are not associated with the underlying 
disease, unless judged by the invest igator to be more severe than expected for 
the participant's condit ion.
All laboratory  tests wi th values considered clinically  significantly abnorm al 
during participat ion in the study or within 4weeks after the l ast dose of study  
intervent ion shoul d be repeated until the v alues return to normal or most recent 
baseline or are no longer considered clinically significant by  the invest igator or 
medical mo nitor.
○If such values do not return to normal/ most recent baseline within a period 
of time j udged reasonable by the invest igator, the eti ology shoul d be 
ident ified and the sponsor notified.
○All protocol -requi red laboratory  assessments, as defined in Section 10.2, 
must be conducted in accordance wit h the SoA, standard collection 
requi rements , and laboratory  manual .
If laboratory  values fro m non-protocol  specified l aboratory  assessments 
perform ed at aninvest igator -designated local laboratory  requi re a change in 
participant m anagement or are considered clinically  significant by  the 
investigator ( for example , SAE ,AE,or dose m odificat ion), then report the 
inform ation as an AE .
Repeat or unscheduled sam ples m ay be taken for safet y reasons or for technical issues with the 
samples. Unless otherwise stated in the subsect ions below, all samples collected for specified 
laboratory  tests will be destroyed within 60 days of receipt of confirmed test results. Cer tain 
samples may  be retained for a l onger peri od, if necessary , to com ply wi th applicable laws, 
regul ations, or laboratory  certificat ion standards .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
558.2.5. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods. The study  team  will review safet y reports in a blinded fashio n according to the schedule 
provi ded in the Trial- Level  Safety  Review plan. Lilly  will also revi ew SAEs wi thin time frames 
mandated by  com pany  procedures. The Lilly CRP will, as appropri ate, consul t with the 
funct ionally  independent Gl obal Patient Safet y therapeuti c area physician or clinical scient ist.
8.2.5.1. Hepatic Safety Monitoring
Close Hepatic Monitoring 
Laboratory  tests ( Secti on 10.6, Appendix 6 ), including ALT, AST, ALP, TBL, direct bilirubin , 
gamma- glutamyl  transferase , and creatine kinase , shoul d be repeated wi thin 48 to 72 hours to 
confirm the abnormalit y and to determ ine if it is increasing or decreasing, if 1or more of these 
condi tions occur: 
If a participant with baseline results of… develops the following elevations:
ALT or AST <1.5X ULN ALT or AST ≥3XULN
ALP <1.5X ULN ALP ≥2XULN 
TBL <1.5 XULN TBL ≥2XULN (except for patients with Gilbert’s 
syndro me)
ALT or AST ≥1.5X ULN ALT or AST ≥2Xbaseline 
ALP ≥1.5X ULN ALP ≥2Xbaseline 
TBL ≥1.5X ULN TBL ≥1.5Xbaseline (except for patients with 
Gilbert’s syndrome)
Abbreviations: ALP = a lkaline phosphatase ;ALT = a lanine aminotransferase ; AST = a spartate aminotransferase ; 
TBL =total bilirubin level; ULN = upper limit of normal.
Note : In this study  baseline m ay refer to l ead-in enrollment visit sor randomizat ion visit, 
whichever i s the m ost recent point of r eference.
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with 
the Lilly -designated m edical mo nitor. At a minimum , this evaluat ion shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (includ ing over -the-counter), herbal and dietary  supplements, and history  of alcohol  
drinking and other substance abuse. 
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipan t’s clinical condit ion and hepat ic biochemical tests. 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
56Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and l ab resul ts stabilize. Moni toring of ALT, AST, ALP, and TBL 
shoul d cont inue unt il levels normalize or return to approximate baseline levels.
Comprehensive Hepatic Evaluation
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur: 
If a participant with baseline results of… develops the following elevations:
ALT or AST <1.5X ULN ALT or AST ≥3XULN with hepat ic 
signs/symptom s*, or ALT or AST ≥5XULN 
ALP <1.5X ULN ALP ≥3XULN 
TBL <1.5 XULN TBL ≥2XULN (except for patients with Gilbert’s 
syndro me) 
ALT or AST ≥1.5X ULN ALT or AST ≥2X baseline wit h hepat ic 
signs/symptom s*, orALT or AST ≥3Xbaseline 
ALP ≥1.5X ULN ALP ≥2Xbaseline 
TBL ≥1.5X ULN TBL ≥2X baseline (except for patients with 
Gilbert’s syndrome)
Abbreviations: ALP = a lkaline phosphatase ; ALT = a lanine aminotransferase ; AST = a spartate aminotransferase ; 
TBL =total bilirubin level; ULN = upper limit of normal.
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, jaundice, right upper quadrant abdominal pain, fever, 
rash, and/or eosinophilia >5%. 
Note :In this study  baseline m ay refer to l ead-in enrollment visit sor randomizat ion visit, 
whichever i s the most recent point of reference.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin -time-INR; tests for viral hepatit is A, B, 
C, or E; tests for autoimmune hepat itis; and an abdominal imaging study  (for exam ple, ul trasound 
or computed tomography ( CT)scan).
Based on the pa rticipan t’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, urine 
toxicology screen, Wilson’s disease, blood alcoho l levels, urinary ethyl glucuronide, and blood
phosphatidylethanol. Base d on the ci rcumstances and the investigator’s assessment of the 
participant’s clinical condit ion, the invest igator should consider referring the participant for a 
hepatol ogist or gastroenterologist consultation, magnet ic resonance cho langiopancreatography ,
endoscopi c retrograde cholangiopancreatography ,cardi ac echocardi ogram , or a liver biopsy. 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
57Additional Hepatic Data Collection ( Hepatic Safety CRF) in Study Participants Who Have 
Abnormal Liver Tests During the Study
Addit ional hepatic safet y data collect ion in hepat ic safet y case report forms (CRF s) shoul d be 
perform ed in study  parti cipants who meet 1 or more of the fo llowing 5 condi tions: 
1. El evation of serum ALT to ≥5XULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5 XULN) 
In parti cipants wi th baseline ALT ≥1.5
XULN, the thresho ld is ALT ≥3Xbaseline on 
2 or m ore consecut ive tests 
2. El evated TBL to ≥2XULN (if baseline TBL <1.5X ULN) (except for cases of known 
Gilbert’s syndrome) 
In parti cipants w ith baseline TBL ≥1.5X ULN, the thresho ld should be TBL ≥2X
baseline 
3. El evation of serum ALP to ≥2XULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5XULN) 
In parti cipants wi th baseline ALP ≥1.5X ULN, the thresho ld is ALP ≥2Xbaseline on 
2or more consecut ive blood tests 
4. Hepatic event considered to be an SAE 
5. Di scontinuati on of  intensive lifest yle intervent ion or study drug intervent ion due to a 
hepat ic event
Note: the interval between the 2 consecut ive blood tests should be at lea st 2 day s. 
Note :In this study  baseline m ay refer to l ead-in enrollment visit sor randomizat ion visit, 
whichever i s the m ost recent point of reference.
8.2.6. Depression, Suicidal Ideation and Behavior Risk Monitoring
Patients who have obesit y or are overwei ghtare at increased risk for depression (Luppino et al. 
2010). Depression can increase the risk for suicidal ideation and behavior. Therefore, study  
participants will be screened at trial entry  and m onitored during the study  for depressi on,suicidal 
ideat ionand behavior. 
Parti cipants should be monitored appropriately and observed closely for suicidal ideation and 
behavior or any  other unusual changes in behavior, especially at the beginning and end of the 
course of treatment, or at the time of dose changes, either increases or decreases. Considerat ion 
shoul d be given to discont inuing intensive lifest yle intervent ion or the study  drug intervent ion in 
participants who experience signs of suicidal ideat ion or behavior, fo llowing a ri sk assessment
(Secti on 7.1).
Baseline and treatm ent em ergent assessment of depressio n, suicidal i deati on and behavior will be 
monitored during the study using the C -SSRS and PHQ -9 (Section 8.3.2.13 ).
8.3. Adverse Events ,Serious Adverse Events , and Product Complaints
The definit ions of the fo llowing events can be found in Section 10.4 (Appendix 4 ):
 Adverse events (AEs)
CONFIDENTIAL Protocol  number I8F -MC-GPHM
58 Serious adverse events (SAEs)
 Product complaints (PCs)
These events will be reported by  the parti cipant (or, when appropriate, by  a caregiver, surrogate, 
or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definit ions and remain responsible for following up events that 
are seri ous, considered related to the study  drug intervent ion, or study  procedures (for example, 
intensive lifest yle intervent ion), or that caused the participant to discont inue the study  
intervent ion (see Section 7).
Care will be taken not to introduce bias when detecting events . Open -ended and non -leading 
verbal quest ioning of the participant is the preferred method to inquire about event occurrences .
After the init ial report, the invest igator is required to proactively fo llow each participant at 
subsequent visits/contacts. All SAEs, will be fo llowed unt il reso lution, stabilizat ion, the event is 
otherwi se explained, or the participant is lost to follow
-up (as defined in Sect ion7.3). For product 
complaints, t he invest igator is responsible for ensuring that fo llow
-up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y.Further i nformation on 
follow-up procedures is provi dedin Section10.4 (Appendix 4) .
8.3.1. Timing and Mechanism for Collecting Events
This table describes the timing, deadlines, and mechanism for collect ing events.
Event Collection Start Collection Stop Timing for 
Reporting to 
Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Adverse Event
AE signing of the 
informed consent 
form (ICF) the safety follow -
up visit OR 
participation in 
study has endedAs soon as possible 
upon site awarenessAE eCRF N/A
Serious Adverse Event
SAE and SAE 
updates –prior 
to start of study
drug
interventio n 
anddeemed 
reasonably 
possibly related 
with study 
proceduressigning of the 
informed consent 
form (ICF)start of study drug
interventio nWithin 24 hours of 
awarenessSAE eCRF SAE paper 
form
CONFIDENTIAL Protocol  number I8F -MC-GPHM
59Event Collection Start Collection Stop Timing for 
Reporting to 
Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
SAE and SAE 
updates –after 
start of study 
drug
interventio nstart of study  
drug interventio nThe safety follow -
up visit OR 
participation in 
study has endedWithin 24 hours of 
awarenessSAE eCRF SAE paper 
form
SAE –after 
participant’s 
study 
participation 
has ended and
the investigator 
becomes awareAfter 
participant’s 
study 
participation has 
endedN/A Promptly SAE paper form N/A
Pregnancy
Pregnancy in
female 
participants and 
female partners 
of male 
participantsAfter the start of 
study 
interventio nFour mo nths after 
the last injection 
for female 
partners ofmale 
participants and 2 
months after the 
last injection for 
female 
participantsWithin 24 hours of 
learning of the 
pregnancyeCRF SAE paper 
form
Product Complaints
PC associated 
with an SAE or 
might have led 
to an SAEStart of study
drug interventionEnd of study drug 
interventio nWithin 24 hours of 
awarenessProduct 
Complaint formN/A
PC not 
associated with 
an SAEStart of study
drug interventionEnd of study drug
interventio nWithin 1 business 
day of awarenessProduct 
Complaint formN/A
CONFIDENTIAL Protocol  number I8F -MC-GPHM
60Event Collection Start Collection Stop Timing for 
Reporting to 
Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Updated PC 
information— — As soon as possible 
upon site awarenessOriginally 
completed 
Product 
Complaint form 
with all changes 
signed and dated 
by the investigatorN/A
PC (after 
partic ipant’s 
study 
participation 
has ended and
theinvestigator 
becomes aware)After 
participant’s 
study 
participation has 
endedN/A Promptly Product 
Complaint formN/A
Abbreviations: AE = adverse event; eCRF = electronic case report form; N/A = not applicable; PC =product 
complaint; SAE = serious adverse event. 
8.3.2. Special Safety Topics
8.3.2.1. Hypoglycemia 
Upon ICF signing, all participants will be educated about signs and symp toms of  hypoglycemia, 
how to treat hy poglycemia, and how to collect appropriate informat ion for each episode of 
hypoglycemia.
Hypoglycemia may  be identified by spontaneous reporting of symptoms from part icipants 
(whether confirmed or unconfirmed by simultaneous glucose values) or by  blood gl ucose (BG) 
samples co llected during study visits.
All participants who develop diabetes du ring the study  will be provi ded wi th glucometers. 
Parti cipants wi thout di abetes m ay be given glucometers to assist in the evaluat ion of reported 
symptoms consistent with hypoglycemia at the investigator’s discret ion. Participants receiving 
glucometers will be provided a diary  to record rel evant informat ion (for example, glucose values, 
symptoms).
All hypoglycemic episodes will be recorded on a specific eCRF (Hy poglycemic Events eCRF) 
and should not be recorded on the AE eCR F, unless the event meets serious criteria. If a 
hypoglycemic event meets severe criteria (see definit ion below), it should be recorded as serious 
on the AE and SAE eCRFs, and reported to Lilly as an SAE. All hypoglycemic events collected 
on the hypoglycemic eCRF will be considered as trea tment-emergent (TE) and included in the 
analysis of incidence and rate of hypoglycemic events . 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
61Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an episode considered to be related to hy poglycemia (the BGvalues in this sect ion refer to values 
determined by a laboratory  or Internati onal Federati on of  Clinical  Chemistry  and Laboratory  
Medicine blood -equivalent glucose meters and strips) in accordance with the 20 20American 
Diabetes Association posit ion statem ent on glycemic targets (ADA 2020):
Glucose Alert Value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels that he or 
she is experiencing symptoms and/or signs associated with hypoglycemia and has a BG
level of <70 m g/dL ( <3.9 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not accompanied by 
typical symptom s of hypoglycemia, but with a measured BG <
70mg/dL ( <3.9mmo l/L).
Documented unspecified hypoglycemia is define d as any  event wi th no inform ation 
about symptoms of hypoglycemia available, but with a measured BG <70 m g/dL ( <3.9
mmo l/L).
Clinically Significant Hypoglycemia (Level 2):
Documented symptomatic hypoglycemia is defined as any time a participan t feels that 
heor she is experiencing symptoms and/or signs associated with hypoglycemia and has a 
BG l evel of <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not accompanied by 
typical symptom s of hypoglycemia but with a measured BG <54 mg/dL (<3.0 mmo l/L).
Documented unspecified hypoglycemia is define d as any  event wi th no inform ation 
about symptoms of hypoglycemia available but with a measured BG <54 m g/dL 
(<3.0 mmo l/L).
Severe hypoglycemia (Level 3):
Severe hypoglycemia is defined as an episode with severe cognit ive impairment requiring 
the assistance o f another person to actively  administer carbohy drate, gl ucagon, or other 
resuscitat ive act ions. These episodes may be associated with sufficient neuroglycopenia to 
induce seizure or com a.Blood gl ucose m easurements m ay not be available during such an 
event, but neurological recovery attributable to the restoration of BG to normal is 
considered sufficient evidence that the event was induced by a low BG concentration.
To avoid duplicate re porting, all consecutive BG values <70mg/dL ( <3.9 mmo l/L) occurring 
within a 1- hour period may be considered to be a single hypoglycemic event (Weinberg
etal.2010; Danne et al. 2013).  
8.3.2.2. Pancreatitis 
Diagnosis of Acute Pancreatitis
Acute pancreat itis isan AE of interest in all studies w ith tirzepat ide, including this study . The 
diagnosis of acute pancreat itis requires 2 of the fo llowing 3 features (Banks et al. 2006; Koizumi  
2006): 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
62abdo minal pain, characterist ic of acute pancreat itis (that i s, epigastri c pain radiat ing to 
the back, often associated with nausea and vo miting)
serum  amylase (total, pancreat ic, or both) and/or lipase ≥3X ULN
characterist ic findings of acute pancreat itis on CT scan or magnet ic resonance imaging 
(MRI)
If acute pancrea titis is suspected, the invest igator should
obtain appropriate laboratory  tests, including pancreatic amylase (p -amylase) and 
lipase
perform  imaging studies, such as abdo minal CT scan wit h or without contrast, 
abdo minal MRI , or gallbladder ultrasound
Note: Abdo minal ultrasound may be used as an alternat ive method only if CT and MRI 
cannot be performed .
evaluate for possible causes of acute pancreatit is, including alcoho l use, 
gallstone/gallbladder disease, hypertriglyceridemia, and concomitant medications.
Discontinuation for A cute Pancreatitis
If acute pancreat itis is diagnosed after randomizat ion, the participant must discont inue use of the 
IP, but will cont inue in the study .
Case Adjudication and Data Entry
An independent clinical endpo int committee (CEC) will adjudicate all suspected cases of acute 
pancreat itis. In addit ion, AEs o f severe or serious abdo minal pain o f unknown et iology will also 
be submitted to the adjudication co mmittee to assess for possible pancreat itis or other pancreatic 
disease. 
Asymptomatic Elevation of P ancreatic Amylase and/or Lipase
Serial measures of pancreat ic enzymes have limit ed clinical value for predicting episodes of acute 
pancreat itis in asymptom atic patients (Nauck et al. 20 17; Steinberg et al. 2017a, 2017b). 
Therefore, further diagnostic fo llow
-up of  cases of asymptom atic elevat ion of pancreatic enzymes 
(lipase and/or p -amylase ≥3X ULN) i s not m andated but m ay be performed based on the 
investigator’s clinical judgment and as sessment of the participant’s overall clinical condit ion. 
8.3.2.3. Thyroid Malignancies and C -Cell Hyperplasia 
Individuals with personal or family history  of MTC and/or MEN syndro me type 2 will be 
excluded fro m the study . Parti cipants who are diagnosed with MTC and/or MEN syndrome t ype2 
during the study  will have intensive lifest yle intervent ion or study drug intervent ionstopped and 
shoul d cont inue follow-up wi th an endocrino logist.
The assessment of thy roid saf ety during the tri al will include reporting of any case o f thyroid 
malignancy (including MTC ,papillary  carcinom aand others ) and m easurements of calcitonin. 
Thesedata will be captured in specific eCRFs. The purpose of calcitonin measurements is to 
assess the potential of t irzepat ide to affect thyroid C -cell funct ion, which may  indicate 
development of C -cell hyperpl asia and neopl asms. 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
638.3.2.4. Calcitonin Measurements 
If an increased calcitonin value (see definit ions below) is observed in a participan t who has been 
administered a medicat ion that is known to increase serum calcitonin , then this medicat ion shoul d 
be stopped ,and calcitonin levels should be measured after an appropriate washout period.
For participan tswho require addit ional endocrine assessment because of increased calcitonin 
concentration as defined in this sect ion, data from the fo llow-up assessment will be co llected in 
the specific sect ion of the eCRF.
Calcitonin Measurements in Participants with eGFR ≥60 mL/min /1.73 m2
A significant increase in calcitonin for participants with eGFR ≥60 mL/min /1.73 m2is defined 
below. If a participant ’s laboratory  resul tsmeet th esecriteria, these clinically  significant 
laboratory  resul tsshoul d be recorded as an AE.  
Serum calcitonin value ≥20 ng/L and <35 ng/L AND ≥50% increase from the baseline
valu
e.These participants will be asked to repeat the measurement within 1 month. If thi s 
repeat val ue is increas ing (≥10% increase), the study  drug shoul d be stopped, and the 
participant encouraged to undergo addit ional endocrine assessment and longer term,
follow-up by  an endocrinol ogist to excl ude a nyserious adverse effect on the thyroid.
Serum calcitonin value ≥35 ng/L AND ≥50% over the baseline value . In these participants , 
study  drug shoul d be stopped, and the participant recommended to immediately under go 
additional endocrine assessments and lo nger term ,follow
-up by  an endocrinol ogist.
Calcitonin Measurement in Participants with eGFR <60 mL/min /1.73 m2
A significant increase in calcitonin for participants with eGFR <60 mL/min /1.73 m2is defined as 
a serum calcitonin value ≥35 ng/L AND ≥50% over the baseline value. If a participant ’s labs meet 
thesecriteria, these clinically  significant l abs should be recorded as an AE.  
In these participants, study  drug shoul d be di scontinued (after first confirming the value) and the 
participant recommended to immediately undergo addit ional endocr ine assessments and lo nger 
term,follow
-up by an endocrino logistto exclude any serious adverse effect on the thy roid.
Note: In this study  baseline m ay refer to l ead-in enrollment visit sor randomizat ion visit, 
whichever i s the m ost recent point of reference.
8.3.2.5. Major Adverse Cardiovascular Events
Deaths and nonfatal cardi ovascular AEs will be adjudicated by  a commi ttee of  physicians external 
to Lilly  with cardi ology expert ise. This committee will be blinded to treatment assignment. The 
nonfatal  cardi ovascular AEs to be adjudicated include
 myocardial  infarct ion 
 hospi talizati on for unstable angina
 hospi talizati on for heart failure
 coronary  intervent ions (such as coronary  artery bypass graft or percu taneous 
coronary  intervent ion), and 
 cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
648.3.2.6. Supraventricular A rrhythmias and Cardiac Conduction Disorders
Treatment -emergent cardiac conduction disorders will be further evaluated. Participants who 
develop any event from these groups of disorders should undergo an ECG, which should be 
submitted to the central reading center. Additional diagnostic tests to determine exact diagnosis 
shoul d be perform ed, as needed. The specific diagnosis will be recorded as an AE. Events that 
meet criteria for serious conditions as described in Section 10.4 mustbe reported as SAEs .
8.3.2.7. Hypersensitivity Reactions
Many  drugs, but parti cularly biologic agents ,carry the ri sk of systemic hypersensit ivity react ions.
If such a react ion occurs, a dditional data describing each symptom should be provide dto the 
sponsor in the eCRF .
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment available 
when study  parti cipants are receiving study  drug. It is recommended that participants who 
experience a systemic hypersensit ivity react ion be treated per national and internat ional 
guidelines.
In the case of generalized urticaria or anaphylaxis, addit ional blood and urine samples should be 
collected as described in Secti on 10.3, Appendix 3, “Laboratory  Test ing for Hypersensi tivity 
Events”. Laboratory re sults are provi ded to the sponsor via the central laboratory .
8.3.2.8. Injection -Site Reactions
Symptoms of a localinject ion-site reacti on may  include ery thema, indurati on, pain, pruri tus, and 
edem a. If an inject ion site event is reported, the AE will be recorded, and additional data will be 
provi ded to the sponsor in the eCRF.  
Inject ion site reactions will be co llected on theeCRF separate from the hypersensit ivity react ion 
eCRF. At the time of AE occurrence, samples will be co llected for measurement of tirzepati de
antidrug ant ibodies ( ADA )and tirzepat ideconcentrati on.
8.3.2.9. Antid rug Antibodies
The occurrence of ADA format ion will be assessed as outlined in Section 8.9.
8.3.2.10. Hepatobiliary Disorders
All events of TE biliary  colic, chol ecyst itis, or oth er suspected events related to gallbladder 
disease shoul d be evaluated and addit ional diagnostic tests performed, as needed. In cases of 
elevated liver m arkers, h epati c monitoring shoul d be init iated as outlined in Sect ion8.2.5.1 .
8.3.2.11. Severe Gastrointestinal Adverse Events 
Tirzepati de m ay cause severe GI AEs, such as nausea, vomit ing, and diarrhea. Informat ion about 
severe GI AEs as well as ant iemetic/ant idiarrheal use will be collected in the eCRF/AE form. For 
detailed informat ion concerning the management of GI AEs, please refer to Secti on6.6.2 .
8.3.2.12. Acute Renal Events
Renal safety  will be assessed based on repeated renal funct ion assessment as well as assessment 
of AEs suggest ive of acute or worsening of chronic renal failure. Gastrointestinal AEs have been 
reported with tirzepat ide, including nausea, di arrhea, and vo miting.This is consistent with other 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
65GLP -1Ragoni sts (Aroda and Ratner 2011). The events may lead to deh ydrat ion, which could 
cause a deterioration in renal funct ion, including acute renal failure. Participants shoul d be 
advised to notify invest igators in case of severe nausea, frequent vomit ing, or symptoms of 
dehydrat ion.
8.3.2.13. Depression, Suicidal Ideation or B ehavior Monitoring
Parti cipants will be m onitored f or depressi on and sui cidal i deati on or behavior through AE 
collect ion and by using the C -SSRS and the PHQ -9. Parti cipants will be referred to a nMHP if in 
the opi nion ofthe invest igator it is necessary  for the safe ty of the parti cipant or if the participant 
had any  of the f ollowing:
a PHQ -
9 score ≥15
C-SSRS responses of
oA “yes”answer to Question 4 (Act ive Suicidal Ideation with So me Intent to Act, 
Without Specific Plan) on the “Suicidal  Ideat ion”porti on of  the C -SSRS
or
oA “yes”answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and Intent) 
on the “Suicidal Ideati on”porti on of  the C -SSRS 
or 
oA “yes”answer to any  of the suici de-related behaviors (actual attempt, interrupted 
attem pt, aborted attempt, preparatory  act,or behavior) on the “Suicidal  Behavi or”
porti on of  the C -SSRS
8.4. Treatment of Overdose
Study  drug overdose (more than the specified number of injections) will be reported as an AE. In 
the event of overdos e, refer to the IB for tirzepat ide.
8.5. Pharmacokinetics
Not applicable .
8.6. Pharmacodynamics
Samples to assess the PD properties of tirzepat ide are included in the efficacy measures and not 
applicable in this sect ion.
8.7. Genetics
A who le blood sample will be co llected for pharmacogenet ic analysis as specified in the SoA 
(Secti on1.3) where local regulat ions allow.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either now 
or in the future. Samples will be used to invest igate variable response to tirzepat ide and to 
investigate genet ic variants though t to pl ay a rol e in obesi ty. Assessment of var iable response may 
include evaluat ion of AEs or differences in efficacy.  
All samples will be coded with the pa rticipant number. These samples and any data generated can 
be linked back to the participant only by  the investigator site personnel.  
CONFIDENTIAL Protocol  number I8F -MC-GPHM
66Samples will be retained at a facilit y selected by  Lilly  or its designee for a m aximum  of 15years 
after the l ast parti cipant visit for the study , or f or a shorter peri od if l ocal regulat ions and/or 
Ethical  Review Boards (ERBs)/ InstitutionalReview Boards (IRBs )impose shorter time limit s. 
This retention period enables use of new techno logies, response to regulatory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of 
tirzepat ide or after tirzepatide beco me(s ) commercially  available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named. However, exi sting approaches include who le geno me or exome 
sequencing, geno me wide association studies, a nd candidate gene studies. Regardless of 
techno logy utilized ,genoty ping data generated will be used only for the specific research scope 
described in this sect ion.
8.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, PD, mechanism of act ion, variabilit y of parti cipant response (including safet y), and 
clinical outcome. Sample collection is incorporated into clinical studies to enable examinat ion of 
these quest ions through measurement of b iomo lecul es including deoxy ribonucleic acid (DNA), 
proteins, lipids, and other cellular elements.
Serum  and plasma samples for bio marker research (non-pharmacogenet ic stored sample) will be 
collected at the times specified in the SoA (Section 1.3) where local regulat ions allow.
Samples will  be used for research on the drug target, disease process, variable response to 
tirzepat ide, pathways associated with obesit y, mechanism o f action of  tirzepat ide, and/or research 
method or i n validat ing diagnost ic tools or assay(s) related to o besit y.  
All samples will be coded with the participant number. These samples and any data generated can 
be linked back to the participant only by the investigator site personnel.  
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  15years 
after the l ast parti cipant visit for the study , or f or a shorter peri od if l ocal regulat ions and ERBs 
impose shorter time limits. This retent ion peri od enables use of new technologies, response to 
regul atory  questi ons, and invest igation of variable response that may not be observed unt il later in 
the developmen t of tirzepat ide or after tirzepat ide beco me(s) commercially  available.
8.9. Immunogenicity Assessments
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collected to determine ant ibody  producti on against tirzepat ideas specified in the SoA
(Secti on1.3).
For immunogenicit y testing, venous blood samples will be co llected from each participant 
according to the S oA(Secti on 1.3) to determine antibody  producti on against ti rzepat ide.To 
interpret the resul ts of immunogenicit y, a PK sample will be co llected at the same t ime points as 
the immunogenicit y sample . All samp les for immunogenicit y shoul d be taken predose when 
applicable and possible. 
In the event of systemic drug hypersensit ivity reacti ons (immediate or nonimmediate), addit ional 
unscheduled samples will be collected as detailed in Section 8.3.2.7 (Hypersensi tivity React ions).
CONFIDENTIAL Protocol  number I8F -MC-GPHM
67Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor. The 
actual date and time (24 -hour clock time) of each sampling will be recorded. Sample scollected at 
Visit 801 will  assess immunogenicit y at washout of t irzepat ide (5 half -lives post end of 
treatm ent).
Immunogenicit y will be assessed by  a validated assay  designed to detect ADAs in th e presence of 
tirzepat ide at a labo ratory  approved by the sponsor. Antibodies may be further characterized for 
their abili ty to neutralize the activit y of tirzepat ide on GIP and GLP -1 receptors. Posit ive 
tirzepat ideADA samples willbe tested for cross -reactivit y with native GIP and GLP -1, and, if 
positive, m ay then be tested for neutralizing ant ibodies against native GIP and/or GLP -1. In vivo 
laboratory  indicators for effect on weight loss and PK will be utilized to detect potential 
neutralizing effect of ADA against tirzepatide .
Treatment -emergent ADAs are defined in Section9.4.6 .  
Samples will  be retained for a m aximum  of 15 y ears after the last participant visit, or for a shorter 
period if local  regulat ions and ERBs allow, at a facilit y selected by  the sponsor. The duration 
allows the sponsor to respond to future regulatory  request s related to tirzepat ide. Any samples 
remaining after 15 y ears will be destroy ed. 
Concentrations of tirzepat ide will be assayed using a validated liquid chro matography  mass 
spectrometry  method. Bi oanaly tical samples collected to m easure ti rzepat ide conce ntrations will 
be retained for a maximum o f 1 year following last subject visit for the study .During this t ime, 
samples remaining after the bioanalyses may be used for exploratory  analyses such as metabolism 
work, protein binding, and/or bioanalyt ical met hod cross -validat ion.
8.10. Health Economics
Health Economics param eters are not evaluated in this study .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
689. Statistical Considerations
9.1. Statistical Hypotheses
The al ternat ive hypothes is for the primary  object ive isthe following:
H1: QW ti rzepat ide MTD is superio r to pl acebo for mean percent change in body  weight AND 
proporti on of  parti cipants who achi eve ≥5% body  weight reducti on from rando mizat ion to
72weeks.
The above hypothes is will be tested at 2 -sided significance level o f 0.05.
The al ternat ive hypotheses for the key  secondary object ivescontrolling for ty pe 1 error rate are 
the following: 
H2:QW tirzepat ide MTD is superior to placebo for percentage of participants who maintain ≥80% 
of the body  weight lost during the 12- week lead-in period.
H3:QW tirzepat ide MTD is superior to placebo for proportion of participants who achieve ≥10% 
body  weight reducti on from rando mizat ion to72 weeks.
H4:QW tirzepat ide MTD is superior to placebo for proportion of participants who achieve ≥15% 
body  weight reduct ion from rando mizat ion to72 weeks.
H5: QW ti rzepat ide MTD is superior to placebo for mean change in waist circumference (cm) 
from randomization to72 weeks.
9.2. Sample Size Determination
Approximately  
1100 participants will be screened and 800 participants enro lled into the 12 -week 
lead-in period in order to achieve approximately 600 parti cipants randomly  assigned to study  drug 
intervent ion (300 participants per treatm ent group). 
The sample size determinat ion assumes that evaluation of superi ority of tirzepati de MTD (10 mg 
or 15 m g) to placebo will  be conducted at a 2 -sided significance level o f 0.05 using a 2
-sample 
t-test. Addit ionally , a difference of at l east 1 2% mean body  weight percentage reduction from 
rando mizat ion at 72 weeks fo r tirzepati de MTD compared to pl acebo, a commo n SD of 10%, and 
a dropout rate of 25% are assumed for statist ical power calculat ions. Under the assumpt ions 
above, rando mizing 600 participants in a 1:1 ratio to MTD (300 participants ) and placebo ( 300
participants ) provi des m ore than 90% power to demo nstrate superiorit y of tirzepat ide MTD to 
placebo. 
The chosen sample size and rando
mization ratio also provides >90% power to establish 
superi ority of tirzepat ide MTD to placebo in term sof proporti on of  parti cipants achieving at least 
5% body  weight reducti on from rando mizat ion at 72 weeks, based on a Chi -square test at a 2 -
sided si gnificance l evel of 0.05, assuming 20% placebo treated participants and 46% ti rzepat ide 
treated participant s achieve the goal  and a dropout rate of 25%.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
699.3. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Entered All participants who sign informed consent
Enrolled All participants who are enrolled in12-week lead - in period 
Randomized All participants who are randomly assigned a study drug.  
Modified Intent -to-Treat (mITT) All randomly assigned participants who are exposed to at least 1 dose of study 
drug. Participants will be included in the treatment group to which they were 
randomized.
Efficacy Analysis Set (EAS) Data obtained during the double -blind treatment period fro m the mITT
populatio n, excluding data after discontinuation of study drug (last dose date + 7 
days)
Full Analy sis Set (FAS) Data obtained during the treatment period from mITT population , regardless of 
adherence to study drug. 
Safety Analy sis Set (SS) Data obtained during the treatment plus follow up period from the mITT
populatio n, regardless of adherence to study drug. 
9.4. Statistical Analyses
9.4.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly o r its desi gnee .Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of the protocol. Any other change to the data analysis methods 
described in the protocol, and the just ificat ion for making t he change, will be described in the 
statist ical analysis plan (SAP) or the clinical study  report (CSR). Additional exploratory  data 
analyses may be conducted as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2-sided alpha level o f 
0.05,and the confidence interval (CI) will be calculated at 95%, 2 -sided. In statist ical summaries 
and analyses, data will be analyzed as rando mized.
Unless specified otherwise, efficacy analyses will be conducted using efficacy analysis set (EAS) 
and safet y analyses will be conducted using safety  analysis set (SS). 
Unless otherwise specified, for analyses in the double -blind period, b aseline is define d as the l ast 
non-missing data collected prior to or at randomization (prior to fi rst dosing of study  drug) ; for 
analys es in the lead -in period, baseline is defined as the last non -missing data collected prior to or 
at study  entry  (Visi t 1 and Visi t 2).  
CONFIDENTIAL Protocol  number I8F -MC-GPHM
70Summary  statistics for continuous m easures will  includesample size, mean, SD, median, 
minimum, and maximum. T heanalysis model to make comparisons am ong treatment groups
relative to continuous measurements assessed over time will be a mixed model for repe ated 
measures (MMRM), with terms of treatm ent, visi t, treatm ent-by-visit interaction ,stratificat ion 
factors and baseline measurement as a covariate. An unstructured covariance structure will model 
relationship of wit hin-patient errors.
Kaplan -Meier m ethod will be used for estimation of cumulat ive event -free survival rates over 
time, and cox proportional hazards regression analysis will be used to compare hazard rates 
among treatm ents.
Summary  statistics for categorical measures (including categorized conti nuous m easures) will 
include sample size, frequency, and percentages. Logistic regressio n will be used to examine the 
treatm ent difference in binary  efficacy  outcomes if there is a need to adjust for covariates . 
Otherwi se, Fisher’s exact test will be used to examine the treatment difference in categorical 
outcom es.  
Summary  statistics for discrete coun t measures will include sample size, mean, SD, median, 
minimum, and maximum. The negat ive binomial regressio n model will be used for the treatment 
comparison of discrete count m easures. 
Other stati stical methods may be used, as appropriate, and details will be described in the SAP.
9.4.2. Treatment Group Comparability
9.4.2.1. Participant Disposition
A detailed description o f participant disposit ion will be provided at the e nd of the study . 
Frequency counts and percentages of all part icipants screened, enrolled, rando mized, and 
receiving at least 1 dose of study  drug will  be summarized by treatment group. Of the randomized 
popul ation, frequency  counts and percentages of part icipants who completed the study , 
prem aturely  discontinued the study  (and/or study  drug), including reason for premature 
discontinuat ion, will be summarized by treatment group.
A Kaplan -Meier analysis o f time fro m rando mizat ion to premature discontinuat ionfrom study  
and/or study  treatm entby treatment group will be provided. 
9.4.2.2. Participant Character istics
Dem ographics will be summarized for all enrolled participants. 
Dem ographics will also be summarized by  treatm ent group for all randomized participants. 
9.4.2.3. Concomitant Therapy 
Concomitant medicat ion, including previous therapy , will  be summarized by  treatm ent group for 
all rando mized part icipants. 
9.4.2.4. Treatment Compliance
Frequency counts and percentages of participants compliant to study  drug will be summarize d by 
treatm ent arm s and visits for FAS. 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
719.4.3. Efficacy Analyses
9.4.3.1. Primary Analyses
There will be 2 estimands o f interest in comparing efficacy o f tirzepati de MTD with placebo. For 
theFDA , the primary  efficacy  analysis will be guided by  the “ hybrid ” estimand and will be 
conducted using the FAS. This assessment will analyze percent change in body  weight obtained at 
the 72-week visit using an analysis o f covari ance (ANCOVA) and the percentage of participants 
achieving at least 5% body  weight reducti onobtained at th e 72-week visit using a logist ic 
regression model. Both models (ANCOVA and logist ic regressio n model)will include terms of
treatm ent, stratification factors, and baseline body  weightas a covariate . 
Missing data solely due 
to a pandemic or natural disaste r (after other reasons for missing data are ruled out) will be 
considered missing at random, and missing data will be imputed using all non -missing data of the 
primary  outcom e measurement from the sam e treatment arm . Missing data of the primary 
outcom e mea surement due to all other Intercurrent Events (ICEs) will be imputed based on 
retrieved dropouts i n the same treatm ent arm , defined as observed primary outcom e 
measurements from participan ts in the same tre atment group who had their efficacy assessed after
early  discontinuat ion of study  drug. In cases where there are not enough retrieved dropouts to 
provi de a reliable imputation model (for example, the model implemented by  the SAS program  
does not converge), an alternat ive multiple imputatio n method wi th reference to the placebo 
group ( that is, placebo mult iple imputation) will be used. Analysis will be conducted with 
multiple imputations .  
For all other purposes, t he primary efficacy analys es will be guided by  the “e fficacy” est imand , 
which represents efficacy  prior to discont inuat ion of study drug ,and conducted using the EAS. 
The primary  analysis m odel will be anMMRM for body  weight percentage change over time and 
a longitudinal logist ic regressio n for proporti on of  parti cipants achieving at least 5% body weight 
reducti on over tim e. The response variable of the MMRM will be the percent change in body  
weight from baseline values obtained at each scheduled post baseline visit. The response variable 
of the longitudinal logist ic regressio n will be the pro portion of participants achieving at least 5% 
body  weight reducti on at each scheduled post randomizat ion visit. The Kenward- Roger 
approximat ion will be used to estimate deno minator degrees of freedo m. 
Since the mean percent change in body  weight and propo rtion of  parti cipants wi th ≥5% body  
weight reducti on needs to be achieved at the same time, no mult iplicit y adjustment i s planned for 
these 2 tests.
9.4.3.2. Key Secondary Efficacy Analyses
Superi ority of tirzepati de MTD to pl acebo for the percentage of participant s who maintain 
≥80% of the body  weight l ost during the 12-week lead-in period
Superi ority of tirzepati de MTD to placebo for the proportion of participants who achieve 
≥10% body  weight reducti on from rando mization to72 weeks 
Superi ority of tirzepati de MTD to placebo for the proportion of participants who achieve 
≥15% body  weight reducti on from rando mization to72 weeks 
Superi ority of tirzepati de MTD to placebo for the mean change in waist circumference 
(cm) from rando mization to72 weeks 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
72Addit ional details, including analysis methods for key secondary endpo ints and the strategy  for 
controlling the overall Type 1 error rate at a 2 -sided al pha of 0.05 of primary  and key secondary  
endpo int evaluat ion, will be provided in the SAP. 
9.4.3.3. Other Secon dary Efficacy Analyses
All otherefficacy  analyses will  be guided by “efficacy” estimand and will be conducted using 
EAS. Details will be provided in the SAP.
9.4.4. S afety Analyse s
Unless specified otherwise, s afety assessments will be guided by  an estimand co mparing the 
safet y of tirzepat ide MTD with placebo irrespective of adherence to study  drug. Thus, safet y 
analys es will  be conducted using SS. 
9.4.4.1. Study Drug Exposure
Study  drug e xposure will be calculated for each participant and summarized by treatment group.
9.4.4.2. Adverse Events
Adverse events will be coded from the actual term using the Medical Dict ionary for Regul atory  
Activities (MedDRA) and reported with preferred terms and system organ class. Counts and 
proporti ons of  parti cipants experiencing events will be re ported for each treatment group, and 
Fisher’s exact test will be used to compare the treatment groups.
The proporti on of  participants experiencing TEAE , SAE, and discontinuation due to AE (DCAE)
will be summarized by treatm ent group.
9.4.4.3. Special Safety Topics
This sect ion includes areas of interest whether due to observed safet y findings, potential findings 
based on drug class, oragreed upon consultation wit h regulatory  agencies for the reasons 
previously mentioned.
The fo llowing AEs are AEs of special intere st (AESI) for this study:
Severe hypoglycemia
Major adverse cardiovascular events (adjudicated) .Includes, but not limited to 
cardi ovascular death, nonfatal myo cardi al infarct ion, nonfatal stroke, and hospitalization 
for heart failure
Treatment -emergent supraventricular arrhy thmias and cardiac conduct ion disorders
Hepatobiliary  disorders. Incl udes biliary  colic, cholecyst itis, and other gallbladder disease
Severe GI events
Acute renal events
MDD/ suicidal behavi or and ideati on  
Pancreat itis(adjudicated)
C-cell hyperplasia and thy roid malignancies
Allergic/ hypersensit ivity reactions. Includes inject ion site reactions and ADA formation
Summa ries and analyses for the incidence of AESIs will be provided by treatm ent. 
The details of 
analysis of AESI will be prov ided in the SAP.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
739.4.4.4. Other Adverse Event Assessments 
9.4.4.4.1. Gastrointestinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting,and diarrhea will be 
provi ded by each treatment.  
9.4.4.4.2. Events Related to Potential Abuse Liability
Summa ries and analyses for incidence of potential abuse liabilit y TEA Es will be provided by
treatm ent. The details will be provided in the SAP.
9.4.4.4.3. Depression, Suicidal Ideation and Behavior
In addit ion to the summary  of TEAEs, s uicidal  ideati on and behavi or will be assessed by C- SSRS, 
and depressi on related symptom s will be assessed using the PHQ -9. 
The analysis details will be provided in the SAP .
9.4.4.4.4. Central Laboratory Measures, Vital Signs, and Electrocardiograms
Actual  values and chan ge from rando mizat ionto post rando mizat ionvalues of central laboratory  
measures, vital signs, and s elected ECG parameters will be summarized at each scheduled visit. 
Change from randomizat ionto post randomizat ionvalue will be summarized for participant swho 
have both a randomizat ionand at least 1 post randomizat ionresul t.  
The percentages of partici pants with TEabnormal, high, or low measures (including laboratory , 
vital, and ECG param eters) at any  time will  be summarized and compa red between treatm ent 
groups using Fisher’s exact test.  
The analysis details will be provi ded in the SAP.
9.4.5. Pharmacokinetic/Pharmac odynamic Analyses
No PK/PD analyses are planned for this study . 
9.4.6. Evaluation of Immunogenicity 
The frequency and percentage of participants with preexist ing ADA and with TE ADA+ to 
tirzepat idewill be tabulated . Treatment -emergent ADAs are defined as those with a titer 2 -fold 
(1dilution) greater than the minimum required dilution (1:10) of the ADA assay if no ADAs were 
detected at baseline (t reatment -induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter 
compared to baseline if ADAs were detected at baseline (treatment -boosted ADA). For the TE 
ADA+ participants , the di stributi on of  maximum  titers will be described. The frequency o f 
neutralizing ant ibodies , if assessed, and cross reactivit y to native GIP and GLP -1 may  also be
tabul ated in TE ADA+ participants .
The relat ionship between the presence of ant ibodies and the PKparameters and PDresponse , 
including safet y and efficacy to tirzepati de,may be assessed.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
749.4.7. Other Analyses
9.4.7.1. Health Outcomes
Analyses of actual and change fro m rando mizat ionin thedomains and/or summary  scores of
patient-reported outcom esquest ionnaires will be conducted using the EAS . The details on 
questi onnai re-specific analyses will be provided in the SAP .
9.4.7.2. Subgroup Analyses for Primary Analysis
Details o f the subgroup analyses will be provi ded in the SAP.  
The following subgroup variables will be considered (but not limited to) :
age(<65 y ears and ≥65years )
sex (female and male)
race 
ethnicity 
BMI at study  entry (<30, ≥30 and <35, ≥35 and <40, ≥40 kg/m2)
percent body  weight loss at the end of lead -in(<10% and ≥10%)
The outcome measures for the subgroup analyses will include:
percent change in body  weight from  randomizat ion to72 weeks
proporti on of  parti cipants achieving at least 5% body  weight reducti on from rando mizat ion 
to72 weeks.
9.5. Interim Analyses 
No interim analyses are planned for this study . If an unplanned interim analysis is deemed 
necessary  for reasons other than a safet y concern, the protocol must be amended.
9.6. Data Monitoring Committee (DMC)
Not applicable .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
7510. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Conside rations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the 
following:
oConsensus ethical principles derived from international guidelines 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethi cal 
Guidelines
oApplicable ICH Good Clinical Practice (GCP) Guidelines
oApplicable laws and regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an IRB/IEC by  the invest igator and 
reviewed and approved by the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the stu dy design, except for changes necessary 
to eliminate an immediate hazard to study  parti cipants.
Protocol s and any substantial amendments to the protocol will require healt h authorit y 
approval  prior to init iation except for changes necessary to eliminate an immediate hazard 
to study  parti cipants.
The invest igator will be responsible for the fo llowing:
○Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  
or more frequent ly in accordance wit h the requirements, policies, and 
procedu res established by the IRB/IEC
○Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required 
by IRB/IEC procedures
○Provi ding oversight of study  conduct for parti cipants under thei r responsibilit y 
and adherence to requirements of 21 Code of Federal Regulat ions (CFR) , ICH 
guidelines, the IRB/IEC, European regulat ion 536/2014 for clinical studies (if 
applicable), and all other applicable local regulat ions
 Invest igator sites are compensated for participat ion in the study as detailed in the 
clinical trialagreement (CTA) .
10.1.2. Informed Consent Process
 The invest igator or his/her representative will explain the nature of the study , 
including the risks and benefit s,to the participant or his/her legally authorized 
representative and answer all quest ions regarding the study .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
76 Study  participants m ust be informed that their participat ion is vo luntary. Study  
participants or thei r legally authori zed representative will be required to sign a 
statement of informed consent that meets the requirements of 21 CF R 50, l ocal 
regul ations, ICH guidelines, Health Insurance Portabilit y and Accountabilit y Act 
(HIPAA) requirements, where applicable, and the I RB/IEC or study  center.
 The m edical  record m ust include a statem ent that wri tten inform ed consent was 
obtained bef ore the parti cipant was enter ed in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
 Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during 
their parti cipat ion in the study .
 A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s 
legally authorized representati veand is kept on file
.
10.1.3. Data Protection
 Parti cipants will be assigned a unique ident ifier by the sponsor. Any participant 
records ,datasets or tissue samples that are transferred to the sponsor will contain 
the identifier only; participant names or any  informat ion which would make the 
participant i dentifiable will not be transferred.
 The parti cipant must be inform ed that hi s/her personal  study -related data will  be 
used by the sponsor in accordance wit h local data protecti on law. The level o f 
disclosure m ust al so be explained to the participant who will be required to give 
consent for his/her data to be used as desc ribed in the informed consent .
 The parti cipant must be inform ed that hi s/her m edical  records m ay be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appo inted by  
the sponsor, by  appropri ate IRB/IEC m embers, and by  inspectors f rom regulatory  
authori ties.
 The sponsor has processes in place to ensure data protection, informat ion securit y 
and data integrit y. These processes include appropriate contingency plan(s) for 
appropriate and timely  response in the event of a data securit y breach.
10.1.4. Committees Structure
Prospective adjudicat ion of major adverse cardio vascular events and pancreat ic AEs will be 
perform ed for this study . Secti ons 8.3.2.2 ,and 8.3.2.5 outline addit ional informat ion on 
pancreat ic and cardiovascular adjudica tion commit tees. 
10.1.5. Dissemination of Clinical Study Data
Requi red clinical  trial registri es (for example, ClinicalTrials.gov) will be updated with the results 
from registered clinical trials regardless of the research outcome in accordance wit h local laws 
and regulati ons. 
All CSRs, amendments and addenda will be submitted to external regulatory  authori ties, external 
partners (as applicable) and sites. 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
77The publicat ion policy for Study  GPH Mis outlined in Sect ion10.1.9 and further described in the 
CTA .
10.1.6. Data Quality Assurance
 All participant data relat ing to the study  will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or desig nee electronically ( for example , 
laboratory  data). The investigator is responsible for verifying that data entries are 
accurate and correct by  physically  or electronically si gning the CRF.
 The invest igator must maintain accurate documentation (source data) that 
supports the informat ion entered in the CRF.
 The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, 
and regulatory  agency inspect ions and provide direct a ccess to source data 
docum ents.
 Moni toring details describing strategy  (for example , risk-based init iatives in 
operati ons and qualit y such as risk management , mitigation strategi es,and 
analyt ical risk-based monitoring), methods, responsibilit ies and requirements, 
including handling of nonco mpliance issues and monitoring techn iques are 
provi ded in the Monitoring Plan.
 The sponsor or designee is responsible for the data management of this study  
includin g qualit y checking of the data.
 The sponsor assumes accountabilit y for acti ons delegated to other individuals ( for 
example , 
contract research organizat ions).
 Study  monitors will perform  ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and 
verifiable fro m source docum ents; that the safet y and ri ghts of  participants are 
being protected; and that the study  is being conducted in accordance with the 
currently approved protocol and any other study  agreem ents, ICH GCP, and all 
applicable regu latory  requi rements.
 Records and documents, including signed ICFs, pe rtaining to the conduct of this 
study  must be retained by  the invest igator for the time period outlined in the CTA 
unless local regulat ions or inst itutional policies requi re a l onger retenti on peri od. 
No records may be destroy ed during the retention period without the wri tten 
approval  of the sponsor. No records may  be transferred to another location or 
party  without wri tten notificat ion to the sponsor .
 In addit ion, sponsor or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study  site. The study  
may be audited by s ponsor or its representati ves, and/or regulatory  agencies at 
any time. Invest igators will be given noti ce before an audit occurs.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
78Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF data. 
The invest igator maintains a separate source for the data entered by the investigator or designee 
into the sponsor -provided EDC system. The investigator is responsible for the identificat ion of 
any data to be considere d source and for the confirmat ion that data reported are accurate and 
complete by  signing the CRF .
Addit ionally , clinical  outcom e assessment (COA) data ( participant -focused outcom e instrum ent) 
and other data (for example, diary ),will be co llected by the partici pant,caregiver ,orauthorized 
study  personnel , via a paper source document and will be transcribed by  the authori zed study  
personnel into the EDC sy stem .
Data collected via the sponsor- provided data capture system (s)will be stored at third parti es. The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem (s).Prior to decommissioning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  acentral  vendor, such as laboratory  test data, will be stored electronically  in the 
central  vendor’s database .Data will subsequent ly be transferred fro m the central  vendor to the 
sponsor data warehouse.
Data from co mplaint forms submitted to sponsor will be encoded and stored in the global product 
complaint m anagement sy stem .
10.1.7. Source Documents
 Source documents provide evidence for the existence of the participant and 
substant iate the integrity  of the data collected. Source documents are filed at the 
investi gator’s si te.
 Data reported on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies 
must be explained. The invest igator may need to request previous medical records 
or transfer records, depending on the study . Also, current medical records must be 
available.
 Definit ion of what constitutes source data can be found in study  training material .
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the c linical study  will be open for recruit ment of 
participants.
The sponsor or designee reserves the right to close the study  site or terminate the study  at any  
time for any  reason at the sole discret ion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
79The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cau se 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are not 
limited to:
 Failure of the invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authorit ies, the sponsor's procedures, or GCP guidelines
 Inadequate recruit ment of parti cipants by  the investi gator
 Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory requi rements. The investigator shall prompt ly inform  the participant and assure 
appropriate participant therapy  and/or foll ow-up.
10.1.9. Publication Policy
In accordance with the sponsor’s publication po licy,the resul ts of this study  will be submitted for 
publication by a peer -reviewed journal.
The spon sor will co mply wit h the requirements for publication o f study  resul ts. 
Authorship will be determined by  mutual  agreement and in line wit h Internat ional 
Committee of Medical Journal Editors authorship r equi
remen ts.
The publicat ion policy for Study  GPHM i s described in the CTA .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
8010.2. Appendix 2: Clinical Laboratory Tests
The tests detailed below will be performed by a central  lab unless designated as 
local in the S oA and in the table below.
●In circumstances where the sponsor approves local laboratory  testing in lieu of 
central  laboratory  testing (in the table below), the local laboratory  must be 
qualified in accordance wit h applicable local regulations.
Protocol -specific requirements for inclusio n or exclusio n of p articipants are 
detailed in Sect ion 5of the protocol.
Addit ional tests may be performed at any  time during the study  as determined 
necessary  by the invest igator or required by local regulat ions.
Pregnancy testing (Refer to Section 5.1Inclusio n Criteria for screening pregnancy 
criteria) .
Invest igators must document their review of each laboratory  safety  report.
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative sites or 
other blinded personnel and are denoted in the table below.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
81Clinical Laboratory Tests
HematologyaClinical Chemistrya
Hemoglobin Bicarbonate
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose
Urine ChemistriesaAlbumin
Albumin Creatine kinase (CK)
Creatinine
Cystatin -CaHormones (females)
Pregnancy Test serum aand/or urine (local)
Follicle -stimulating hormone (FSH)a
HbA1ca
Endocrinea
Calcitonin Pancreas (exocrine)a
Thyroid-stimulating hormone (TSH) Pancreatic amylase
Lipase
Nonpharmacogenetic Stored Samplesa,b
Serum
EDTA plasma
P800 plasmaImmunogenicitya,b
Anti-tirzepatide antibod ies
Anti-tirzepatide antibody neutralization
Pharmacokinetic Sample for Immunogenicity
Lipid Panela
Pharmacogen etics Samplea,b
Whole blood (EDTA)Triglycerides
VLDL -C
HDL -C
LDL -Cc
Total cholesterol
Free Fatty Acidsa
Insulina
C-peptideaCalculationsa
eGFR (calculated by CKD -EPI equation)
UACR
Abbreviations: CKD -EPI=Chronic Kidney Disease -Epidemiology; eGFR =estimated glomerular filtration rate; 
EDTA =ethylenediaminetetraacetic acid ; HbA1c =hemoglobin A1c; HDL -C = high-density lipoprotein
cholesterol ; LDL -C = low-density  lipoprotein cholesterol ; RBC = red blood cells ; UACR = urine albumin to 
creatinine ratio; VLDL -C = very low -density  lipoprotein cholesterol; WBC = white blood cells .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
82aAll tests will be performe d by a Lilly -designated central laboratory, unless otherwise noted .
bResults will not be provided to the investigative sites.
c    This value will be calculated. If triglycerides are >400 mg/dL , the direct LDL will be assayed.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
8310.3. Appendix 3: Laboratory Assessments for Hypersensitivity Events
Laboratory  assessments should be performed if the participant experiences generalized 
urticaria or if anaphylaxis is suspected .
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the
event; however, samples may be obtained as late as 12 hours after the event as analytes 
can remain altered for an extended period of time. Record the time at which the sample 
was collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit o r after 4 weeks, 
whichever i s later.
The table below summ arizes the l aboratory  parameters that will be evaluated. These laboratory  
tests are bundled in the hypersensit ivity laboratory  testing kit.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
84Clinical Lab Tests for Hypersensitivity Events
Hypersensiti vity Tests Notes
Selected test may be obtained in the event of anaphylaxis or systemic 
allergic/hypersensitivity reactions.
Tirzepatide anti -drug 
antibodies 
(immunogenicity/ADA)Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Tirzepatide concentrations 
(PK)Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Tryptase Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Note: If a tryptase sample is obtained more than 2 hours after the event (that is, 
within 2 to 12 hours), or is not obtained because more than 12 hours have lapsed 
since the event, obtain urine sample for N -methy lhistamine testing. Not e that for 
tryptase serum samples obtained within 2 to 12 hours of the event, urine 
N-methy lhistamine testing is performed in addition to tryptase testing. Collect the 
first void urine sample following the event. Obtain a follow -up urine sample for 
N-methy lhistamine testing at the next regularly scheduled visit or after 4 weeks, 
whichever is later.
N-methy lhistamine Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Drug-specific IgE Will be performed if a validated assay is available.
Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Basophil activation test Will be performed if a validated assay is available.
Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Note: The basophil activation test is an in vitro cell based assay that only requires 
a serum sample. It is a surrogate assay for drug specific IgE, but is not specific for 
IgE.
Complement ( C3, C3a, and 
C5a)Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Cytokine panel (IL ‐6, IL‐1 β, 
IL‐10)Assay ed by Lilly -designated laboratory. Results will not be provided to the 
investigative sites.
Abbreviations: ADA = anti -drug antibody; IgE = immunoglobulin E; IL = interleukin; PK = pharmacokinetic.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
8510.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.4.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a participant administered a pharmaceutical 
product and which does not necessarily have a causal relat ionship wi th the study  
intervent ion. An AE can therefore be any unfavourable and unintended sign (including an
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of a m edicinal (investigational) product, whether or not related to 
the medicinal (invest igational) product .
Events Meeting the AE D efinition
Any abnorm al laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( for example , ECG, radi ological scans, vi tal signs 
measurements), including those that worsen from baseline, considered clinically 
significant in t he medical and scientific judgment of the invest igator ( that is, not rel ated to 
progression of underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after intensive lifest yle int ervent ion or study  drug 
intervent ion administration even though theymay have been present before the start of the 
study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interacti on.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  drug 
intervent ion or a concomitant medicat ion. 
“Lack of efficacy” or “failure of expected pharmacological act ion” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy 
will be reported as an AE or SAE if they fulfill the definit ion of an AE or SAE. 
Events NOT Meeting the A E Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure ( for example , endoscopy , appendectomy ): the condi tion 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
86that leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.4.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met ( for example , hospi talizat ion for signs/symptom s of the disease under s tudy, death due to 
progression of disease).
SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  ‘life-threatening’ in the definit ion of ‘serious ’refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal for 
observat ion and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complicat ions that occur during hospitalizat ion are AEs. If a 
complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, the event i s 
serious. When in doubt as to whether “hospitalizat ion” occurred or was necessary, the AE 
shoul d be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen fro m 
baseline is not con sidered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct norm al 
life funct ions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, and 
accidental  traum a (for example , sprained ankle) which may  interfere wi th or prevent 
everyday life functions but do not constitute a substantial disrupt ion.
e.Is a congenital anomaly/birth defect
Abnorm al pregnancy outcom es (for example , spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
87f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room  or at hom e for allergic bronchos pasm , blood dy scrasias or convulsio ns 
that do not result in hospitalizat ion, or development of drug dependency or drug abuse.
g.Resulted in medical or surgical intervent ion to prevent life -threatening illness or injury or 
perm anent impairment to a b ody structure or a body funct ion.
10.4.3. Definition of Product Complaint
Product Complaint
A product complaint is any written, electronic, or oral communicat ion that alleges 
deficiencies related to the identit y, qualit y, durability , reliabilit y, safet y, effect iveness or 
perform ance of a study interventi on.When the abilit y to use the study  intervent ion safely  
is impacted, the fo llowing are also product complaints:
oDeficiencies in labeling informat ion, and
oUse errors for device or drug -device co mbination products due to ergonomic 
design elements of the produ ct.
Product complaints related to study  intervent ions used in clinical trials are collected in 
order to ensure the safet y of parti cipants, m onitor quali ty, and to facili tate process and 
product improvements.
Invest igators will instruct p articipants to cont act the siteas soon as possible if he or she 
has a product complaint or problem wit h the study  intervent ionso that the situation can be 
assessed.
An event may meet the definit ion of both a product complaint and an AE/SAE. In such 
cases, it should be repo rted as both a product complaint and as an AE/SAE.
10.4.4. Recording and Follow -Up of AE and/or SAE and Product Complaints
AE, SAE , and Product Complaint Recording
When an AE/SAE /product com plaint occurs, i t is the responsibilit y of the investi gator to 
review all docum entati on (for example , hospi tal progress notes, l aboratory  reports, and 
diagnosti cs reports) rel ated to the event.
The invest igator will then record all relevant AE/SAE /product com plaint inform ation in 
the participant’s medical records, in accorda nce with the invest igator’s normal clinical 
practi ce. Adverse event /SAE information is reported o n the appropriate (e)CRF page and 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
88product complaint informat ion is reported on the Product Complaint form.
Note: An event may meet the definit ion of both a product complaint and an AE/SAE. In 
such cases, it should be reported as both a product complaint and as an AE/SAE.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to the sponsor or designee in lieu of com pletion of  the (e)CR F page for AE/SAE 
and the Product Complaint form for product com plaints .
There m ay be instances when copies of medical records for certain cases are requested by  
sponsor or desi gnee . In thi s case, all participant ident ifiers, wi th the e xcept ion of the 
participant number, will be redacted on the copies of the medical records before 
submissio n tothe sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical info rmation. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during the 
study  and assi gn it to 1of the f ollowing categories:
Mild: A type of AEthat is usually  transient and may  requi re only  minimal  treatm ent or 
therapeuti c intervent ion. The event does not generally  interfere wi th usual act ivities of 
daily  living .
Moderate: A type of AEthat is usually alleviated with addit ional specific therapeut ic 
intervent ion. The event interferes wit h usual activit ies of daily living, causing disco mfort 
but poses no significant or permanent risk of harm to the research part icipant .
Severe: A type of AE that interrupts usual act ivities of daily living, significant ly affects 
clinical status, or may  require intensive therapeutic intervent ion. An AE that is assessed as 
severe should not be confused with a nSAE. Severe is a category  utilized for rating the
intensity of an event ,and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1of the predefined outcomes as described 
in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between intensive lifest yle 
intervent ion or study  drug intervent ion and each occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship cannot be rul ed out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to intensive lifest yle int ervent ion 
or study drug intervent ion administration will be considered and invest igated.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
89The invest igator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the inv estigator has minimal 
inform ation to include in the init ial report to the sponsor or designee . However, i t is very  
important that the invest igator always make an assessment of causalit y for every  event 
before the init ial transmissio n of the SAE data to thesponsor or desi gnee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up inform ation 
and send a nSAE fo llow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining r egulatory  reporting 
requi rements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by the sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies dur ing participation in the study or during a recognized fo llow-up 
period, the invest igator will provi de the sponsor or desi gnee wi th a copy  of any 
post-mortem findings ,including histopathology.
10.4.5. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion tool .
If the electronic system is unavailable, then the site will use the paper SAE data collect ion 
tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be taken 
off-line to prevent the entry  of new data or chan ges to exist ing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated data 
on a previously reported SAE after the electronic data collect ion tool  has been taken off -
line, then the site can report this informat ion on a paper SAE form (see next section) or to 
the sponsor contact for SAE reporting by telep hone.
Contacts for SAE reporting can be found in study  training m aterial. 
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
90inform ation to the sponsor contacts for SAE reporting .
Initial notificati on via telephone does not replace the need for the invest igator to complete 
and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in study  training m aterial.
10.4.6. Regulatory Reporting Requirements
SAE Regulatory Reporting
Prom pt notificat ion by the invest igator to the sponsor of a nSAE is essent ial so that 
legal obligations and ethical responsibilit ies towards the safet y of parti cipants and 
the safet y of a study  intervent ion under clinical investigation are met.
●The sponsor has a legal responsibilit y to notify both the l ocal regul atory  authori ty 
and other regulatory  agencies about the safet y of a study  interventi on under 
clinical invest igation. The sponsor will comply wit h country -specific regulatory  
requi rements rel ating to safety reporting to the regulatory authorit y, IRB/IEC , and 
investigators.
●An invest igator who receives an invest igator safety report describing a nSAE or 
other specific safet y informat ion (for example ,summary  or list ing of SAEs) from 
the sponsor will review and then file it along w ith the IB and will notify  the 
IRB/IEC, if appropriate ,according to local requirements.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
9110.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear ( for example , amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study  intervent ion, addi tional evaluat ion shoul d be
considered.
Women in the fo llowing categori es are not considered women of childbearing p otential
Article I. Prem enarchal
Article II. Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above,
(for example ,
Mullerian agenesis, androgen insensitivit y), investi gator di scret ion shoul d be 
applied to determining study  entry .
Note: Determinat ioncan co me from the si te personnel’s review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
Article III. Postmenopausal  female
A postm enopausal  state is defined as either
oA wo man at l east 40 years of age with an intact uterus, not on hormone
therapy , who has cessat ion of menses for at least 1 year without an alternative 
medical cause, AND a nFSH ≥40 m IU/mL; or 
oA wo man 55 or older not on hormone therapy , who has had at l east 12 m onths 
of spontaneous am enorrhea; or 
oA wo man at l east 55 years o f age wi th a diagnosi s of menopause pri or to 
starting hormone replacement therapy (HRT) . 
Females on HRT and whose menopausal status is in doubt will be required to use one 
of the nonestrogen hormonal highly effect ive contraception methods if they wish to 
continue their HRT during the study . Otherwi se, they  must discont inue HRT to allow 
confirmat ion of postmenopausal status before study enrollment.
Contraception Guidance:
Contraceptive use by men and wo men shoul d be consistent with local regulat ions regardi ng the 
methods of contraception for those participat ing in clinical studies .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
92Two forms of effect ive contraception, where at least 1form is highly  effect ive, will be used. 
Effect ive contraception may be used as the second therapy . Barri er protecti on m ethods wi thout 
concomitant use of a spermicide are not a reliable or acceptable method. The use of male and 
female condo ms as a double barrier method is not considered acceptable due to the high failure 
rate when these methods are combined. 
Highly Effective Methods of Contraception:
Combined oral contraceptive pill and mini pill
NuvaRing®
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Total  abstinence (if this is their preferred and usual lifestyle) or in a same -sex 
relationship with no sexual relationship with males (as part of their preferred and usual 
lifest yle), and agrees to maintain this status throughou t trial follow-up 
Note:   periodic abst inence ( for example , calendar, ovul ation, symptothermal, and 
postovulat ion methods), declarat ion of abst inence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraception
Vasectomy  – for m en in clinical studies
Note :  Implantable contraceptives and injectable contraceptives (such as Depo Provera) 
are only permitted if started more than 18 m onths prior to screening. Participants should 
not start these methods of contraception after being enrolled in the study .
Effective Methods of Contraception (must use combination of 2 methods):
Male condom wit h spermicide
Female condo m with spermicide
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
Men, regardless of their fertil ity status, with nonpregnant women of childbearing potential 
partners must agree to either remain abstinent (if this is their preferred and usual lifest yle) or use 
condoms plus 1additional highly  effect ive (less than 1% failure rate) method of contracepti on 
(such as co mbinat ion oral  contraceptives, implanted contraceptives, or intrauterine device) or
effect ive method of contraception (such as diaphragms wit h spermicide or cervical sponge) for 
the duration of the study  and for 5 half -lives of study  drug pl us 90 days , which is approximately  4 
mont
hsafter the lastinject ion. Periodic abst inence ( for example , calendar, ovul ation, 
CONFIDENTIAL Protocol  number I8F -MC-GPHM
93symptothermal, and postovul ation methods), decl aration of  abst inence just for the duration of a 
trial, and wi thdrawal are not acceptable methods of contraception .
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated relevant potential exposure in women of childbearing potential. 
Men who are abstinent (if th is is co mplete abst inence, as their preferred and usual lifest yle) or in a 
same -sex rel ationship (as part of their preferred and usual lifestyle) must agree to either remain 
abstinent or stay  in a same -sex relati onship wi thout sexual relationships with fem ales.In these 
situations, m enare not required to use contraception. 
Men should refrain fro m sperm  donat ion for the durati on of  the study  and f or 5 half -lives o f study  
drug pl us 90 days after the last dose of study  drug, corresponding to 4 months after t he last 
inject ion. 
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male participant is in 
this study . 
After obtaining the necessary  signed informed consent from the pregnant female 
partne r directly, the invest igator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy. If pregnancy occurs during study  drug intervent ion peri od, 
the female partner will a lso be fo llowed to determine the outcome o f the 
pregnancy. Informat ion on the status of the mother and child will be forwarded to 
the sponsor. Generally, the fo llow-up will be no l onger than 6 to 8 weeks 
following the est imated delivery date. Any terminati on of  the pregnancy will be 
reported regardless of fetal status (presence or absence of ano malies) orindicat ion 
for the procedure. 
Female Participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who 
becomes pregnant while participat ing in this study .The init ial informat ion will be 
recorded on the appropriate form and submitted to the sponsor within 24hours of 
learning of a participant's pregnancy. 
The parti cipant s who bec omepregnant during the study  drug intervent ion peri od
will be fo llowed to determine the outcome of the pregnancy. The invest igator will 
collect fo llow-up informati on on the parti cipant and the neonate and the 
inform ation will be forwarded to the sponsor. Generally, fo llow-up will not be 
requi red for longer than 6 to 8 weeks bey ond the estimated delivery  date. Any  
termination o f pregnancy will be reported, regardless of fetal status (presence or 
absence of ano malies) or indicat ion for the procedure.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
94While pregnancy  itself is not c onsidered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for medical  reasons will be 
reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0weeks gestational age) or still birth 
(occurring at > 20 weeks ge stational age) i s always considered to be an SAE and 
will be reported as such. 
Any post -study pregnancy related SAE considered reasonably related to the study 
intervent ion by the investigator will be reported to the sponsor as described in 
protocol .While the invest igator is not obligated to actively seek this informat ion in 
former study  parti cipants, he or she may  learn of an SAE through spontaneous 
reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will 
discontinue intensive lifest yle intervent ionor study drug intervent ion.If the 
participant is di scontinued from the study  interventio n, follow the standard 
discontinuat ion process for each study  period.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
9510.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments 
For testing selected, analysis is required to be completed by the Lilly designated 
central  laboratory , except for microbio logy.
Local  testing m ay be performed in addit ion to central testing when required for 
immediate participant management.
Results will be reported if a validated test or calculation is available.
Hepatic Evaluation Labs
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
Neutrophils, segmented Gamma -glutamyl transferase (GGT)
Lymphocytes Creatine kinase (CK)
Monocytes Other Chemistry
Basophils Acetaminophen
Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
Coagulation Copper
Prothrombin Time, INR (PT -INR) Ethyl Alcohol
Serology Haptoglobin
Hepatitis A Virus (HAV) testing: IgA (Quantitative)
HAV total antibody IgG (Quantitative)
HAV IgM antibody IgM (Quantitative)
Hepati tis B Virus (HBV) Testing: Phosphatidylethanol (PEth)
Hepatitis B surface antigen (HBsAg) Urine Chemistry
Hepatitis B surface antibody (Anti -HBs) Drug Screen
Hepatitis B core total antibody (Anti -HBc) Ethyl glucuronide (EtG)
Hepatitis B core IgM antibody Other Serology
Hepatitis B core IgG antibody Anti- nuclear antibody (ANA)
CONFIDENTIAL Protocol  number I8F -MC-GPHM
96Hematology Clinical Chemistry
HBV DNAaAnti-smooth muscle antibody (ASMA) b
Hepatis C Virus (HCV) Testing: Anti- actin antibodyc
HCV antibody Epstein -Barr Virus (EBV) Testing:
HCV RNAaEBV antibody
Hepatitis D Virus (HDV) Testing: EBV DNAa
HDV antibody Cytomegalovirus (CMV) Testing:
Hepatitis E Virus (HEV) Testing: CMV antibody
HEV IgG antibody CMV DNAa
HEV IgM antibody Herpes Simplex Virus (HSV) Testing:
HEV RNAaHSV (Type 1 and 2) antibody
MicrobiologydHSV (Type 1 and 2) DNAa
Culture: Liver Kidney Microsomal Type 1 (LKM -1) Antibody
Blood
Urine
Abbreviations: Ig = immunoglobulin; INR = international normalized ratio.
aReflex/confirmation dependent on regulatory requirements, testing availability, or both.
bThis is not required if anti -actin antibody is tested.
cThis is not required if anti -smooth muscle antibody is tested.
dAssay ed by investigator-designated local laboratory ONLY. No central testing available.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
9710.7. Appendix 7: Protocol GPH MStandardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, Vital 
Signs and Electrocardiogram
The fo llowing inform ation has been adapted fro m standardized physical measurement protocols 
for the Worl d Heal th Organizati on’s STEPwi se approach to Surveillance (STEPS) (WHO 2017) 
Measuring Height
Step 1. Ask the participant to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by the participant at every  clinic 
visit when their height i s measured).
Step 2. Ask the participant to stand on the calibrated height measuring board (stadiometer) or 
against a wall wit h their feet together and their knees straight with their heels against 
the backboard, the stadio meter or the wall.
Step 3. Ask the participant to look straight ahead without tilt ing their head up.
Step 4. Ask the participant to breathe in and stand tall. Measure and record the participant’s 
height in cent imeters (cm) to one decimal place. 
Measuring Weight
Body  weight measurements should be done in a consistent manner using a calibrated 
electroni c scale capable of measuring weight in kilograms (kg) to one decimal place.
All weights for a given participant should be measured using the same scale, whenever 
possible, at approximately the same time in the mo rning after evacuat ion of bladder 
contents .  
Body  weight m ust be m easured in fasting state. If the participant is not fast ing, the 
participant shoul d be called in for a new visit wit
hin the visit window to have the fast ing 
body  weight m easured.
Step 1 .Ask the participant to empt y their pockets, rem ove thei r footwear, outerwear (coat, 
jacket, etc.), and any  headgear (li ght headgear worn for religious reasons can remain, but 
this shoul d be worn by  the parti cipant at every clinic visit when weight is measured).
Step 2 .Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a sloping 
surface, or a rough, uneven surface).
Step 3 .Ask the participant to step onto the scale wit h 1 foot on each side o f the scale.
Step 4 .Ask the participant to stand still wit h arm s by sides and then record weight in kilograms 
(kg) to the nearest one -tenth kilogram .
Measuring Waist Circumference
 Waist circumference should be measured in the horizontal plane and at the midpoint 
between the lower margin o f the last pal pable rib and the top of the iliac crest .
 Measurements should be taken at the end of a normal expirat ion using a non- stretchable 
measuring tape. The tape should lie flat against the skin without compressing the soft 
tissue.
CONFIDENTIAL Protocol  number I8F -MC-GPHM
98 The waist circumference should be measured twice, rounded to the nearest 0.5 cm. The 
measuring tape should be removed between the 2 measurements. Both measurements will 
be recorded in the eCRF. If the difference between the 2 measurements exceeds 1 cm, 
this set of m easurements shoul d be discarded and the 2 measurements repeated.
Step 1 :Ask the participant to wear little clothing (if available, patient gowns could also be 
used).
Step 2 :Ask the participant to stand with their feet close together, arms at their side, body  weight 
evenly distributed.
Step 3 :Ask the participant to relax and measure the participant’s waist circumference.
Vital Sign Measurements
Vital sign m easurements (bl ood pressure and heart rate, measured by pulse) should be 
taken before obtaining an ECG tracing and before collect ion of blood samples for 
laboratory  testing
The parti cipant shoul d sit quietly for 5 minutes before vital signs measurements are taken
For each parameter, 2 measurements will be taken using the sam e arm , pref erably  the 
nondo minant arm
The recordings should be taken at least 1 minute apart. Each measurement of sitting pulse 
and BP needs to be recorded in the eCRF
Blood pressure m ust be taken with an automated blood pressure instrument.
If blood press ure and pulse measurements are taken separately, pulse should be taken prior 
to blood pressure. 
Note:   In the event pulse measurement cannot be taken via an automated blood pressure 
instrum ent, the preferred location for measurement of pulse is the radial artery . 
Electrocardiogram
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electroni cally transmitted to a designated central ECG laboratory .
12-lead ECGs should be obtained after the subject has rested in a supine position for at 
least 10 minutes.
Electrocardiograms should be co llected at least 30 minutes prior to collection of blood 
samples for laboratory  testing, including PK samples (collected with immunogenicit y 
testing) .
CONFIDENTIAL Protocol  number I8F -MC-GPHM
9910.8. Appendix 8: Suggested Visit Structure
Abbreviations:  AE=adverse event; ECG=electrocardiogram; PRO=patient reported outcomes; S oA=Schedule of 
Activities

CONFIDENTIAL Protocol  number I8F -MC-GPHM
10010.9. Appendix 9: Management of Gastrointestinal Symptoms
Abbreviation :  GI= gastrointestinal

CONFIDENTIAL Protocol number I8F -MC-GPHM
10110.10. Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances
Implementation of this appendix
The changes to procedures described in this appendix are temporary measures intended to be 
used only d
uring specific time periods as directed by  the sponsor in partnership wit h the 
investigator.
Exceptional circumstances
Except ionalcircumstances are rare events that may cause di srupt ions to the conduct of the study .
Examples include pandemics or natural disasters . These disrupt ions may limit the abilit y of the 
investigators, participants, or both to attend on -site visi ts or to conduct pl anned study  procedures.
Implementing changes under exceptional circumstances
In an except ional cir cumstance, after receiving the sponsor’s written approval, sites may  
implement changes if permitted by local regulat ions. 
After approval by local ERBs , regul atory  bodi es and any  other rel evant l ocal authori ties, 
implementation of these except ional circums tance changes will not ty pically requi re addi tional 
notification to these groups, unless they  have specific condi tions in which notificati on is requi red. 
To protect the safet y of study  partici pants, urgent changes may be implemented before approval 
but nee d to be reported as soon as possible. All approvals must be retained in the study  records.
If the sponsor grants written approval for changes in study  conduct, the sponsor will also provide 
additional written gui dance, if needed.
Considerations for making a change
The prevailing considerat ionfor making a change is e nsuring the safet y of study  parti cipants.
Addit ional important considerat ions for making a change are compliance with GCP , enabling 
participants to continue safely in the study and m aintaining the integrit y of the study . 
Informed consent
Addit ional consent fro m the parti cipant will  be obtained , if required, for:
participat ion in remote visits, as defined in Section “Remote visits,”
dispensat ion of addit ional study  interventi onduring an extended treatment period, 
alternate delivery  of study  interventi on and ancillary  supplies, and
provi sion of their personal  or medical  information requi red pri or to implementation of 
these activit ies. 
Changes in study conduct during exceptional circumstances
Changes in study  conduct not described in this appendix, or not consistent with applicable local 
regul ations, are not allowed .
The fo llowing changes in study  conduct will not be considered protocol deviat ions.
1. Remote visits
CONFIDENTIAL Protocol number I8F -MC-GPHM
102In source document sand the CRF , the study site should capture the visit method ,with a specific 
explanat ion for the reason of conducting a remote visit instead of an onsite visit and for any data 
missing because of missed in -person site visits .
Telemedicine: 
Telephone or techno logy-assisted virtual  visits, or both, are acceptable to complete 
appropriate assessments . Assessments to be completed in this manner include, but are not 
limited to, concomitant medicat ions, review of study  parti cipant di ary (including study  
drug compliance), review diet and exercise goals, lifest yle counseling, C-SSRS (Since 
Last Vi sit Versi on), Self -Harm  Supplement Form, Self -Harm Fo llow-up Form  (if 
applicable), and PHQ -9.
Mobile healthcare:
Healthcare visi ts may be perform ed by  a mobile heal thcare provi der at l ocati ons other 
than the study  site when parti cipants cannot travel to the site due to an except ional 
circumstance if written approval is provided by  the sponsor .Procedures performed at 
such visit s include, but are not limited to,weight and waist measurements, physical 
assessments, vital signs , ECG , PRO questionnaires administration, collection o f blood 
samples and health informat ion. 
Other alternative locations:   
Laboratory  draws may be done at an al ternate l ocati on in except ional circumstances .
Regardless of the ty pe of  remote visi ts implemented, the protocol r equirements regarding the 
reporting of AEs, SAEs, and product complaints remain unchanged . Furtherm ore, every effort 
shoul d be made to enable participant sto retu rn to on -site visi ts as soon as reasonably possible, 
while ensuring the safet y of both the participant sand the sitestaff.
2.Local laboratory testing option
Local  laboratory  testing m ay be conducted in lieu of central laboratory  testing. The l ocal 
laboratory  must be qualified in accordance with applicable local regulat ions.
3.Study intervention and ancillary supplies (including participant diaries)
When a participant is unable to goto thesite to receive study supplies during normal on -site 
visits, the si te shoul d work wi th the sponsor to determine appropriate actions . These act ions may
includ e: 
asking the participant to go to the site and receive study supplies from site staff 
without com pletion of a full study  visit, 
asking theparticipant ’s designee to go to the site and receive study supplies on a 
participant’s behalf, and
arranging delivery  of study  supplies .
CONFIDENTIAL Protocol number I8F -MC-GPHM
103These requirements must be met before action is taken:
Alternate delivery  of study  interventi on shoul d be perform ed in a manner that does 
not com promise treatm ent blinding and ensures product integrit y. The exist ing 
protocol  requi rements for product accountabilit y remain unchanged, including 
verification o f participant’s receipt of study  supplies.
When delivering suppli es to a l ocati on other than the study  site (for exam ple, 
participant’s ho me), the invest igator , sponsor , or both shoul d ensure oversight of the 
shipping process to ensure accountabilit y and product qualit y (that is, storage 
condi tions maintained and intact packaging upon receipt) .
Instructi ons may be provided to the participant or designee on the final disposit ion of 
any unused or com pleted study  supplies .
4.Screening period guidance 
To ensure safet y of study  participants, l aboratory values and other eligibilit y assessments taken 
at or prior to Visit 2 are valid for a maximum of 90days. The fo llowing rul es will  be applied for 
active, not y et enrolled participants whose participatio n in the study  must be paused due to 
exceptional circumstances :
If paused for less than 90days fro m Visit 1 to Vi sit 2: the participant will proceed to 
the next study  visit per the usual  Schedule of Activit ies, provided that Visit 2must be 
conducted within 90days fro mVisit 1. 
oThe site should conduct the next visit if the participant’s eligibilit y criteria are 
confirmed, and the site should document the reason for delay in the CRF.
oDue to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document this confirmat ion in the source 
docum entati on.
If paused for more than 90days from Visit 1 to Visi t 2: The participant must be 
discontinued because of screening interruption due to an except ional circumstance. 
This is documented as a screen fail urein the CRF .The part icipant can reconsent and 
be rescreened as a new participant. The screening procedures per the usual SoA
shoul d be f ollowed, starting at Visit 1 to ensure parti cipant eligibilit y byVisit 2.
5.Adjustments to visit windows 
Whenever possible and safe to do so, as determined by the invest igator’s discretion , participants 
shoul d complete the usu
alSoA. To m aximize the possibilit y that these visits can be conducted as 
on-site visi ts, the windows for visits may  be adjusted, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct of the study.
Randomization visit (Visit 10) should be co mpleted as per original schedule whenever possible 
and safe to do so. However, the visit may be broug ht forward no sooner than 7 days or extended 
up to 14daysrelative to the target visit date . 
CONFIDENTIAL Protocol number I8F -MC-GPHM
104Primary endpo int visit (Visi t 28 or 99) shoul d be com pleted as per ori ginal  schedule whenever 
possible and safe to do so. However, the visit may be brought forward no sooner than 14 days or 
extended up to 28 days relative to the target visit date . 
For parti cipants whose visits have extended windows, additional study  interventi onmay need to 
be provided to avoid interruption and maintain overall integrit y of the study .
Documentation
Changes to study  conduct will be docum ented:
Sites will ident ify and document the details o f how participants, visit ty pes, and 
conducted activit ies were affected by except ional circumstances .
Dispensing/shipment records of study  intervent ionand relevant communicat ions, 
including delegat ion, should be filed with site study records.
Source documents generated at a location other than the study site should be part of 
the invest igator’s source documentation and should be transferred to the site in a 
secure and t imely manner. 
CONFIDENTIAL Protocol number I8F -MC-GPHM
10510.11. Appendix 11: Abbreviations
Term Definition
ADA antidrug antibod y
AE adverse event : Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment . An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (in vestigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
AMA American Medical Association
ANCOVA analysis of covariance
AST aspartate aminotransferase
baseline A fixed point of reference that is used for comparison purposes. In this study baseline 
may refer to lead -in enrollment visits(Visit 1 and Visit 2) or randomization visit.
BG blood glucose
BMI body mass index
BMR basal metabolic rate
CEC clinical endpoint committee
CFR Code of Federal Regulations
CHF congestive heart failure
CIOMS Council forInternational Organizations ofMedical Sciences
CK creatine kinase
CKD- EPI Chro nic Kidney Disease -Epidemiology
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adhe rence to all study -related, GCP, and applicable regulatory requirements.
CONSORT Consolidated Standards of Reporting Trials
CONFIDENTIAL Protocol number I8F -MC-GPHM
106CRP clinical research physician : Individual responsible for the medical conduct of the study . 
Responsibilities of the CRP may be p erformed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR clinical study report
C-SSRS Columbia -Suicide Severity Rating Scale
CT computed tomography
CTA Clinical Trail Agreement
DMC Data monitoring committee
DNA deoxyribonucleic acid
DPP-4 dipeptidy l-peptidase -4
EAS efficacy analysis set
ECG electrocardiogram
eCRF electronic case report form
ED early  discontinuation
EDC electronic data capture
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
enroll In this study enroll refers to all participants who en terthe12-week lead - in period at 
Visit 2.
enter Participant sentered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB Ethical Review Board
FAS full analy sis set
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GIPR glucose -dependent insulinotropic polypeptide receptor
CONFIDENTIAL Protocol number I8F -MC-GPHM
107GLP-1 glucagon -like peptide -1
GLP-1R glucagon -like peptide -1 receptor
HbA1c hemoglobin A1c
HDL high-density lipoprotein
HIPAA Health Insurance Portability and Accountability Act
HRQoL health -related quality of life
IB Investigator’s Brochure
ICF informed consent form
ICH The International Council for Harmoni zation of Technical Requirements for 
Pharmaceuticals for Human Use
informed consent A process by which a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decisio n to participate . Informed consent is documented by 
means of a written, signed and dated informed consent form .
INR internatio nal no rmalizatio n ratio
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IP Investigational product; a pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical trial, including products already on th e market 
when used or assembled (formulated or packaged) in a way different from the 
autho rized form, or marketed products used for an unauthorized indication, or marketed 
products used to gain further information about the authorized form.
IRB/IEC Institutional Review Boards /Independent Ethics Committees 
IWQOL -Lite- CT Impact o f Weight on Quality of Life -Lite-Clinical Trials Version
IWRS interactive web -response sy stem
LCD low calorie diet
LDL low-density  lipoprotein
MAD multiple ascending dose
MDD Major Depressive Disorder
MedDRA Medical Dictionary for Regulatory Activities
MEN multiple endocrine neoplasia
MHP mental health professional
CONFIDENTIAL Protocol number I8F -MC-GPHM
108mITT modified intention -to-treat
MMRM mixed model for repeated measures
MRI magnetic resonance imaging
MTC medullary thyroid carcinoma
MTD maximum tolerated dose
NAFLD nonalcoholic fatty liver disease
NYHA New York Heart Association
p-amylase pancreatic amylase
PAL physical activity level
PCOS polycystic ovar iansyndrome
PGIs Patient Global Impression of status
PHQ -9 Patient Health Questionnaire -9
PK/PD pharmacokinetics/pharmacodynamics
PRO s patient -reported outcomes
QW once weekly
randomized All participants who are indiscriminately assigned a study drug.
SAD single ascending dose
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SD standard deviation
SF-36v2 Short Form -36 Health Survey (SF -36), version 2 acute form
SoA Schedule of Activities
SS Safety analysis set
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
CONFIDENTIAL Protocol number I8F -MC-GPHM
109TBL total bilirubin level
TE Treatment -emergent
TE ADA+ treatment -emergent antidrug antibody positive
TEAE treatment -emergent adverse event : An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TEE total energy expenditure
THC tetrahy drocannabinol
TSH thyroid-stimulating hormone
ULN upper limit of normal
VLCD very low calorie diet
WHO World Health Organization
CONFIDENTIAL Protocol number I8F -MC-GPHM
11011. References
[ADA] . Glycemic targets: s tandards of medical care in diabetes -2020. Diabetes Care
2020(s uppl 1):S66 –S76. https://doi.org/10.2337/dc20 -S006
[AMA] .American Medical Association House of Delegates resolution: 420 (A -13):
recogni tion of  obesi ty as a di sease. May 2013. Accessed May 21, 2020. 
https://m edia.npr.org/documents/2013/jun/ama -resol ution-obesit y.pdf
Aroda VR, Ratner R. The safety and tol erabilit y of GLP -1 receptor agonists in the treatment of 
type 2 di abetes: a review. Diabetes Metab Res Rev . 2011;27( 6):528 -542. 
https:// doi.org/10.1002/dmrr.1202
Baggio LL, Drucker DJ. Bi ology of incretins: GLP -1 and GIP. Gastroenterol ogy. 
2007;132(6):2131 -2157. https://doi.org/ 10.1053/j.gastro.2007.03.054
Banks PA, Freeman ML .Practice Parameters Committee of the American Co llege of 
Gastroenterology . Practi ce gui delines in acute pancreatit is. Am J Gastroenterol.
2006;101(10):2379 -2400. https://doi.org/10.1111/j.1572 -0241.2006.00856.x
Coskun T, Sl oop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP -1 receptor 
agonist for the treatment of ty pe 2 di abetes m ellitus: f rom discovery  to clinical  proof  of 
concept. Mol Metab . 2018;18:3 -14. https://doi .org/10.1016/j .molmet.2018.09.009
Council on Science and Public Health. R eport of the Council on Science and Public Healt h:is 
obesit y a disease? ( Resolution 115 -A-12): R eport number: 3 -A-13. 2013. Accessed May 21, 
2020. https://www.ama -assn.org/si tes/ama -assn.org/files/corp/media -browser/public/about-
ama/councils/Council%20Rep orts/council -on-science -public -healt h/a13csaph3.pdf. 
Danne T, Philotheou A, Goldman D, et al. A randomized trial co mpar ing the rate of 
hypoglycemia –assessed using continuous glucose monitoring –in 125 preschool children 
with type 1 diabetes treated wit h insulin glargine or NPH insulin (the PRESCHOOL stud y). 
Pediatr Diabetes . 2013;14(8):593 -601. https://doi/ 10.1111/pedi.12051
Dolan P. Modeling valuations for EuroQol healt h states. Medical Care. 1997;35(11):1095 -1108. 
https:// doi/10.1097/00005650-199711000-00002
Doucet É, McInis K, Mahmoodianfard S. Compensation in response to energy deficit s induced 
by exercise or di et. Obesity Rev . 2018; 19(suppl 1):36 -46.https://doi.org/10.1111/obr.12783
[EMA]. Guideline on clinical evaluation of medicinal products used in weight management.
EMA/CHMP/311805/2014. Published June 23, 2016. Accessed May 22, 
2020ht tps://www.ema.europa.eu/en/documents/scient ific-guideline/guideline -clinical -
evaluat ion
-medicinal -produ cts-used-weight-management -revisio n-1_en.pdf. Published 23 June 
2016.
EuroQol  Research Foundat ion. EQ -5D- 5L User Guide, Version 3.0. Updated September 2019. 
Accessed March 13, 2020. https://euroqol.org/publicat ions/user -guides.
[FAO/WHO/UNU] Food and Agriculture Organization of the United Nat ions/Worl d Heal th 
Organizat ion/United Nations Universit y. Human energy  requirements: report of a joint 
CONFIDENTIAL Protocol number I8F -MC-GPHM
111FAO/WHO/UN Uexpert consul tation.Published October 2004 Accessed May 21, 
2020. http://www.fao.org/3/y5686e/y5686 e00.ht m. 
[FDA] .Guidance for industry : devel oping products for weight management. Published February 
2007. Accessed May 22,
2020. https://www.fda.gov/media/71252/download .
[FDA ].FDA requests the withdrawal o f the wei ght-loss drug Belviq, Belviq XR (lorcaserin) 
from the market : potenti al risk of cancer outweighs the benefit s. Published 14January  2020. 
Accessed June 5, 2020.  https://www.fda.gov/media/135189/download . 
Frias JP, Nauck MA, Van J, et al.Efficacy and safety  of LY3298176, a novel dual GIP and 
GLP -1 receptor agonist, in pat ients with type 2 di abetes: a randomized, placebo -controlled and 
active comparator -controlled phase 2 trial. Lancet. 2018;392 (10160) :2180-2193.
https://doi .org/10.1016/S0140 -6736(18)32260
-8
Garvey WT , Mechanick JI , Brett EM , et al. American Associ ation of Clinical Endocrinologists 
and American College of Endocrino logy com prehensive clinical practice guidelines for 
medical care of pat ients with obesit y.Endocr Pract . 2016;22(suppl 3):1- 203. 
https://doi .org/ 10.4158/EP161365.GL
Gerstein HC, Co lhoun HM, Dagenais GR, et al. Dulaglut ide and cardiovascular outcomes in type 
2 diabetes (REWIND): a double -blind, randomized placebo -controlled trial. Lancet. 
2019;394(10193):121- 130. https://doi.org/10.1016/S0140 -6736(19)31149 -3
Goldstein DJ. Beneficial healt h effects of modest weight loss. Int J Obes Relat Metab Disord . 
1992;16(6): 397 -41
Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using 
a meal replacement strategy : meta and pooling analysis from six studies. Int J Obes Relat 
Metab Disord. 2003 May;27(5):537- 49. https:// doi: 10.1038/sj.ijo.0802258. PMID: 12704397.
Jensen MD, Ryan DH, Donato KA, et al. Execut ive summary: guidelines (2013) for the 
management of overweight and obesit y in adults: a report of the American College of 
Cardi ology/American Heart Associat ion Task Force on Practice Guidelines and the Obesit y 
Society published by the Obesit y Society and Ameri can Co llege of Cardio logy/American 
Heart Associ ation Task Force on Practice Guidelines. based on a systemat ic review from the 
Obesit y Expert Panel , 2013. Obesity. 2014;22(suppl 2):S5 -S39. 
https://doi .org/10.1002/oby .20821
Knowl er WC, Barrett -Connor E, Fowler SE, et al. Reducti on in the incidence of ty pe 2 di abetes 
with lifestyle interventi on or m etformin. N Engl J Med. 2002;346 (6):393-403.
https://doi .org/10.1056/NEJMoa012512
Koizumi M, Takada T, Kawarada Y, et al. JPN Guidelines for the management of acute 
pancreat itis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 -32.https://doi.org/10.1007/s00534 - 005-1048-2
Kolotkin RL, Andersen JR. A systematic review of reviews: expl oring the rel ationship between 
obesit y, weight l oss and healt h
-related qualit y of life. Clin Obes . 2017;7(5):273 ‐289. 
https://doi .org/10.1111/cob.12203
Kolotkin RL, Ervin CM, Meincke HH, et al. Development of a clinical trials versio n of the 
Impact of Weig ht on Qualit y of Life -Lite questi onnaire (IWQoL -Lite Clinical Trials Versio n): 
CONFIDENTIAL Protocol number I8F -MC-GPHM
112resul ts from two qualitat ive studies. Clin Obes. 2017;7(5):290 -299. 
https://doi .org/10.1111/cob.12197
Kolotkin R L, Williams VSL, Erv in CM, et al. Validati on of  a new m easure of qualit y of life in 
obesit y trials: I mpact of Weight on Quality of Life–Lite Clinical Trials Versio n. Clin Obes.
2019;9 (3):e12310. https://doi.org/10.1111/cob. 12310
Lauby -Secretan, B, Scocci anti C, Loomis D, et al. ; Internati onal Agency  for Research on Cancer 
Handbook Working Group. Body fatness and cancer -viewpo int of the IARC Wor king Group. 
N Engl J Med. 2016;375 (8):794-798. https://doi.org/10.1056/NEJMsr1606602
Leibel RL, Rosenbaum M, Hirsch J. Changes in energy  expendi ture resul ting from altered body
weight. N Engl J Med . 1995;332(10):621‐628. 
https://doi .org/10.1056/NEJM199503093321001
Luppino FS, de Wit LM, Bouvy  PF, et al. Overweight, obesit y, and depressio n: a systemat ic 
review and meta -analysis of lo ngitudinal studies. Arch Gen Psychiatry. 2010;67(3):220 -229.
https://doi .org/10.1001/archgenpsychiatry .2010.2
Marso SP, Bain SC, Conso li A, et al . Sem agluti de and cardi ovascular outcom es in pat ients with 
type 2 di abetes. N Engl J Med. 2016a;375(19):1834 -1844. 
https://doi .org/ 10.1056/NEJMoa160714 1
Marso SP, Daniels GH, Brown -Frandsen K, et al. Liraglut ide and cardiovascular outcomes in 
type 2 di abetes. N Engl J Med. 2016b;375(4):311 -322. 
https://doi .org/10.1056/NEJMoa1603827
Maruish ME, ed. User’s Manual for the SF -36v2 Health Survey . 3rd ed. Lincoln, RI: Qualit y 
Metri c Incorporated; 201 1.
Mertens IL, Van Gaal LF. Overweight, obesit y, and bl ood pressure: the effects of modest weight 
reducti on. Obes Res . 2000;8(3):270 -278. https://doi.org/ 10.1038/oby .2000.32
Müller TD, Clemmensen C, Finan B, et al. Anti
-obesity therapy: from rainbow pills to 
polyagonists. Pharmacol Rev . 2018;70(4):712 ‐746. https://doi.org/10.1124/pr.117.014803 
Nauck MA, Meier JJ, Schmidt WE. Incretin -based glucose -lowering medicat ions and the risk o f 
acurte pancreatit is and/or pancreati c cancer: reassuring data from cardio -vascular outcome 
trials. Diabetes Obes Metab . 2017;19(9):1327- 1328. https://doi.org/10.1111/dom.12981
[NHLBI]. Managing overweight and obesit y in adults: systematic evidence review fro m the 
Obesit y Expert Panel, 2013. Available at: 
https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesit y-evidence -review.pdf .
Published 2013. Accessed J une12, 2020.
[NHLBI]. The practical guide identificat ion, evaluati on, and treatment of overweight and obesit y 
in adults. Available at: https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf .
Published October 2000. Accessed June 12, 2020.
Ryan DH, Yockey  SR. Weight l oss and improvement in co morbidity: differences at 5%, 10%, 
15%, and over. Curr Obes Rep. 2017;6(2):187 -194. https://doi.org/10.1007/s13679 -017-0262-
y
SAXENDA [summary of product characterist ics].Bagsv
ærd, Denmark: Novo Nordi sk, 2015 . 
CONFIDENTIAL Protocol number I8F -MC-GPHM
113SAXENDA [package insert] .Bagsv ærd, Denmark: Novo Nordisk ; 2014 .
Skow MA, Bergma nn NC, Knop FK. Diabetes and obesit y treatm ent based on dual incret in 
receptor acti vation: “twincret ins”. Diabetes Obe Metab. 2016;18 (9):847-854.
https://doi .org/10.1111/dom.12685
Srivastava G, Apovian CM. Current pharmacotherapy  for obesi ty.Nat Rev Endocrinol. 
2018;14(1):12 -24. https://doi.org/10.1038/nrendo.2017.122
Steinberg WM, Buse JB, Ghorbani MLM, et al. 
LEADER Steering Committee; LEADER Trial 
Invest igators. Amylase, lipase, and acute pancreatitis in people wit h type 2 di abetes treated 
with liraglut ide: results from the LEADER rando mized trial. Diabetes Care.
2017a;40( 7):966 -972. https://doi.org/10.2337/dc16 -2747
Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of liraglut ide on amylase, lipase, and 
acute pancreatit is in part icipants wi th overwei ght/obesi ty and norm oglycemia, predi abetes, or 
type 2 di abetes: secondary  analyses of pooled data fro m the SCALE clinical development 
program. Diabetes Care. 2017b;40(7):839 - 848.https://doi.org/10.2337/dc16 -2684
Sumithran P, Prendergast LA, Delbridge E, et al. Long -term persistence of hormonal adaptations 
to wei ght loss. N Engl J Med . 2011;365(17):1597‐1604. 
https://doi .org/10.1056/NEJMoa1105816
Tomlinso n B, Hu M , Zhang Y, et al. An overview of new GLP -1 receptor agonists for ty pe 2 
diabetes. Expert Opin Investig Drugs . 2016;25(2):145 -158. 
https://doi .org/10.1517/13543784.2016.1123249
van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. Effects of glucagon -like pept ide 1 on 
appeti te and body  weight: focus on the CNS. J Endocrinol . 2014;221(1):T1 -T16. 
https://doi .org/10.1530/JOE -13-0414
Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesit y: com parison of 
moderate and severe caloric restri ction and the effects of weight maintenance therapy . 
JConsult Clin Psychol . 1994;62
(1):165-171. https://doi.org/10.103 7//0022 -006x.62.1.165
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent ly repeated glucose measurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577 -
582. https://doi.org/ 10.1177/193229681000400311
[WHO]. WHO STEPS surveillance manual: the WHO STEP wise approach to noncommunicable 
disease risk factor surveillance. Updated 26 January 2017. Accessed May 4, 2020. 
https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf . 
Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefits of modest 
weight loss in improving cardiovascular risk factors in overweight and obese individuals with 
type 2 di abetes . Diabetes Care . 2011; 34(7):1481‐1486. https://doi.org/ 10.2337/dc10 -2415 
Leo Document ID = a1f37e94-98cb-4d3e-b822-c86293aa4b40
Approver: 
Approval Date & Time: 19-Nov-2020 21:02:18 GMT
Signature meaning: Approved
Approver:
Approval Date & Time: 19-Nov-2020 21:05:48 GMT
Signature meaning: Approved
PPD
PPD